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In late 2019, the first cases of an unknown lung disease appeared in the Chinese city of Wuhan. On 
31st December 2019, the WHO Country Office on the People's Republic of China officially reported the 
cases to the World Health Organisation, following an official media statement from the Wuhan Municipal 
Health Commission. In January 2020, the previously unnamed virus continued to spread outside of China, 
leading the WHO Director-General to declare the outbreak of the novel coronavirus a public health 
emergency of international concern with the highest level of alarm on 30th January 2020. On 
11th February 2020, the virus was given the name SARS-CoV-2 (severe acute respiratory syndrome 
coronavirus type 2) and the corresponding disease COVID-19. Since then, the virus has been spreading 
rapidly all over the world, with partly more than 600,000 new infections per day worldwide [1]. One year 
later, on 12th February 2021, there are 106,991,090 confirmed cases and 2,347,015 deaths associated 
with COVID-19 worldwide [2]. An unprecedented situation for our generation is bringing the entire 
society to a standstill. While life is being shut down, the research for effective treatment and prevention 
is in full swing. 
COVID-19 is mainly transmitted via droplets and aerosols and has an average incubation period of five 
to six days. Since COVID-19 causes substantially the same unspecific symptoms like the usual cold or flu 
(cough, fever, fatigue) a clear distinction is hard to make. This, as well as asymptomatic, but infectious 
patients promote further spreading and hence the danger of the virus. A disturbance of the sense of 
smell and/or taste that persists also after the infection is a common symptom of the lung disease. 
COVID-19 can manifest itself in many ways and not only in the respiratory tract, but also in other organ 
systems [3]. The high contagiousness in combination with the severity of the related disease 
substantiates the importance to minimise the chances of getting the disease and to develop vaccines to 
prevent COVID-19. 
SARS-CoV-2 is a new beta coronavirus. Coronaviruses are enveloped RNA viruses and possess, among 
other things, spike proteins in their membrane, which are responsible for the entry into the host cell. 
This spike protein induces protective antibodies and is therefore of great interest for vaccine 
development. Since the beginning of the circulation of COVID-19 in humans, the viruses have acquired 
an increasing number of mutations. Virus variations with, e.g., different spike mutations were still rare at 
the beginning of the pandemic, but are now prevalent worldwide [4]. That is why it is important to 
broadly diversify the research for an appropriate vaccine. 
Currently, a total of four different approaches to vaccine development are being pursued by various 
companies: gene-based vaccines, protein-based vaccines and virus-like particles, vector vaccines and 
inactivated whole-virus vaccines [5–8].  
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So far, three vaccines have received conditional approval from the European Medicine Agency (EMA): 
two m-RNA vaccines and one vector vaccine [9]. 
The two m-RNA vaccines from BioNTech and Pfizer as well as from Moderna are administered 
intramuscularly in two doses at an interval of three to four weeks and showed an efficacy of 
approximately 95 % [10]. As the name suggests, m-RNA vaccines contain m-RNA, which is produced 
during transcription where a section of DNA is transcribed into an RNA single strand and is subsequently 
translated into the corresponding amino acid sequence of a protein. The m-RNA has to be delivered 
into the cytoplasm of the cell in order to initiate the formation of proteins on ribosomes. To facilitate 
the uptake into the cells, the m-RNA can be packed in liposomes or lipid nanoparticles. Another 
possibility of gene-based vaccines are DNA vaccines. Here, an antigen-coding gene is inserted into a 
non-replicable expression plasmid. In the cell nucleus of the vaccinated person, the DNA is then 
transcribed into RNA followed by the formation of the proteins/antigens [5].  
The vector vaccine from AstraZeneca is also administered intramuscularly in two doses and has shown 
an efficacy of approximately 82 % for doses separated by 12 weeks [10]. In vector vaccines, the genetic 
material for an antigen is inserted into an infectious, well known carrier virus. The additional gene in the 
vector virus is then read and translated into a viral protein. Vector vaccines are divided into replicating 
and non-replicating viral vectors. In the case of AstraZeneca's vaccine, it is a non-replicating viral vector 
platform, i.e., a modified chimpanzee adenovirus without the ability to replicate in the host’s body [6]. 
Whole virus vaccines are the traditional vaccines. In this case, the pathogens are cultivated in eggs, 
animal or human cell lines and administered in an attenuated form that will not lead to the outbreak of 
the disease. Whole virus vaccines can be distinguished in attenuated and inactivated viruses. The 
attenuated viruses are mutants of the actual virus, in which the pathomechanisms are no longer 
functional. This means that it can still replicate and multiply, but would not trigger any relevant disease 
symptoms. The inactivated virus vaccine does not contain any replication-capable viruses, but has been 
completely inactivated chemically or physically [7]. 
Protein-based vaccines and virus-like particles contain purified viral proteins as antigens. Since the spike 
protein is already identified as antigen, this approach to vaccine development is very obvious in the case 
of COVID-19. Suitable cells are genetically equipped with the corresponding gene to produce the spike 
proteins. In culture, these cells can produce the vaccine antigen in large quantities, which then has to be 
isolated and purified. Since the purified protein is usually not sufficiently immunogenic, the vaccines are 
often equipped with an adjuvant. Virus-like particles are a further development of protein-based 
vaccines, as they consist of viral structural proteins that, at least partly, have an inherent property of self-
organisation and spontaneously assemble into small vesicles that mimic the morphology of the 
pathogen [8]. Most protein-based vaccines currently in phase-2 or phase-3 clinical trials are administered 
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intramuscularly, but three nasal vaccines are also being studied in phase-1 trials [10]. Phase-1 studies 
are human pharmacology studies. In these studies, the pharmacokinetics, tolerability and safety of the 
vaccine are first tested on a small number of healthy volunteers [11]. Since COVID-19 is transmitted via 
droplet infection and aerosols [3], the point of entry of the viruses into humans is, as for many other 
pathogens, the respiratory tract. In this context, mucosal immunisation via the respiratory tract is an 
obvious route of administration that has been little used to date, but which has numerous advantages 





Mucosal immunisation via the respiratory tract is one non-invasive chance to prevent infectious diseases. 
As already mentioned, an adjuvant has to be added to a vaccine if the antigen used is not sufficiently 
immunogenic. Since aluminium hydroxide or aluminium phosphate, the most commonly used adjuvants 
for intramuscular administration, are not effective on the mucosa, the aim of this work is to investigate 
zinc oxide in formulation for respiratory vaccination. The focus of the thesis is on the use of zinc oxide 
in formulation for respiratory vaccination as an alternative to aluminium hydroxide and aluminium 
phosphate. Following the thesis, zinc oxide as adjuvant will be investigated in in-vivo studies.  
In the first part of the thesis, the adsorption properties of different zinc oxides are investigated in relation 
to different proteins. The question to be answered is: what is the influence of the production method, 
the shape and the particle size of the different zinc oxides on the adsorption of proteins with varying 
molecular weights and isoelectric points. 
The second part of the thesis starts with the production and characterisation of nasal formulations 
followed by the production and characterisation of corresponding pulmonary formulations. Both the 
nasal and the pulmonary formulations already contain the model antigen and different concentrations 
of zinc oxide. Finally, the question to be answered is: which formulation has the most promising 
properties with regard to mucosal vaccination via the respiratory tract. In addition to the question of 
whether it is a nasal formulation or a pulmonary formulation, the question of the "right" zinc oxide 
concentration will also be considered. 
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3 Mucosal vaccination via the respiratory tract 
Chapter 3 with the title “Mucosal vaccination via the respiratory tract” was published as a review in 2019 
in Pharmaceutics 11 (8) by Marie Hellfritzsch and Regina Scherließ [12]. 
3.1 Introduction 
Active immunisation, which can achieve a lifelong immunity, is one chance to prevent infectious diseases. 
It has proven to be one of the most cost-effective public health interventions through the years and the 
number of immunised children is continuously increasing. Thus, the World Health Organisation (WHO) 
specifies that approximately two to three million lives could be saved every year because of 
immunisation and the highest number of vaccinated children was reported in 2017: 116.2 million [13]. 
One of the most recent examples of how vaccinations are important to prevent diseases is the measles 
vaccination. Measles are a viral illness and one of the most infectious diseases, especially in young 
children. Since the 1960s, where the first measles vaccine was used, the number of cases worldwide 
decreased from almost 4.5 million in 1980 to 90,000 in 2016 because of different types of measles 
vaccines, regardless of whether mono or combination preparations were used [13,14]. But in 2018, 
almost 83,000 cases were reported just in Europe again and, according to WHO, that is three times 
higher than in 2017 and 15 times higher than in 2016 [15]. Increasing outbreaks show that hard-won 
gains are easily lost. Even in countries with well-established health and national immunisation systems, 
political and economic changes can have an influence on vaccination status without constant attention 
[13]. Two of the main goals of the Global Vaccine Action Plan of the WHO [13] are increasing vaccination 
rates again and treating other infectious diseases with vaccines. The focus is on the research and 
development of vaccines against diseases that are widespread worldwide, such as malaria and HIV as 
well as new technologies. While Mosquirix®, a vaccine against malaria, has received positive scientific 
feedback from the European Medicines Agency and is now being tested in studies in three African 
countries, the vaccine development for HIV is more challenging in a technological view, because of great 
variability and mutability. However, regarding HIV vaccines, multiple candidate vaccines are in clinical 
and preclinical evaluation. 
As already mentioned, vaccines can be divided into mono vaccines and combination vaccines. Another 
possibility of subdivision is the division into the following four groups: live attenuated (e.g., measles, oral 
polio virus), inactivated (e.g., whole-cell pertussis, inactivated polio virus), subunit (e.g., hepatitis B, 
pneumococcal) and toxoid (e.g., tetanus toxoid, diphtheria toxoid). Live attenuated vaccines are 
produced from disease-causing pathogens and weakened under laboratory conditions. They can grow 
and cause no or very mild infection in vaccinated individuals. The immune response is almost as good 
as that of the original pathogen as all pathogen components are present. However, it is conceivable that 
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this may go hand in hand with negative effects. Live attenuated vaccines have the rare potential to revert 
to the pathogenic form and cause diseases or adverse effects, immunosuppressed individuals may not 
be able to react to the antigen and they should also not be administered during pregnancy. In 
connection with pregnancy and childbirth, another problem may arise during vaccination: maternal 
antibodies [16]. Early in life, infants have an immature immune system and maternal antibodies are 
transferred from mother to child. These antibodies inhibit vaccination of the newborn and provide 
inadequate protection despite vaccination with different mechanism. In order to avoid inactivation and 
inadequate vaccination protection, different strategies are discussed, including maternal immunisation. 
It has the advantage that the maternal immune system will react well to vaccination and, thus, provides 
high levels of antibodies for the infant [16]. In addition, the vaccination of the mother would be possible 
through various methods of administration. 
Because of a reliable systemic immune response and exact dosing possibilities, intramuscular 
administration is the most used method. Due to the fact that it is an invasive procedure, usage of a 
needle is always necessary. Hence, trained personnel for administration and a sterile dosage form are 
indispensable and undesired effects can occur as a result, e.g., accidental needle sticks. By far the biggest 
problem associated with injury to an infected needle is the transmission of infectious diseases, e.g., HIV, 
hepatitis, and the risk of sepsis [17]. 
In his review on needle-free immunisation, Mitragotri [17] shows various alternatives to intramuscular 
application (Table 3.1). Cutaneous and mucosal immunisations are possibilities of non-invasive 
administration. Particular emphasis should be placed on the mucosal immunisation via the respiratory 
tract, because pathogens mostly have their first contact with nasal and pulmonary mucosa when entering 
the human body. 
Table 3.1. Various alternatives to intramuscular application [17]. 
Cutaneous immunisation Mucosal immunisation 
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This review takes a closer look at mucosal immunisation via the respiratory tract as an alternative to 
intramuscular application. Different aspects will be investigated, starting with the immune system of the 
respiratory tract and particle uptake through formulations to therapeutic vaccination. 
3.2 The immune system of the respiratory tract 
To understand the function of the mucosal immune system, it is important to look at the structures of 
the upper (from the nasal and oral cavities to the throat) and lower (trachea and lung) respiratory tract. 
It should be noted that there are large differences between species and age groups. The immune system 
in the upper and lower respiratory tract can be structured in three parts (Table 3.2). As mentioned before 
the first parts are epithelial compartments with immunocompetent cells with four different cell types: 
alveolar macrophages, dendritic cells, M cells and intraepithelial lymphocytes. The second parts are the 
lymphoid structures of the nose and the bronchus: nose-associated lymphoid tissue (NALT), larynx-
associated lymphoid tissue (LALT) and bronchus-associated lymphoid tissue (BALT). The third parts are 
lymph nodes that drain the respiratory system [18]. 
Pavot and coworkers [19] divide the mucosal immune system into inductive and effector sites. At the 
lamina propria, which is the effector site level, effector cells control foreign material and secretory 
antibodies are produced, especially IgA. The secretory IgA is very important in preventing infections, 
because it inhibits the adhesion of bacteria, viruses and other pathogens to epithelial cells. 
Immunoglobulin G is also produced and plays a role in neonatal immunity, because there is a passive 
delivery of IgG from mother to child. Intraepithelial T lymphocytes are concentrated in the surface 
epithelium; NK-like cells, macrophages and B and T cells are located in the sub-epithelial compartment; 
antigen presenting cells and dendritic cells are present in the mucosal lymphoid tissue. At the inductive 
site, which is the mucosa-associated lymphoid tissue (MALT), an immune response is initiated. The MALT 
is the biggest lymphoid tissue in the human body with 4/5 of all immune cells [20] and has three main 
functions: 
1. Protect the mucosal surface against invasion by microbial pathogens; 
2. Prevent internalisation of commensal bacteria or antigens as non-degraded proteins; 
3. Induct tolerance against innocuous soluble substances. 
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Table 3.2. Location of immune cells within the respiratory tract [18,20–25]. 
Parts of the immune system Location Cells/structures 




Dendritic cells (DCs) 
M cells 
T and B lymphocytes 
Lymphoid structures of the nose 
and the bronchus 







Lung: upper and lower 
airways (branching site) 
Bronchus-associated 
lymphoid tissue (BALT) 
Lymph nodes  T and B cells 
 
3.2.1 Immune system in the nose 
As the respiratory tract and especially the nose as part of the upper respiratory tract is one of the main 
entry ports for pathogens, it is well equipped with immunocompetent cells. The lymphoid tissue of the 
nose (nose-associated lymphoid tissue, NALT) is located in the nasopharynx and the tonsils as part of 
the Waldeyer’s ring [18,21]. It is part of the common mucosal immune system, being characterised by 
circulation and homing of mature immune cells to the different mucosal sites [22], and can induce a local 
immune response in the respiratory tract as well as systemic immune reactions [23,25]. The NALT is 
characterised by a reduced number of ciliated and goblet cells compared to the normal respiratory 
epithelium present in the nose, numerous intraepithelial T and B lymphocytes and some macrophages 
[21]. It is known that in these areas, specialised epithelial cells allow intimate contact with lymphoid cells 
and antigens are taken up following this route to be presented to underlying dendritic cells [25]. Whereas 
NALT is located in confined structures, dendritic cells (DCs) as antigen presenting cells are also present 
throughout the complete epithelium. They might congregate immediately under epithelia, migrate into 
the epithelial layer and even extend dendrites into the lumen to capture antigens. Dendritic cells will 
then travel to the nearest draining lymph nodes, the cervical lymph nodes, to present the captured 
antigen to T cells [24]. Upon uptake the antigen is processed by a DC, which then will stimulate CD4-
positive T cells to induce IgA-committed B cell development in the lymphoid follicle. After maturation, 
these B cells migrate from NALT to the regional cervical lymph nodes. Finally, antigen-specific CD4-
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positive T cells and IgA-positive B cells migrate to effector sites (such as the nasal passage) through the 
thoracic duct and blood circulation [26]. 
3.2.2 Immune system in the lung 
In the lung, MALT structures (here named bronchial-associated lymphoid tissue, BALT) can be found 
along the upper and lower airways, where they are mostly stretched out at the branching sites, where 
turbulent flow occurs which enhances the likelihood of antigenic particles impacting on these structures 
[21]. Within this lymphoid tissue the number of ciliated cells is reduced compared to normal respiratory 
epithelium, whereas numerous lymphocytes and macrophages are present. The frequency of 
immunocompetent cells varies between the upper bronchial airways, where a dense network of those 
cells can be found, and the lower respiratory tract with an increased number of alveolar macrophages 
compared to dendritic cells. Whereas macrophages play an important role in the first line defence of the 
innate immune system, dendritic cells are key players in adaptive immune responses [27]. Dendritic cells 
are found in the epithelial linings of the conducting airways, in the submucosa, within alveolar septal 
walls as well as on the surface of the alveoli [28]. From the cells in the conducting airways, about 2 % of 
the total cell population are airway mucosa dendritic cells, whereas only 1 % of the cell population in 
the lung parenchyma are dendritic cells. Nonetheless, there are indications that these cells are more 
efficient in antigen uptake than the DCs of the upper airways [27]. Due to the differences in distribution 
of the different immune cells throughout the lung, a targeted delivery to certain cells may be possible, 
which in turn can induce the desired immune response. 
3.3 Advantages of mucosal immunisation 
Inhalable pathogens enter the body or directly infect the host via the mucosal surface. For this purpose, 
it would be interesting to achieve an immune response at the mucosal surface. The problem is that 
intramuscular vaccination often creates a poor mucosal immune response [29]. Nasal and pulmonary 
delivery are the most effective routes to reach a local immune response besides a systemic immune 
response. That means mucosal immunisation produces antigen-specific IgA antibodies at the infection 
site as well as IgG for an additional systemic response and defence mechanism against the 
microorganism [18]. Furthermore cell-mediated responses can be stimulated, e.g., helper CD4-positive 
T cells and CD8-positive cytotoxic T lymphocytes [30]. 
The nasal mucosa is a very interesting route of drug delivery [31]. Partidos [32] mentioned in his review 
different reasons why the nose is an attractive route for immunisation: 
• Easily accessible; 
• Highly vascularised; 
• After intranasal immunisation, both mucosal and systemic immune responses are induced; 
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• Immune response can be induced at distant mucosal sites owing to the dissemination of 
effector immune cells in the common mucosal immune system; 
• Can be used for the immunisation of large population groups; 
• Does not require needles and syringes, which are potential sources of infection. 
Lu and Hickey [28] confirmed the reasons for nasal immunisation also for pulmonary immunisation and 
complement the arguments of Partidos: 
• Rapidly immunisation of the population; 
• Avoid the risk of transmitting hepatitis B, HIV and other blood-borne diseases; 
• Highly responsive immune system. 
Mucosal immunisation is a promising application technique, because of a rapid onset of action, 
activation of all the different arms of the immune system, fewer side effects and all the practical 
advantages [18,30,33,34]. 
3.4 Prerequisites for mucosal vaccination 
For mucosal vaccination, there are some specific requirements, which differ from parenteral vaccination. 
Most importantly, the antigen needs to be presented in a particulate form in order to provoke local and 
systemic immune response. Further, an adjuvant with mucosal effectivity is needed. Finally, the 
formulation needs to be capable for respiratory delivery via a suitable device, deposition at the target 
site and interaction with the immune cells. 
3.4.1 Particle uptake in immune cells 
To induce an immune response in the respiratory tract, the antigen has to be taken up by antigen-
presenting cells (APCs) in a particulate form [35]. This is easy if the antigen itself is a particle similar to 
an attenuated or inactivated pathogen, but it is more complicated for subunit vaccines, where the 
antigen needs to be formulated with a particulate vaccine carrier. Dendritic cells are efficient stimulators 
for B and T cells [36]. DCs are able to take up microbes and particles by phagocytosis, further they are 
able to form large pinocytotic vesicles incorporating extracellular fluid and solutes with this taking up 
soluble antigens by macropinocytosis. They are also equipped for targeted uptake following receptor-
mediated endocytosis via C-type lectin receptors or mannose receptors [35]. Upon uptake, DCs are able 
to form large amounts of peptide-MHC II complexes which are then shown on the cellular surface 
instead of degrading protein antigens in lysosomes. 
3.4.2 Particle size 
De Temmerman and coworkers [35] describe the targeting of particulate antigens to dendritic cells, 
which are the most potent and versatile antigen presenting cells. The corresponding particle size ranges 
from nanometres to the lower micrometre range. For particulate uptake in DCs, it can be shown that 
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there is a certain size-dependent efficacy in terms of immune response, as smaller particles of about 
200 nm provoke a higher immune response than larger particles of 700 nm [37]. Own studies found a 
particle size of 200 nm to 300 nm to be optimal for dendritic cell uptake [38]. Smaller particles in a virus-
like size (20 nm to 200 nm) are taken up by endocytosis and rather provoke a cellular immune response, 
whereas very small nanoparticles are not processed locally, but are directly drained to the lymph nodes 
similar to soluble antigens [35]. This results in local tolerance and a predominantly systemic immune 
response, if at all [39]. Larger particle (> 0.5 µm) are absorbed by phagocytosis or micropinocytosis and 
lead to a bacteria-like humoral response [40]. 
Nonetheless, nanoparticles, as discussed in more detail in Section 3.9.3, may only carry a small antigen 
load. This can be increased largely with microparticulate carriers, which are not very well taken up by 
DCs, but can be taken up by M cells in the MALT. Tafaghodi and coworkers [41] report on the size 
analysis of microspheres and how size influences the uptake by M cells. Particles up to 10 µm are taken 
up. Furthermore, the sizes are subdivided with regard to their immune response. While particles smaller 
than 5 µm stimulate the mucosal and systemic immune responses, particles in the range of 5 µm to 
10 µm stimulate only the mucosal immune system. Some studies implicate, that particles larger than 
5 µm can be taken up by M cells, but will remain in these cells rather than being transferred to underlying 
APCs [42]. 
Furthermore, Fifis and coworkers [43] and Singh and coworkers [44] published papers on size-dependent 
immunogenicity and opportunities and challenges of pulmonary route for vaccination. They report on 
size restrictions for uptake in macrophages of particles in the micrometre range starting from 0.5 µm. 
Alveolar macrophages are reported to be especially efficient in the uptake of particles between 3 µm 
and 6 µm [45]. Therefore, for DC-targeted uptake in the respiratory tract the particle size should be lower 
than 3 µm, best lower than 0.5 µm. 
3.4.3 Particle shape 
Apart from size, the shape of the particles also plays a role for cellular uptake [46]. When particles of 
different aspect ratios are compared, it was shown that elongated particles are taken up better than 
spherical particles or cylindrical particles and that disc-shaped particles are taken up to the least extent 
[47]. Aspect ratio will not only determine the ratio of volume to surface, but can also determine particle 
orientation and recognition [48]. For macrophages it could be shown that the particle extension at the 
point of cell attachment is more important for uptake than the total size [47]. Shape could also play an 
important role in intracellular particle transport. Here, a shape not correlating with intracellular actin- or 
microtube-dependent transporting could prevent further particle processing. In a study from Liquidia, 
the immunological response on antigens being formulated in differently shaped PRINT particles was 
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looked at and they found, that the antibody titre was highest from earthworm-like particles compared 
to cylindrical, hexnut formed or cubic particles [49]. 
3.4.4 Charge and functionalisation 
Further characteristics such as charge and functionalisation of the particles also play a role in the efficacy 
of uptake [50]. Generally, positively charged particles can better interact with negatively charged cell 
membranes than negatively charged particles, with this increasing contact time and mediating uptake 
[51]. This effect can also result in a higher immune response of cationic particles in-vivo [52]. Whether 
cationic particles exceed uncharged particles is discussed controversially and may also depend on 
hydrophobicity of the particle [53]. Particle functionalisation comprises PEGylation which may increase 
stability of the particulate system and minimise aggregation [54], and also comprises attachment of 
receptor ligands for targeted cell interaction and uptake [55] such as lectins, toll-like receptor (TLR) 
ligands and other pathogen-associated molecular patterns (PAMPs) [56], which may also serve as 
adjuvants because of their immunostimulatory effects. 
In areas where both DCs and macrophages are present such as the epithelium of the respiratory tract, 
uptake into macrophages should be avoided as these cells are not presenting antigen to subsequent 
immune cells [27], but predominantly clear the respiratory tract from particulate waste. It is reported 
that the phagocytic activity of macrophages is generally higher than of DCs, but uptake in DCs can be 
enhanced if the particle carries a positive charge [57]. 
3.5 History of respiratory vaccination 
First reports on respiratory vaccination (called “variolation”) reach back to ancient China and India as 
early as 100 BC, where a treatment with powdered scabs from patients infected with smallpox for the 
protection of other people is reported [58]. The scabs of patients smallpox lesions of the skin were 
collected and dried with this attenuating the virus and ground to a powder. The powder was then 
administered to the nose of non-infected patients by a small blow pipe or it was air-dispersed for 
inhalation. This treatment was not harmless and bore a risk for a deadly smallpox infection of 0.5 % to 
2 %, but compared to a mortality of 20 % to 30 %, when the disease was obtained through natural 
infection, this was a great success. For long, this application remained the only reported respiratory 
vaccination and it was in use in India until the 1970s. 
In the last century, major trials were performed in the former Soviet Union where several thousand 
humans were successfully aerosol vaccinated over a period of many years with live-attenuated strains 
such as dry anthrax spores [28,59]. The first major clinical trial was probably performed by Albert Sabin 
and colleagues in Mexico in the 1980s when around 4 million children were vaccinated by a nebulised 
attenuated Edmonston Zagreb measles vaccine. This trial and the following trials showed that the 
immune response in children following the aerosol route of delivery was superior to injection [60]. They 
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used a custom-made device for aerosolisation, which made use of the commonly available product for 
injection, which was reconstituted and had to be kept on ice during nebulisation in order to keep it 
stable. 
These examples prove the respiratory tract to be highly interesting as route of vaccine administration 
and many more preclinical and clinical trials are currently being undertaken to strengthen the scientific 
basis for respiratory vaccination as well as to develop vaccine products for respiratory vaccination for 
disease prevention and in the therapeutic field. 
3.6 Formulations for respiratory vaccination: general considerations 
Unlike parenteral vaccine formulations, which have to be injectable liquids, formulations for the 
respiratory tract comprise solutions or suspensions administered by nasal sprays, pressurised nasal 
sprays/pressurised metered dose inhalers or nebulisers as well as dry powder formulations which can be 
administered by passive or active dry powder dispensers. However, for all formulations, whether liquid 
or solid, it is important that the antigens are presented in a particulate form to induce a local and 
systemic immune response. Various factors influencing particle properties are discussed in Section 3.4. 
Liquid preparations face a high risk of instability over storage due to the high molecular mobility and 
with this, increased likelihood of chemical reactions and physical instability [61]. This is the reason why 
many liquid vaccine preparations need to be stored and transported under refrigeration. For a liquid 
antigen preparation, stability can be enhanced by a selection of pH buffering salts and often amino acids 
are also used for stabilisation [62,63]. The aim is to ensure and maintain optimal antigen hydration 
without physical instability or chemical degradation. Hence, osmolarity may play a critical role. For the 
respiratory mucosa, the osmolarity and pH of the administered liquid (solution or suspension) are also 
important parameters, as preparations, which deviate largely from physiological conditions, may cause 
irritancy. In addition, it has been shown that buffer ionic strength may influence the uptake of 
nanoparticles into M cells [64]. 
Stability, especially thermal stability, can be increased largely if the antigen can be stabilised and dried. 
Liquid preparations are often freeze dried to enhance storage stability, with this minimising molecular 
mobility and, hence, risk of intermolecular reactions. If they shall be administered in liquid form, they 
need to be re-dispersed in buffer directly prior to administration. With this, the antigen needs to be 
stable in liquid and has to be stabilised during freezing (cryoprotection) and the subsequent drying step 
(lyoprotection) [65]. During freezing the molecule needs to be protected from harmful effects of the 
forming ice crystals and a shift in pH, which may easily occur due to the formation of saturated solutions 
differing in salt composition from the original buffer during freezing [66]. Afterwards, the molecule needs 
to be stabilised from dehydration during the removal of water. This can be achieved by an exchange of 
water with other hydrophilic molecules which may replace it as hydrogen bond forming partner. Another 
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possibility is the formation of a sugar glass matrix, which has been shown to stabilise vaccine 
preparations [67]. This principle can also be used in other drying techniques such as spray-freeze drying 
or spray drying. Formulations, which shall be administered as dry powder, face the same problem as 
intermediate formulations in the dried state: the antigen and its carrier system need to be stabilised 
during drying. Amorij and coworkers [66] describe different possibilities to stabilise vaccines. As protein 
formulations are more stable in a solid state than in a liquid state, they discuss different sugars, which 
can stabilise proteins during spray and freeze drying (Table 3.3). 
The described mechanisms and stabilisers are not only used in influenza vaccines, but also in numerous 
other formulations in literature [68,69]. Furthermore, the dried formulation needs to have a particle size 
allowing deposition in the targeted area of the respiratory tract, should have good dispersion 
characteristics and low agglomeration and adhesive tendencies to allow powder handling, packaging 
and efficient release from the device. Particle size can be controlled by the parameters of the drying 
procedure. Here, processes resulting in a dispersible dry powder in one step (such as spray drying) are 
favoured to freeze drying, where the freeze dried cake might need to undergo a milling step to obtain 
the desired particle size [70,71]. Cohesive and adhesive behaviour are, in part, determined by particle 
size: the larger the particles, the better their flow characteristics and the lower their agglomeration. 
Powder characteristics can further be controlled by the use of dispersion modifiers, which either cover 
the surface of the microparticles resulting in reduced hygroscopicity and surface energy [72–74] or which 
form separate particles in the dry powder [75] increasing the dispersion capability. 
Its particulate carrier may also achieve stability of the antigen. Drying nanoparticles without further 
bulking excipients normally leads to highly aggregated particles of undefined size, which are difficult to 
re-disperse and have a very low yield. Therefore, further excipients can be added which serve as a matrix, 
embedding and stabilising the individual nanoparticles in a Nano-in-Microparticle (NiM) formulation 
and increasing re-dispersibility upon matrix dissolution [76]. The matrix component should consist of a 
material which is capable of quickly releasing the particulate vaccine carrier upon dispersion in media or 
deposition on the respiratory mucosa. Normally, this is secured by the use of water-soluble carbohydrate 
matrices, which dissolve in the aqueous mucus. 
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Table 3.3. Stabilisers used in vaccine during the drying process [66,68,69]. 



















Air drying D-xylose 
Smallpox Freeze drying Mannitol 












3.7 Adjuvants for respiratory vaccines 
Antigens for mucosal vaccination often require an adjuvant to achieve both systemic and local immune 
response. Adjuvants are substances that have to be administered together with the antigen in the 
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formulation to obtain the desired immune response [77]. This is of special need when the antigen does 
not bear a strong immunogenicity such as for subunit vaccines and purified antigens, especially for 
mucosal delivery routes. Here, the targeted epithelium, which naturally is in contact with many potential 
antigens, need a strong immunostimulating signal in order not to induce tolerance [38,78]. 
Table 3.4. Mucosal adjuvant in the respiratory tract [79,80]. 
Mucosal adjuvant Mechanism 
Immune response 




Cholera enterotoxin (CT) 
Heat-labile enterotoxin (LT) 
from E. coli 
Enhance antigen-specific mucosal IgA and 
systemic IgG responses to administered 
proteins [81] 
Yes [28] 
Monophosphoryl lipid A (MPL) 
Activate cells via Toll-like Receptor 4 
(TLR4) [82] 
Yes [83] 
Muramyl dipeptide (MDP) 




Stimulate B cells to proliferate and secrete 
immunoglobulins, activate APCs and 
stimulate cytokine production [86] 
Yes [87] 
Saponins like QuilA (e.g., 
ISCOMS) 
Improve T cell responses and antigen 
uptake by APC [88,89] 
Yes [89] 
Non-ionic block polymers 
(Poloxamers) 
Enhance antigen presentation by binding 
protein antigens to the surface of the oil 
droplets [90] 
Yes [86] 




Enhance B cell growth (Il-12) and influence 
the differentiation of Th cells (Il-1) [92] 
Yes [92] 
 
Further, adjuvants can be used to guide the immune response as they may determine whether a 
predominant Th1- or Th2-mediated immune response or an immune response based on cytotoxic T 
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lymphocytes (CTL) is developed [39]. This is of special interest when a CD8-positive CTL-specific immune 
reaction is needed such as it is the case for therapeutic vaccines [93,94]. 
Chadwick and coworkers [79] present various mucosal adjuvants in their review of nanotechnologies, 
whereas only those listed in Table 3.4 can be used in the respiratory tract, and Lu and coworkers [28] 
talk about different mechanisms of action. 
To be feasible as mucosal adjuvant, the substance should enhance immunogenicity of the co-
administered antigen but should not have intrinsic immunoactivity or toxicity. It has to be noted, that 
enterotoxins such as the heat-labile toxin from E. coli or the cholera toxin, which have proven to be 
effective mucosal adjuvants, may not be used in the nose due to the possible neurotoxic effects [95]. 
Non-toxic mutants or derivatives such as MPL are a feasible alternative, but the efficiency for subunit 
vaccine preparations may be questionable [96]. 
3.8 Therapeutic vaccination 
Active immunisation utilises vaccination to prevent infectious diseases. Therapeutic vaccination provides 
a new tool for the treatment of cancer, autoimmune diseases or persistent infections, but it is much more 
challenging [97]. Several mechanisms are described for developing or influencing these diseases, e.g., 
genetic factors, exogenous factors and a dysregulated function of the immune system [98]. Cancer cells 
are characterised by the fact that they are genetically altered and have lost normal cellular regulatory 
processes. As a result, they tend to express different surface markers which could be recognised by 
immune cells followed by a presentation on MHC I complexes. These complexes can be recognised by 
CD8-positive T cells. In cancer patients, the immune system does not react in the right way. DCs and T 
cells may treat cancer antigens more as body’s own components than as foreign antigens. This leads to 
a T regulatory cell response rather than an effector response, T cells cannot infiltrate the tumour and 
factors in the microenvironment of the tumour suppress effector cells [99]. Here, therapeutic vaccines 
may help teach the immune system to regain its full function by (repeated) administration of a tumour-
specific antigen along with immune-stimulating adjuvants and typically a tumour-suppressive 
chemotherapy [100]. As mentioned before, the therapy is usually not successful with a single 
administration, but typically is needed as a routine therapy. Further, a monotherapy by therapeutic 
vaccination is often not possible, because of the tumour-induced immunosuppression in the 
surrounding tissue and comedication by chemotherapy has to be administered [101]. 
Currently, there are many different approaches to therapeutic vaccination against cancer. Basically, a 
distinction must be made between three different approaches: cell vaccines (tumour or immune cell), 
protein/peptide vaccines and genetic (DNA, RNA, viral-based vectors) vaccines [100]. 
Tumour cell vaccines use, as the name suggests, tumour cells for vaccination. A differentiation has to be 
made between the use of the patient’s own tumour cells, which are removed, specially treated and re-
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applied (autologous tumour cell vaccines) and a whole tumour cell vaccine, which typically contains two 
to three typical cell lines (allogeneic tumour cell vaccines). In addition to tumour cell vaccines, there are 
also immune cell vaccines. Autologous DCs of the patients are loaded with tumour-associated antigens 
and the mature DCs are re-administered to the patients together with an adjuvant. Individualised tumour 
therapy sounds like a promising approach, but the availability of patient samples and the complex 
manufacturing process greatly limit its use [100]. 
Protein/peptide vaccines are recombinant vaccines containing peptides from defined tumour-associated 
antigens. They are then administered together with an adjuvant. Even if they are cheaper than 
individualised vaccines, they have a decisive disadvantage as they only target one or a few epitopes of 
the tumour-associated antigen and the one tumour type does not always have to be the same. An 
exception is the Stimuvax®, which contains CD4-related and CD8-related epitopes [100]. 
Genetic vaccines are another strategy to deliver antigen or fragments of antigens. After the 
administration of genetic vaccines, DCs that infiltrate the tissue during an inflammatory reaction are 
transfected, which leads to a direct antigen production and subsequent presentation. A distinction is 
made between DNA, RNA and viral-based vector vaccines. A big advantage is the easy administration 
of DNA or RNA encoding for different antigens and a complex activation of the immune system [100]. 
What all approaches have in common is that a rational vaccine design is needed to achieve a 
concentrated antigen delivery to DCs and effective DC activation leading to the induction of CD4-
positive and CD8-positive T cell responses [97]. For this reason, a mucosal vaccination is to be preferred, 
since here a high cytotoxic effect and a good cellular immune response can be achieved. 
3.9 Respiratory vaccine formulations 
3.9.1 Nasal vaccine formulations 
Primary antigen carriers are usually too small to be delivered directly to the nasal cavity, they would 
mostly get inhaled to the lung, hence, they need to be processed further to a formulation which can be 
deposited securely in the nose. Nanoparticles in suspension would be delivered within larger spray 
droplets. Spray droplet size will mainly be defined by the spray nozzle of the device as well as by further 
parameters like viscosity and surface tension of the dispersion medium. For nasal spray products, FDA 
guidelines require most of the spray droplets to be larger than 10 µm to ensure nasal deposition without 
a major postnasal fraction which would get inhaled to the lung [102]. For nasal dry powders, Hickey and 
coworkers [58] propose to use particles larger than 50 µm to ensure predominant nasal deposition. Dry 
nanoparticles tend to form uncontrolled agglomerates due to the large surface area, hence, they would 
be formulated in NiM particles. If dry powder Nano-in-Microparticle formulation, where the vaccine 
carrier is immobilised in a larger matrix particle, is directly administered to the nose, particles may cause 
physical irritancy depending on their size and concentration. Furthermore, all water-soluble components 
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start dissolving in the nasal mucus. This may result in a concentrated solution of high osmolarity, which 
can also cause irritancy and increased ingression of water to dilute the substance causing a running 
nose. Finally, the nose is a highly sensitive organ for olfaction. Therefore, formulation smell is an 
important factor for patient compliance as well as taste, because all formulations will be cleared to the 
pharynx and will also be tasteable on the tongue. In order to increase nasal retention time and with this 
the time for interaction between the formulation and the nasal mucosa to allow uptake of particulate 
antigen preparations, mucoadhesive substances (hydrophilic polymers such as chitosan, hydroxypropyl 
methylcellulose or carbomer) can be used. Apart from the variability in formulations, another advantage 
of nasal administration is the difference in microbiological requirements as a nasal formulation does not 
need to be sterile. Further additives may comprise preservatives, which are mandatory for liquid 
multidose devices to ensure microbiological stability, and adjuvanting substances. Preservatives in nasal 
formulations are under controversial discussion especially in chronic use, as they may have an effect on 
ciliary function [103,104]. The choice of an effective and non-toxic adjuvant for nasal vaccination is a 
challenging task. Especially, it must be tested whether vaccine components can enter the central nervous 
system (CNS) and cause safety problems. It has been shown by molecular imaging for a botulism vaccine 
in monkeys that the antigen did not enter the CNS upon nasal administration [105]. The reports on Bell’s 
palsy following a nasal administration of an influenza vaccine adjuvanted with the heat labile E. coli 
enterotoxin (LT) are allocated to translocation of the adjuvant component to the CNS, which led to 
withdrawal of the vaccine from the market [106]. 
Fluenz TetraTM [107] is the first marketed respiratory vaccine. It is licensed in the EU for children (2 years 
to 18 years) and FluMist Quadrivalent® in the USA and Canada for children and adolescents (2 years to 
49 years) for the active immunisation against influenza disease. They are tetravalent vaccines with four 
influenza virus strains, which are cold-adapted, temperature-sensitive and attenuated. The selection of 
the virus strains is based on the annual recommendations of the World Health Organisation (WHO). 
These live virus particles are suspended in a buffered solution containing sucrose, gelatine and amino 
acids to increase stability. For application, a nasal spray syringe with 0.2 mL of the formulation is used, 
wherein 0.1 mL is administered into each nostril. Live attenuated influenza vaccines have to mildly infect 
and replicate in mucosal cells in order to protect. Because of presenting viral proteins in their native 
form, the immune response is similar to those by natural influenza infection. This results in a higher 
efficacy compared to inactivated vaccines in children [108] and also comparable protection for adults. 
3.9.2 Pulmonary vaccine formulations 
Similar to nasal formulations, the primary antigen carrier formulation needs to be processed further to 
obtain a product which is capable for efficient delivery to the lungs. This can be performed either as a 
liquid, which can be nebulised or delivered by a pressurised metered dose inhaler (pMDI) or as a dry 
powder formulation. Comparable to nasal formulations, aerodynamic behaviour and particle size of the 
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administered formulation play an important role for the location of deposition. In general, an 
aerodynamic particle size between 0.5 µm and 5 µm is believed to be optimal for pulmonary delivery. 
Larger particles will already be deposited in the oropharynx, whereas smaller particles might get exhaled 
[109]. Aerodynamic particle size does not only depend on particle diameter, but also on particle shape 
and density, which determine how the particle will behave when moving with the air flow. Aerodynamic 
particle size is the diameter of a sphere with unit density having the same aerodynamic behaviour 
(terminal settling velocity in still air) as the observed particle and is given by the mass median 
aerodynamic diameter (MMAD). The MMAD is a cut-off particle size in which 50 % of the mass of the 
aerosol is smaller and the other 50 % is larger than the referred parameter [110]. As aerodynamic particle 
size is a result of particle dispersion in the air stream, dispersion characteristics of the formulation and 
the device used for dispersion are important influencing factors for the resulting MMAD. For pulmonary 
formulations, the number of fine particles in the inhalable range can be calculated from aerodynamic 
characterisations (e.g., in an impactor) and serves as an important parameter. It is given as the fine 
particle fraction (FPF) of either the loaded dose or the dose being emitted from the respective device. 
With respect to the therapeutic target of the vaccine, different regions in the lung may be interesting for 
delivery. Larger particles > 5 µm could be used for diseases where the pathogen colonises of the upper 
part of the bronchi such as Bordetella pertussis and Chlamydia pneumonia. Small particles < 3 µm are 
able to diffuse into the deep lung and may be used in the prevention of infections from Streptococcus 
pneumonia and Bacillus anthracis [28]. Depending on the dispersion characteristics of the formulation it 
may needed to be modified to the Nano-in-Micro formulation in order to increase the dose delivered 
to the lung. To increase the FPF of a microparticulate powder, interactive mixtures can be used, where 
the fine vaccine formulation adheres to a larger carrier, with this minimising agglomeration and adhesion 
and easing bulk handling, and is separated during inhalation [111,112]. This leaves the large carrier in 
the oropharynx, whereas the smaller particles are entrained in the inhalation flow to reach the deep lung. 
Other approaches make use of a fine particulate excipient to increase dispersion [113]. More advanced 
modifications could take into account in which region the vaccine formulation should deposit and could 
make use of broader or smaller particle size distributions of the formulation or even monodisperse 
particles in order to reach the targeted area. 
A vaccine formulation for the lung will be quite restricted in the choice of excipients, as the list of 
substances already approved for use in pulmonary dosage forms is limited. Apart from lactose, which is 
used as carrier in many dry powder formulations in the treatment of asthma or COPD, mannitol, glucose 
and sorbitol as well as some surfactants, some solvents and a limited number of polymers could be used 
without the need for registration of a novel excipient including all toxicity and safety tests [114,115]. 
Similar to a nasal vaccine NiM formulation, the matrix excipient needs to be capable for rapid dissolution 
in the lung mucus or the surfactant fluid in order to release the vaccine carrier [115]. If the formulation 
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has a sufficient FPF for efficient lung delivery, it should not cause irritancy as this effect is normally caused 
by larger particles impacting in the oropharynx. In the delivery of high-dose antibiotics, single doses of 
as much as 4 × 28 mg (from the Tobi Podhaler, Novartis Pharmaceuticals) have been reported to be 
delivered without adverse reactions [116]. Similar to nasal formulations, pulmonary formulations do not 
need to be sterile, but are usually required to have a very low level of microbial contamination, which 
practically results in aqueous nebuliser preparations to be provided sterile. 
3.9.3 Respiratory vaccines in research and development 
In the last centuries a lot of work and research has been done on respiratory vaccine delivery. The 
particulate vaccine delivery system is a growing technology and is increasingly used strategically in 
vaccine design. Packaging antigens in particles changes its capturing and processing by antigen 
presenting cells. In principle, we differentiate between four particle effects [117], which are influenced 
by different properties of the particle systems. First, modulation of the innate immune system, e.g., using 
polystyrene, PLGA or alum particle. Second, modulation of quality and quantity of antigen presentation, 
e.g., depot effect controlled through particle dissolution rate. Third, targeting dendritic cells, e.g., with 
amphiphilic polymers, or targeting cell compartments, e.g., with usage of surface charge. Fourth, 
enhancing uptake of antigen, e.g., with positive surface charges, in antigen presenting cells, or particle 
entrapment in dendritic cells [117]. 
Polymeric particles are the most stable particle vehicles. Different polymers are described in the literature 
comprising polylactide (PLA), polyglutamic acid (PGA), polylactide-co-glycolic acid (PLGA), polymethyl 
methacrylate (PMMA), polycaprolactone (PCL), cationic polymers, e.g., polyethyleneimine (PEI) and 
biopolymers, e.g., chitosan and alginate. 
Various examples of polymers in mucosal vaccination as well as advantages and disadvantages of the 
polymeric nanoparticles [79,118,119] are described in literature. Rice-Ficht and coworkers discuss 
different vaccine technologies with controlled release and adjuvant effects that occur during 
encapsulation [117]. They speak of a single dose pulsed release using a mixture of PLA and PLGA and 
sufficient immunisation through a single dose by encapsulating, e.g., subunit vaccines with PLA and 
PLGA. 
There are also numerous examples of nasal immunisation in the field of polymers. Jaganathan and Vyas 
developed surface-modified PLGA microspheres with chitosan [120]. A recombinant hepatitis B surface 
protein was used as an antigen. As a result, they observed a lower mucociliary clearance of the modified 
PLGA in comparison to unmodified PLGA and they could measure a humoral and a cellular immune 
response after nasal administration. Pawar and coworkers used a similar approach [121]. They also 
encapsulated the hepatitis surface antigen in PLGA and coated this particle with chitosan. Additional, 
glycol-chitosan-coated PLGA nanoparticles were prepared. Because of the nanoparticle size and a higher 
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mucoadhesive effect of glycol chitosan, glycol-chitosan-coated PLGA nanoparticles seemed to induce a 
higher systemic and mucosal immune response. 
Chitosan has been used as polymer for micro- and nanoparticulate preparations in many studies, as it 
shows numerous beneficial characteristics for mucosal administration such as mucoadhesivity and 
penetration-modulating properties. Ilum and coworkers explain in their paper the mechanism of 
mucoadhesive properties of chitosan. As a cationic polymer, it can bind to negatively charged materials. 
The mucus at the surface of the respiratory tract contains mucin. Sialic acid, which is a significant 
component of mucin, has a negative charge at physiological pH. As a result, chitosan can electrostatically 
interact with mucin [122]. 
Heidland describes in a study the particle formation method of ionic gelation [123]. Chitosan as 
mucoadhesive biopolymer with adjuvant activity [124] was dissolved in diluted acetic acid and 
carboxymethyl cellulose (CMC) or sodium deoxycholate (DOC) as a counter ion, respectively, in water. 
Negatively charged dissolved CMC or DOC was dripped to positively charged dissolved chitosan. 
Particles were formed by ionic interaction and size could be tuned both by the chitosan quality and by 
the ratio of chitosan and counter ion [125]. Ovalbumin was added as a model antigen to the solution 
with chitosan and got incorporated into the nanoparticles upon particle formation. The prepared 
nanoparticle suspension was then spray dried with mannitol to form Nano-in-Microparticles to allow dry 
powder inhalation or dry powder nasal administration, respectively [126]. As an alternative to the method 
of spray drying, freeze drying can also be used to immobilise the nanoparticles, as described in the 
dissertation by Buske [127]. 
Similar particles being loaded with ovalbumin as model antigen have been tested with respect to their 
in-vitro and in-vivo activity with the aim to use them as therapeutic vaccine. It was shown that antigen 
being incorporated in chitosan-CMC nanoparticles is 10 times more effective in creating immunogenic 
cytokine levels and that particle uptake, antigen processing and cross-presentation can be induced in-
vitro in mouse and human cells [128]. In an in-vivo study [129], a mild humoral and good cytotoxic 
immune response can be achieved after pulmonary instillation in combination with cAMP as mucosal 
adjuvant. 
In her dissertation, Trows describes the preparation of chitosan microparticles as antigen carriers by 
spray drying [130]. For comparison, agarose nanoparticles were produced by nanoprecipitation. Both 
particulate vaccine systems have been assessed in a mouse model after nasal dry powder administration 
and without the use of further adjuvants created higher local cellular immune responses than ovalbumin 
alone [131]. 
Different antigens were tested in various preclinical studies of pulmonary vaccine in mice, rats, macaques 
or guinea pigs. The following diseases are the focus of preclinical development: influenza, measles, 
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hepatitis B, diphtheria [132], anthrax, Yersinia pestis, Bordetella pertussis [28], tuberculosis and Bacillus 
Calmette–Guerin (BCG) [133]. Several vaccines with different target groups were already tested in clinical 
trials: measles (± rubella, ± mumps), human papilloma virus, Streptococcus pneumonia [132]. 
To increase the stability of the measles vaccine, Sievers and coworkers developed a dry powder measles 
vaccine which is administered by oral inhalation or nasal–orally via a face mask [134–136]. The first 
phase I clinical trial was performed successfully (NCT01557699, 2013). As mentioned in Section 3.5, an 
aerosolised measles vaccine was developed in the 1980s. Since then, numerous children have been 
treated with it. As the study situation had been very inconsistent, Low and coworkers conducted a 
randomised, controlled trial of an aerosolised vaccine against measles involving children from 
9.0 months to 11.9 months of age in 2015 [137]. The data showed that the aerosolised vaccine against 
measles was immunogenic, but in terms of the seropositivity rate, inferior to the subcutaneous vaccine. 
More recently, two nasal vaccines against seasonal influenza were approved by the authorities: 
Flumist/Fluenz (MedImmune/Astra Zeneca) for the US and Europe, respectively, and Nasovac (Serum 
Institute of India Ltd.) in India. Both vaccines make use of an attenuated influenza virus formulated in a 
liquid, which must be stored cold and is administered by a nasal sprayer. The vaccines have been 
administered to several million patients so far without any reports of severe adverse events or vaccine 
failure [138] and it was shown to produce a long-lasting, humoral and cellular immune response which 
closely resembles natural immunity. Further, nasal vaccination against influenza provides increased 
protection against virus drift variants and, especially, infants and children are better protected than with 
the inactivated, injectable influenza vaccine [108]. 
Audouy and coworkers used the process of spray-freeze drying to produce a dry powder influenza 
vaccine for pulmonary vaccination [86,139]. Inulin as a cryoprotector and different types of inactive 
viruses of influenza were suspended in HEPES buffered saline. This dispersion was further spray-freeze 
dried in liquid nitrogen with a two-fluid nozzle. In in-vivo mouse experiments for pulmonary 
immunisation with this dry powder obtained comparable protection to one single intramuscular 
immunisation with an injection of a subunit vaccine. 
Pulmonary immunisation is of particular interest in developing countries, where the use of intramuscular 
vaccines is often associated with problems. Tuberculosis and hepatitis B are two of the world’s leading 
infectious diseases and the treatment and prevention of these diseases are currently important subjects 
of research. 
Formulation of tuberculosis vaccines as dry powder with nasal or pulmonary administration may provide 
attractive options. Källenius and coworkers [140] discuss in their paper if new tuberculosis vaccines 
should be administered intranasally. They consider protection against different types of mycobacteria 
while using live BCG, killed BCG with adjuvant subcomponent or recombinant adenovirus-based vaccines 
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for intranasal vaccination. However, they also mentioned some disadvantages for nasal application, e.g., 
the potential access to the central nervous system and in connection therewith, the composition of the 
formulation. This point is also an aspect in the paper of Fourie and coworkers [141]. They developed a 
nasal dosage form for pulmonary administration as a preferential route for deep-lung deposition of dry 
powder tuberculosis vaccines and talking about spray dried formulations with leucine, PLGA, sucrose 
and trehalose. Garcia-Contreras and coworkers [142] also used a relatively high amount of leucine (95 %) 
for the spray drying process with the mycobacteria (5 %). After nine months in a refrigerator (4 °C) almost 
no negative effects of biological activity and other characteristics in comparison to day 1 were 
detectable. In in-vivo experiments with guinea pigs, pulmonary application had a higher reduction of 
viable bacteria per millilitre of tissue homogenate than parenteral immunisation, compared with 
untreated controls. 
Dry powder formulations of hepatitis B could also be candidates for pulmonary administration. For this 
purpose, Muttil and coworkers [143] created nanoparticle-aggregate formulations, made of PLGA (core) 
and PEG (shell) with recombinant hepatitis B surface antigen by the double emulsion method. The 
aqueous nanosuspension (10 %) was then spray dried with leucine (90 %). In in-vivo experiments with 
guinea pigs, the formulation showed a protective antibody level and high local IgA antibody titres after 
pulmonary administration, which was higher compared to intramuscular administration. 
These examples show that pulmonary immunisation with dry-powder formulations is possible and would 
be particularly useful for pulmonary diseases. 
3.10 Pulmonary and nasal administration devices 
3.10.1 Nasal administration 
For nasal administration and deposition of vaccine formulations, properties of the devices, in addition 
to the formulation properties, have a great effect, especially with respect to dispersion capacity and 
spray velocity. Usually, nasal application requires a droplet/particle size above 10 µm. Devices that can 
be used for nasal administration can be found in Table 3.5. 
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Table 3.5. Examples of devices for nasal administration. 
Devices for liquid preparations Dry powder devices 
Device Company Device Company 
Nasal pressurised metered 
dose inhaler 
3M, USA 
Unit dose powder 
device 
Aptar, France 
Unitdose System Aptar, France Turbohaler 
Astra Zeneca, 
Sweden 








OptiNose Optinose UK Ltd.   
Single dose spray devices 
Syringe with conical 
nosepiece with a spray tip, 
e.g., MAD Nasal 
Teleflex, USA   
Metered dose spray pumps    
 
3.10.1.1 Liquid preparations 
Liquid nasal formulations are mainly aqueous solutions. Drops delivered with a pipette are the oldest 
forms of nasal delivery and often used in infants. Liquid has to be sucked into a glass pipette and then 
dropped into the nostrils. The handling of nose drops for a perfect distribution in the nose is 
complicated, which leads to the fact that the popularity and also the compliance are rather low. 
Squeeze bottles, where a bottle need to be squeezed for atomising the drug through a jet outlet, 
metered dose spray pumps and single dose spray devices are possibilities for mechanical spray pumps. 
Metered dose spray pumps are the most used ones at the market. They offer high reproducibility of the 
emitted dose and it is possible to avoid preservatives because of special mechanisms or constructions, 
e.g., aseptic air filters. Most over-the-counter (OTC) drugs, like decongestants are available in this device. 
For drugs with a narrow therapeutic window, expensive drugs or vaccines, single dose spray devices are 
preferred. For this purpose, a conical nosepiece with a spray tip can be connected to a normal syringe. 
This device is, for example, used to deliver FluMist®, the influenza vaccine. 
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For single dose or bi-dose applications, simple systems are available, in which a liquid container is 
pierced and emptied upon actuation (e.g., the Unitdose System from Aptar, France, or the Unidose Xtra 
from Bespak, UK). 
Propellant driven spray systems, e.g., nasal pressurised metered dose inhalers, produce, like spray 
pumps, a localised deposition, but because of the quick evaporation of hydrofluoroalkanes (HFA) a 
noticeable “drip-out” could be less problematic. 
Electrically powered nebulisers break up solutions or suspensions into small droplets with pulsation of a 
membrane or a vibrating mesh. They can be directly inhaled into the mouth or the nose. Because of the 
special mechanism characteristics and in connection therewith the deposition can be modified and used 
in a more targeted manner. Usually, nebulisers are bigger, not handheld devices [144]. 
3.10.1.2 Dry powder devices 
Among other things, particle size as a result of the formulation and the dispersion capacity of the device 
has an effect on nasal deposition and absorption. The function of a nasal powder device is based on one 
of three principles: a compressible compartment to provide a pressure and create a plume, breath-
actuated inhalers and nasal insufflators, where a mouthpiece is connected with a nosepiece and the 
patient blows the powder into its own nose while exhaling into the mouthpiece. 
Different nasal powder inhalers already exist and have to be actuated by breathing. Astra Zeneca 
designed a modified Turbohaler for nasal administration (Rhinocort Turbohaler®, Astra Zeneca, 
Södertälje, Sweden). This multi dose inhaler device is marketed for nasal rhinitis. 
Nasal powder sprayers have the advantage in comparison to nasal powder inhalers that the patient does 
not have to apply the powder with his own inspiration. Fit-lizerTM (SNBL Pharma, Japan) is a capsule 
based, single dose powder device. The top and the bottom of a capsule are cut off by sharp blades and 
the compressed plastic chamber passes the air through the device and the powder is emitted. 
The unit dose powder device (UDS powder, Aptar, France) is a single dose, single use device in which an 
air filled compartment is compressed, a pin ruptures a membrane and the released pressure emits the 
plume of powder [144]. 
Nasal powder insufflators are breath powered technologies. OptiNose (Optinose UK Ltd., Swindon, UK) 
developed this breath powered, bi-directional nasal delivery technology. The patient utilises the exhaled 
breath to deliver the drug to the nose. Because of a special mechanism within the administration process 
drug deposition, clearance patterns and clinical device performance are unique and promising. OptiNose 
can be used for both liquid and dry powder formulation and vaccines have already been tested with the 
device [144]. 
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3.10.2 Pulmonary administration 
For pulmonary administration of vaccine formulations, device dispersion must result in an inhalable fine 
aerosol with aerodynamic characteristics suitable for lung delivery, which normally requires an 
aerodynamic particle size below 5 µm. Devices that can be used for pulmonary administration can be 
found in Table 3.6. 
Table 3.6. Examples of devices for pulmonary administration [28,140,145–148]. 
Devices for liquid preparations Dry powder inhalers 
Device Company Device Company 





ResQhaler Aespira, Israel 
Nebuliser  Twister Aptar, France 
Mesh nebuliser, e.g., I-neb 
Adaptive Aerosol Delivery 
System 
Philips N.V., The 
Netherlands 
TwinCaps Hovione, Portugal 
Twincer 
Stichting Groningen Centre 
for Drug Research, The 
Netherlands 











3.10.2.1 Liquid preparations 
For liquid preparations, nebulisation is a feasible approach. Here, devices like mesh nebulisers, ultrasonic 
nebulisers or air jet nebulisers such as the Mexican device, may be utilised. Pulmonary nebulisers are 
normally designed to produce a fine aerosol which can penetrate deep into the lung. Unfortunately, they 
sometimes have been reported to adversely affect macromolecules such as antigenic proteins due to 
the energy stress of the nebulisation procedure. This can result in a loss of potency of the vaccine 
formulation [28]. Similar to nasal administration, liquid solution or suspension preparations can also be 
administered by a pMDI, but the pharmaceutically available propellants are generally not considered as 
suitable dispersants for biologicals such as vaccine preparations [28]. 
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3.10.2.2 Dry powder inhaler 
The most promising pulmonary vaccine delivery devices are dry powder inhalers. Sievers and coworkers 
used two types of dry powder inhalers, which actively disperse the measles vaccine powder and are 
meant for either oral inhalation or inhalation with a face mask from a reservoir, where the dispersed 
powder cloud is captured. Actuation is performed by actively generating an air puff either by a squeeze 
bulb or by an air filled syringe [136]. The air puff entrains the powder, which is dispersed in a powder 
reservoir, from where it is subsequently inhaled. During storage, the vaccine powder is either stored in 
single dose blisters in the case of PuffHaler or in special “capsules” having thin plastic films on either 
side, which rupture upon actuation [145]. Another possibility is to store the single vaccine dose in 
gelatine or HPMC capsules, which can then be used in the commercially available Cyclohaler device or 
other capsule based dry powder inhalers such as the Unihaler [146] or the Twister (Aptar Pharma, France). 
The principle of operation is the same for all of these passive dry powder inhalers. The capsule is placed 
in the device, it is pierced or cut open and upon patient inhalation, the powder is entrained in the 
inhalation air flow and gets inhaled to the lung. The powder is dispersed passively by the patient’s 
inhalation. Hence, efficiency depends on the patient’s inhalation capabilities and manoeuvre. For 
vaccination applications, single or dual use systems might be of advantage as vaccination should best 
be carried out as a single shot, perhaps with one or two boosts after certain time intervals. Here, a dual 
dose system such as the TwinCaps Inhaler (Hovione, Portugal) could be used. Two doses are prefilled in 
capsules within the device and can be inhaled subsequently. The inhaler itself is disposable after use. 
Other single dose devices made for disposal after use are, among others, the Twincer (Stichting 
Groningen Center for Drug Research, The Netherlands) and the DryPod (now resQhaler, Aespira, Israel) 
[147]. Both inhalers have originally been developed for dry powder inhalation of high dose drug 
products, but they could also be used for vaccination. In the resQhaler, the powder dose is prefilled in a 
mesh-like reservoir, which starts beating upon patient inhalation through the device and with this 
release, the powder (ActiveMesh technology). In the Twincer device [148], the powder is sealed in a 
blister, which is opened directly prior to inhalation. The powder is dispersed with the help of two classifier 
chambers and is entrained in the patient’s airflow upon inhalation. 
For all types of inhalers, it is important that the vaccine formulation is compatible with the material it 
directly comes into contact with. This might be an issue for formulations of protein antigens being filled 
in gelatine capsules, but also for inhaler materials, which could adsorb formulation components by 
electrostatic interactions with this minimising the emitted dose or could lead to forced degradation of 
the antigen. In general, the device plays an important role for the dispersion and, hence, delivery of the 
formulation. Therefore, a vaccine formulation for pulmonary delivery must always be developed and 
characterised together with the respective inhalation device. 
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3.11 Conclusion 
Vaccination via the respiratory tract is an attractive strategy for a number of applications in preventive 
and therapeutic immunisation. The mucosa-associated lymphoid tissue is an excellent induction site as 
both systemic and local immune response along with a high cytotoxic effect and a cellular immune 
response can be used. The multitude of formulation possibilities and the comparatively simple handling 
of the devices leave room for the development of new ideas. Precisely for these reasons, the respiratory 





Numerous materials are used in this work. In the following, the most important ones will be discussed 
in more detail. All used reagents, cells, materials and instruments are listed in the appendix. 
4.1 Zinc oxide tetrapods 
Zinc oxide tetrapods in the form of bulk are a white to slightly yellowish white loose powder with a 
cotton wool-like consistence. Zinc oxide tetrapods as single particles have a three-dimensional 
tetrapodial structure with arm diameters of 200 nm to 1 µm and an arm length of 5 µm to 30 µm, 
whereby the angle between the arms is approximately 109.5° [149,150]. 
Zinc oxide tetrapods can be produced by flame transport synthesis (FTS), which is shown in Figure 4.1. 
[151]. A mixture of polyvinyl butyral (PVB), zinc powder (Zn) and ethanol is burned in a ceramic crucible 
at 900 °C in a muffle furnace. The flame generated during the combustion of PVB transports the Zn 
microparticles upwards, where they are subsequently converted to the vapour state, in the form of 
individual Zn atoms, Zn dimers, Zn trimer, etc. These highly unstable variants of zinc in the vapour state 
immediately participate in nucleation and growth processes with the help of oxygen molecules in the 
environment. Initially, Zn and oxygen form a stable core. Further available Zn and oxygen atoms lead to 
the growth of a 1D structure, which develops into a 3D-tetrapod-like structure through homogeneous 
nucleation. This highly efficient and cost-effective process leads to a yield of 99.9 %, whereby the 
structure of the zinc oxide tetrapods is highly dependent on the position of the material to be harvested.  
 




The potential uses of zinc oxide tetrapods are manifold due to its properties. They are summarised in an 
article by Yogendra Kumar Mishra and Rainer Adelung [152]. Particularly worth mentioning is the 
application area in biomedical technology. Zinc oxide tetrapods were used, among other things, for 
nanoimmunotherapy in in-vivo mice experiments with promising results. Zinc oxide tetrapods had a 
strong virus trapping ability, when used as a microbicide, and significantly reduced the clinical signs of 
the disease and effectively decreased the mortality of the animals. In addition, viruses bound to zinc 
oxide tetrapods could be absorbed by antigen-presenting cells in the mucosa and then presented to 
activate the immune system. Furthermore, the administration of the viruses in combination with the zinc 
oxide tetrapods led to an increase in T cell proliferation and in the CD4-positive and CD8-positive cell 
population. These results suggested that zinc oxide tetrapods might be useful as a prophylactic, 
preventive and/or adjuvant formulation for viral infections [149,151]. 
The zinc oxide tetrapods used were provided by the working group “Functional Nanomaterials” headed 
by Prof. Rainer Adelung (Institute of Materials Science, Faculty of Engineering, Kiel University, Germany).  
4.2 Zinc oxide 
Zinc oxide is a white to pale yellowish white powder, which is practically insoluble in water and 
ethanol 96 %, but soluble in dilute mineral acids [153]. Zinc oxide particles are mostly rod and needle-
shaped crystalline particles in a size range from 20 nm to 400 nm [154]. 
Zinc oxide can be produced by three different methods: the French indirect method, the American direct 
method or a wet chemical method [155]. In the French method, zinc metal is melted and evaporated by 
boiling. Afterwards it is oxidised with the oxygen in the air to produce zinc oxide. In the American 
method, the zinc-containing raw material, e.g., zinc ore, has to be first reduced by carbon. The resulting 
zinc vapour is then oxidised by air combustion and zinc oxide is formed. In the wet chemical process, 
zinc scraps are first dissolved in sulphuric acid. Afterwards, the resulting zinc sulphate is purified, 
converted into zinc hydroxide by the addition of sodium hydroxide and separated. To produce zinc 
oxide, the precipitate has to be dried. 
Zinc oxide has many different uses and is, e.g., used as a semiconductor in electronic components, as a 
catalyst in the chemical industry and as a white pigment in the production of various colours. Zinc oxide 
also plays an important role in the manufacture of cosmetic products, e.g., in sunscreens, as it is 
transparent in the visible part of the light spectrum but acts as a physical filter against UV-B and UV-A 
sunlight. Furthermore, zinc oxide is used in the pharmaceutical industry for the production of zinc 
creams, pastes, patches and bandages due to its antibacterial and astringent effect [154]. 
As an essential trace element, zinc is found as a divalent cation in almost all tissues of the human body 
and is a cofactor of numerous enzymes. Zinc is involved in cell growth, insulin storage, wound healing 
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and an intact immune system, whereby the latter is probably due to improved maturation of the  
T lymphocytes and an increased number of T lymphocytes [156,157]. 
The zinc oxide used was purchased as “zinc oxide (for external use)” from Caesar & Loretz GmbH, 
Germany. 
4.3 Aluminium hydroxide and aluminium phosphate 
The aluminium hydroxide used is a white to almost white translucent, viscous colloidal pseudo-boehmite 
gel. It is an aluminium compound consisting of fine crystalline boehmite [158]. Boehmite is a long 
AlO(OH) chain with terminal water molecules. As the chains are considerably shorter in pseudo-
boehmite, the water content increases accordingly at the same concentration [159]. The gel has an 
aluminium concentration of 10.69 mg/mL and an isoelectric point at pH 10.2, which means that at the 
pH value of the gel of pH 7.6, the AlO(OH) chains are positively charged, enabling the adsorption of 
negatively charged antigens [160]. 
The aluminium phosphate used is a wet gel suspension of aluminium hydroxyphosphate (Al(OH)x(PO4)y). 
It is an amorphous material with both hydroxyl and phosphate groups on the particle surfaces [161]. The 
suspension has an aluminium concentration of 0.5 % (w/w) and an isoelectric point at pH 5 [162]. As a 
result, at the pH value of the wet gel suspension of pH 6.4, Al(OH)x(PO4)y is negatively charged and thus 
enables the adsorption of positively charged antigens [163]. 
The binding of the antigens to aluminium hydroxide and aluminium phosphate can be achieved by two 
different interactions: on the one hand, the recently described electrostatic forces and on the other hand, 
a ligand exchange related adsorption, which is stronger in comparison to the non-covalent electrostatic 
interaction, as phosphate groups of an antigen can displace a hydroxyl group on the adjuvant surface. 
This covalent interaction ensures a prolonged antigen release [160,164].  
The associated formation of a depot and the increased production of antibodies describes the first of 
three possible adjuvant mechanisms of alum enhancing humoral immunity. The second mechanism 
comprises the development of an inflammation and the associated activation of antigen-presenting 
cells. The conversion of a soluble antigen into a non-soluble particulate form, resulting in phagocytosis 
by the antigen-presenting cells with subsequent presentation of the antigens, explains the third theory 
[164]. Due to the good adjuvant effect with different antigens and the favourable production method, 
aluminium hydroxide and aluminium phosphate are the most commonly used adjuvants in human and 
veterinary adsorbed vaccines [165].  
As early as 1926 Alexander Glenny discovered the adjuvant effect of vaccines containing aluminium salts 
[164]. Since then, there have been repeated discussions about numerous side effects of these 
formulations, such as neurotoxic effects and accumulation in the human body. A maximum dose of 
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aluminium of 1.25 mg per dose is specified in the monograph Ph. Eur.: "Vaccines for humans" as the 
limit value, with all approved vaccines being well below this value [153]. The Paul-Ehrlich-Institute has 
not found any evidence of aluminium-related toxicity nor any risk to children or adults from aluminium-
containing vaccines [166]. 
As aluminium hydroxide and aluminium phosphate show a very good adjuvant effect in a humoral, but 
not in a cellular immune response, it was only used in this work as a reference in the adsorption 
experiments, analogous to the monograph Ph. Eur.: “Hydrated aluminium hydroxide for adsorption” 
[153]. The method for determining the adsorption capacity was performed in a modified way as 
described in chapter 5.2.4.  
The aluminium hydroxide used as reference substance for adsorption was obtained as “VAC20” from SPI 
Pharma, USA and the aluminium phosphate as “Adju-Phos” from Brenntag Biosector, Denmark. 
4.4 Mannitol 
Mannitol is a white to almost white crystalline powder which is easily soluble in water (216 mg/mL) and 
practically insoluble in ethanol 96 %.  
Mannitol is a non-reducing sugar alcohol that can be obtained from plants, algae or fungi. It is 
industrially synthesised by hydrogenation from hexoses, e.g., fructose or mannose. Mannitol is 
characterised by polymorphism and can occur in three modifications, α, β and 𝛿. The β-modification is 
the most thermodynamically stable one. The used mannitol is Pearlitol 200 SD and was produced by 
spray drying a previously hydrogenated mannose solution. The result is an unhygroscopic powder with 
a molecular mass of 182.2 g/mol, an average particle size of 170 µm and a high stability [167]. Along 
with lactose and glucose, mannitol is one of the sugars approved by the FDA as an excipient in inhalation. 
Mannitol can be used in particle engineering for inhalation, as an active pharmaceutical ingredient for 
inhaled products to treat patients with cystic fibrosis and as a protective excipient for stabilising proteins 
[168]. The main use of mannitol, however, is its use as excipient for direct tableting and, in a mixture with 
0.5 % highly dispersed silica, as a filler for capsule manufacture due to its good properties.  
The mannitol used was obtained as Pearlitol 200 SD from Roquette Frères, France. 
4.5 Hyaluronic acid 
Hyaluronic acid is a white to almost white, very hygroscopic powder, which is slightly soluble to soluble 
in water (5 mg/mL), but practically insoluble in acetone and anhydrous ethanol.  
Sodium hyaluronate, which is the sodium salt of hyaluronic acid, can be produced using two different 
methods. First, sodium hyaluronate can be extracted from rooster combs, whereby the animals must 
comply with food law requirements for human consumption and second, by fermentation with 
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streptococci. It should also be noted that the manufacturing process must ensure that pyrogenic and 
inflammation promoting components are reduced to a minimum [153]. 
Hyaluronic acid is a glycosaminoglycan and is often present as a long-chain, linear polysaccharide. It is 
a key component of connective tissue and involved in numerous processes in the human body, e.g., as 
a pseudoplastic lubricant for all joint movements. Sodium hyaluronate also shows advantages in the 
field of formulation development, e.g., it can be used as an adhesive between individual nanoparticles 
to produce a microparticle as well as a mucoadhesive and penetration enhancing additive [169,170]. 
The hyaluronic acid used for the pulmonary and nasal formulations was purchased as sodium salt from 
Caesar & Loretz GmbH, Germany. 
4.6 Proteins 
Various proteins are used in the experiments as model antigens. Antigens are substances that can be 
recognised by the immune system and induce an immune reaction. In experimental immunology, 
proteins are often used as antigens. A particularly high immunogenicity can be expected if the proteins 
are as large and complex as possible and not closely related to the body's own proteins [171]. The 
proteins used are explained in more detail below. 
4.6.1 Bovine serum albumin 
Bovine serum albumin (BSA), a protein of the blood plasma of the domestic cattle, consists of 583 amino 
acids and has a molecular mass of approximately 66 kDa. The isoelectric point is at pH 4.9. 
BSA is the most abundant protein in the blood plasma of cattles, where it is responsible for colloid 
osmotic pressure and thus for maintaining plasma volume. It has a high binding capacity for both polar 
and non-polar substances and acts as a transport protein [172]. 
Serum albumins can be obtained by various methods, e.g., cold ethanol fractionation (Cohn-
fractionation), modified ethanol fractionation methods, heat shock or preparative chromatography. The 
BSA used is produced using cold ethanol fractionation. This gentle fractionation is performed at low 
temperatures (0 °C to 10 °C). Several fractions are separated by different ethanol concentrations, 
targeted selection of pH value, ionic strength and temperature. Since the fraction five contains albumin, 
BSA is also named Cohn fraction V. With the help of crystallisation or activated carbon filtration the 
albumin solutions are further purified. Finally, the albumin is freeze dried to ensure a stable, storable 
form [173].  
The freeze dried beige “powder” (Bovine serum albumin, Merck KGaA, Germany) used for the adsorption 
experiments has a purity higher than 96 % and is used as a reference substance in numerous biochemical 





Ovalbumin (OVA), the main component of chicken egg white, is a glycophosphoprotein consisting of 
385 amino acids. With a molecular mass of about 44 kDa, it is sufficiently large and complex to be 
immunogenic. For this reason, it is often used as an antigen for immunological research. Ovalbumin 
denatures at a temperature of 84.5 °C and has an isoelectric point at pH 4.5.  
Ovalbumin is produced by crystallisation. It is precipitated from chicken egg white by ammonium 
sulphate and then crystallised. The resulting crystalline ovalbumin is then freeze dried for better storage 
and stability [175].  
The freeze dried beige “powder” used (Albumin form chicken egg white, Merck KGaA, Germany) has a 
minimum purity of 98 % [176]. It was used as model antigen for all in-vitro experiments. 
4.6.3 Alpha-lactalbumin 
Alpha-lactalbumin, a small, globular whey protein, consists of 123 amino acids and has a molecular mass 
of approximately 14 kDa. The isoelectric point is at pH 4.4. 
Together with β-1,4-galactosyltransferase, alpha-lactalbumin forms the lactose synthetase and catalyses 
lactose production in the mammary gland [177].  
Alpha-lactalbumin is a component of whey proteins, the second highest number of proteins in 
mammalian milk. With the help of acid precipitation and ion exchange membranes, the different 
components of the whey proteins are separated. Finally, alpha-lactalbumin has to be freeze dried to 
ensure stability and storage [178].  
The freeze dried white to beige powder used (Alpha-lactalbumin from bovine milk, Merck KGaA, 
Germany) has a purity of at least 85 % and was used for adsorption experiments. 
4.6.4 Avidin 
Avidin, a component of chicken egg white, is a glycoprotein containing four identical subunits. The 
monomer consists of 128 amino acids. This results in a total molecular mass of approximately 66 kDa 
and an isoelectric point at pH 10.5. 
Avidin has the ability to bind biotin and can therefore cause a biotin deficiency. A property which can 
lead to numerous disorders and negative effects in the human body, is used in the biotechnological field 
to breed special maize varieties. The transgenic maize is able to produce avidin and thus bind high 
amounts of biotin. This makes it toxic to and prevents development of insects. 
Avidin can be obtained by various methods, e.g., ion exchange chromatography or affinity 
chromatography. As it is often contaminated with lysozyme after an ion exchange chromatography a 
special ion exchange chromatography procedure with defined pH value, ionic strength and salts can be 
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used for purification purposes. A subsequent chromatography is increasing the purity of avidin. Because 
of the high affinity to biotin, avidin can also be purified using affinity chromatography with a very high 
purity and recovery [179]. The used avidin is purified using affinity chromatography, dialysed and finally 
freeze dried for a better stability and storage.  
The freeze dried white to beige powder used (Avidin from egg white, Merck KGaA, Germany) has a purity 
higher than 98 %. It was used for the adsorption experiments. 
4.6.5 Lysozyme 
Lysozyme, obtained from chicken eggs, consists of 129 amino acids and has a molecular mass of 
approximately 14 kDa. The isoelectric point is at pH 11. 
Lysozyme is able to break glycosidic bonds and thus it has an important role in bacterial defence 
mechanism, e.g., in the human respiratory tract. Lysozyme cleaves a substance in the bacteria wall, 
peptidoglycan, by hydrolysing the 1,4-β-linkages between the N-acetyl-muramic acid and N-acetyl-D-
glucosamine residues. Gram-negative bacteria are less sensitive to lysozymes than gram-positive 
bacteria due to comparably low amounts of peptidoglycan in their bacteria walls 
Different methods can be used to obtain lysozyme, e.g., precipitation, aqueous two-phase system, ion 
exchange chromatography, affinity chromatography and ultrafiltration, whereby different purities are 
produced [180]. The lysozyme used is purified from chicken egg, crystallised three times, dialysed and 
supplied as freeze dried powder for a better stability and storage. 
The lysozyme used for the adsorption experiments (Lysozyme, Merck KGaA, Germany) has a purity of at 
least 90 %. 
4.7 Cells for in-vitro experiments 
To classify the influence of the formulations in-vivo, various in-vitro cell experiments were carried out. 
The cell models used for these experiments are presented below. 
4.7.1 Calu-3 
Calu-3 cells are adherent, pulmonary epithelial cells. They originate from the adenocarcinoma of a  
25-year-old male, Caucasian patient [181]. They are well differentiated, characterised and reflect 
sufficient the properties of the submucosal bronchial glands, i.e., the production of fluid, needed in the 
surface of the respiratory tract, as well as mucus and immunologically active substances. In addition, 




Calu-3 cells were purchased from the American Type Culture Collection (ATCC, USA) and used for 
cytotoxicity tests (passage number 53) in a liquid culture and for pH studies (passage number 56) in an 
air-liquid interface. 
4.7.2 RPMI2650 
RPMI2650 cells are adherent, nasal epithelial cells. They were derived from squamous cell carcinoma of 
the septum of a 56-year-old male patient [183]. Like Calu-3 cells, they are able to form a confluent air-
liquid interface. However, they tend to form clusters with free spaces between them. Nevertheless, their 
use in permeation studies is repeatedly described [184,185].  
RPMI2650 cells (passage number 17) were used for cytotoxicity tests in a liquid culture in cooperation 
with the working group of Prof. Ben Forbes at Kings College London.  
4.7.3 Murine bone marrow-derived dendritic cells 
Murine bone marrow-derived dendritic cells (BMDC) were isolated and cultured from mouse bone 
marrow. Dendritic cells form a bridge between the innate and adaptive immune system. They are 
specialised in taking up a broad spectrum of pathogens and presenting their antigens on the cell surface 
[171]. 
Due to the small number of dendritic cells that can be isolated, ex-vivo studies are often a challenge 
[186]. For this reason, the experiments were conducted with the Vaccine Design and Delivery group of 
Prof. Camilla Foged at University of Copenhagen. Murine BMDC were obtained from 10 weeks to 
12 weeks old female CF57BL/6N mice as described in the methods section in chapter 5.3.2.1. They were 
subsequently used for immunological cell experiments. 
4.8 Devices 
Various inhalers are used for the in-vitro experiments. In the following, the Unit dose system powder 
device (UDS powder, Aptar Pharma, France) for nasal administration and the Cyclohaler (Jenapharm 
GmbH & Co. KG, Germany) for pulmonary administration are presented. 
4.8.1 Unit dose system powder device 
The UDS powder is designed for single dose nasal therapies where a small, precise amount of powder 
formulation is needed. One possible use would be immunisation, as usually only one dose per interval 
is necessary. The UDS powder is a device that is ready to use and also protecting the drug, e.g., from 
light prior to administration. It is independent of the patient's performance and can be used with one 




Figure 4.2. Schematic picture of the unit dose system powder device. A) Plastic ball, B) Sample container + sample, 
C) Plastic thorn, D) Air, E) Bar, F) Lower part. 
The corresponding amount of the formulation is weighed into the sample container, which is already 
closed on one side with a plastic thorn. The container is then closed with a plastic ball and the UDS 
powder is assembled accordingly to the instruction. The UDS powder is activated by pressing the lower 
part of the device. The thorn, pushed up by the bar, can push the ball upwards and an open system is 
created. The compressed air resulting from the activation expands and a cloud of powder is created. 
4.8.2 Cyclohaler 
The Cyclohaler is a passive, capsule based powder inhaler for pulmonary administration of single doses. 
Figure 4.3 shows the schematic of the Cyclohaler. 
 
Figure 4.3. Schematic picture of the Cyclohaler. A) Mouthpiece, B) Mesh, C) Rotation chamber, D) Capsule reservoir 
+ capsule + perforation mechanism. 
The appropriate amount of the formulation is weighed into a capsule and placed in the Cyclohaler in 
advance to the inhalation. By pressing the two buttons while the inhaler is held vertically, the capsule is 
pierced evenly on both sides with four needles and thus opened. This enables the formulation to leave 
the capsule during the inhalation process. The capsule is lifted by the breath of the patient, leaves the 
capsule reservoir, rotates and therefore disperses the powder. A mesh prevents inhalation of the capsule 




5.1 Spray drying 
Spray drying was used to produce both pulmonary and nasal microparticles.  
Dry powders can be produced from liquids in a continuous and rapid process which usually results in 
particles with a low density [188], while the morphology of the dried particles can vary considerably. 
Besides the classical spherical hollow spheres, there is also the possibility to produce solid, shell-only or 
wrinkled particles. This depends, like the particle size, on the drying parameters and the used materials 
[189,190]. Spray drying is suitable for the targeted production of dry powder formulations and for the 
preparation of powders for further processing. Thus, it is used in various areas in the pharmaceutical 
industry like powders for inhalation and tabletting as well as in the food industry, where it for instance 
can be used for the production of milk powder. 
The formulations produced within the project consisted of different concentrations of zinc oxide and/or 
mannitol. The model antigen ovalbumin and hyaluronic acid were constant in concentration. Six nasal 
formulations (Table 5.1) and six pulmonary formulations (Table 5.2) with different concentrations of zinc 
oxide and mannitol were spray dried. The different compositions of the suspensions for spray drying are 
listed in the following tables.  
Table 5.1. Composition of the suspensions for the preparation of the nasal formulations. 
 Zinc oxide, g Mannitol, g 
Acetic  




Formulation 1 5 - 
95 0.05 0.5 
Formulation 2 4 1 
Formulation 3 3 2 
Formulation 4 2 3 
Formulation 5 1 4 





Table 5.2. Composition of the suspensions for the preparation of the pulmonary formulations. 




Formulation 1 1 - 
99 0.01 0.1 
Formulation 2 0.8 0.2 
Formulation 3 0.6 0.4 
Formulation 4 0.4 0.6 
Formulation 5 0.2 0.8 
Formulation 6 - 1 
 
Zinc oxide as alternative adjuvant and mannitol as matrix-forming excipient were added to acetic 
acid 2 % (nasal formulations) or water (pulmonary formulations). This mixture was sonicated (Bandelin 
SONOREX SUPER RK 514 BH, BANDELIN electronic GmbH & Co. KG, Germany) for 30 min at room 
temperature. Hyaluronic acid as adhesive between the single zinc oxide particles was added while mixing 
the suspensions on a magnetic stirrer (IKA IKAMAG RET-GS, IKA-Werke GmbH & Co. KG, Germany) for 
5 min and finally ovalbumin was added. After the suspension had been homogenised on the magnetic 
stirrer for another 10 min, the spray drying process was started.  
Figure 5.1 shows the Mini Spray Dryer B-290 (Büchi Labortechnik AG, Switzerland) being used for the 
project. 
The prepared suspension was continuously stirred during the spray drying process by the help of a 
magnetic stirrer in order to prevent sedimentation of the zinc oxide particles and thus to ensure a 
homogeneous distribution.  
The spray drying process can be divided into three main subprocesses: atomisation, drying and 
separation [191]. The liquid is transported by a pump to the spray nozzle, where it is atomised into fine 
droplets and finely distributed in the gas stream (atomisation). Different nozzles can be used to atomise 
the liquid. In the case of the rotary disc atomiser [192], the liquid is dispensed on a rapidly rotating disc. 
The centrifugal force transports the liquid to the edge and breaks it into fine droplets. The ultrasonic 
nozzle [190,191] generates droplets by high frequency vibration at an atomising surface, which allows 
generating particle sizes between 10 µm and 60 µm. In a single-fluid nozzle [192], the liquid is forced 
through the nozzle at high pressure and set in a rotating motion in a swirl chamber. The two-fluid nozzle 
[192] (Figure 5.2) consists of two tubes, whereby the outer tube is transporting the gas and the inner 
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tube is transporting the liquid. Particles in the range of 2 µm to 25 µm are producible. The three-fluid 
[190,191] nozzle has a total of three channels, whereby it can consist of gas/liquid/gas or 
liquid/gas/liquid. The last three nozzles have in common that the liquid is broken up into small droplets 
when leaving the nozzle.  
 
Figure 5.1. Schematic picture of the used Mini Spray Dryer B-290. A) Pump, B) Two-fluid nozzle, C) Magnetic stirrer, 
D) Drying chamber, E) Drying gas, F) Temperature sensor (outlet temperature), G) Cyclone, H) Dried powder. 
A two-fluid nozzle was used for the project. Both the particle range for nasal application (> 10 µm) and 
the pulmonary application (< 5 µm) could be covered with this nozzle.  
 
Figure 5.2. Schematic picture of a two-fluid nozzle. A) Liquid, B) Spray gas. 
In the drying chamber, finely atomised droplets get in contact with hot drying air (drying). The advantage 
of the so called co-current flow is that the liquid droplet meets the hot air when they are the moistest, 
i.e., the initially high quantities of water are removed and due to the evaporative cooling, the 
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temperature at the droplet surface remains relatively low despite the high inlet temperature. The 
maximum temperature a particle comes into contact with is the outlet temperature, which can be set by 
the spray rate of the liquid. In the cyclone, the dried particles are finally separated from the drying gas 
(separation). 
As already mentioned, the particle size can be controlled by adjusting the process parameters. The 
particles become smaller the lower the concentration of the liquid used and the higher the spray flow 
rate is. Reducing the pump rate and replacing the water with solvents can also have a corresponding 
influence on the particle size, but this effect is less noticeable [189].  
With these considerations in mind, appropriate modifications were made for the production of the nasal 
and pulmonary formulations. In addition to the concentration, the process parameters were also 
adjusted. At an inlet temperature of 110 °C the suspension was atomised with a two-fluid nozzle and a 
spray gas flow rate of 536 L/min (nasal formulations) or 601 L/min (pulmonary formulations). The nozzle 
used consisted of a 0.7 mm nozzle tip and a 1.5 mm nozzle cap. This geometry led to a mixing of the 
gas and the fluid. The aspirator was set to 100 % (corresponds to approximately 35 m3/h) and the nozzle 
cleaner to 4 to prevent the nozzle from being clogged by the zinc oxide particles. The spray dryer was 
operated in a co-current drying gas and the outlet temperature was set to 55 °C ± 2 °C. Dried particles 
were finally separated from the drying gas in the cyclone, collected and analysed with different methods. 
5.2 Characterisation 
Various methods were used to characterise the materials and formulations. 
5.2.1 Morphology and elementary analysis 
The materials were visualised using the method of scanning electron microscopy.  
Finely bundled electron beams are guided over the sample in a specific pattern and the backscattered 
electrons are detected. The interaction of the electrons with the material creates an image of the sample. 
To avoid interactions with air molecules, the entire process takes place in vacuum [193]. Non-conductive 
materials have to be coated with a thin gold layer.  
For this purpose, the samples were first attached to an aluminium stub with double-sided carbon tapes 
and then coated for 40 s using the BAL-Tec SCP 050 Sputter Coater (Leica Microsystems, UK). The 
samples were measured with the Phenom World XL (Thermo Fisher Scientific Inc., USA) scanning electron 
microscope at an acceleration voltage of 5 kV to 15 kV, a vacuum of 10 Pa and a spot size of 3.3 nm. 
After the visualisation, the particle size of the material could be measured, e.g., with the help of the Feret 
diameter (Figure 5.3). In contrast to the volume-based distribution of laser diffraction, only a number-




Figure 5.3. Schematic picture showing the possibility to measure samples with the Feret diameter. Vertical tangents 
are placed at the left and right end of the particle and the distance between the two lines is the diameter of the 
particle. 
Energy dispersive X-ray spectroscopy (EDS) was used for elementary analysis using the scanning electron 
microscope.  
An electron beam is used to stimulate the samples to emit X-rays. This enables the detection of 
substance quantities of less than 0.1 pg [194]. For this method, the materials should not have to be 
coated with a conductive gold layer.  
The samples attached to an aluminium stub with double-sided carbon tapes, were directly measured 
with the Phenom World XL scanning electron microscope at a voltage of 15 kV, a vacuum of 1 Pa and a 
spot size of 5.1 nm. 
5.2.2 Particle size distribution  
Laser diffraction was used to determine the particle size distribution.  
Spherical particles exposed to a beam of monochromatic light are evaluated with the help of the 
resulting diffraction pattern. Fraunhofer diffraction, a theory often used in the pharmaceutical field, 
assumes that the light waves initially spread in a linear and parallel manner. Strictly speaking, Fraunhofer 
theory can only be used if the particles are larger than the wavelength of the light used. With the Mie 
theory it is possible to measure even smaller particles, whereby additional information on the optical 
material properties, such as the refractive index or the absorption, are required [195]. 
If there is a particle in the beam path, the light beam is diffracted and detected by a multielement 
photodetector. Larger particles cause small diffraction rings with high intensity in comparison to smaller 
ones which in turn will lead to greater diffraction rings with less intensity. Numerical values representing 
the diffraction pattern are used to evaluate the measurements and transformed using optical models 
and mathematical algorithms. The optical models are based on spherical particles, which means even 
for non-spherical particles a particle size distribution equivalent to the spherical one is obtained. The 
result is a volume-based particle size distribution, since the ratio of the volume of a particle size class to 
the total particle size range is calculated [153,195]. This type of distribution is symbolised by the index 3, 
e.g., distribution density q3 and distribution sum Q3. The distribution density provides information about 
the volume fraction of a certain particle size class. The distribution sum, on the other hand, indicates the 
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quantity of all particles with an equivalent diameter less than or equal to a certain particle size. Since the 
laser diffraction method cannot distinguish between agglomerates and single particles, the 
agglomerates have to be dispersed to single particles before the measurement. The possibilities used 
are explained in more detail below.  
5.2.2.1 Particle size distribution with the RODOS module 
Particle size distribution of zinc oxide and all spray dried formulation was measured using a HELOS laser 
diffractometer (Sympatec GmbH, Germany) with a RODOS module.  
 
Figure 5.4. Schematic picture of the RODOS module. 
With the RODOS module the powders were manually fed into the system and dispersed with pressurised 
air of 3 bar. The optimum pressure was selected using the span value (Equation 5.1), which gives an 
indication of the width of the distribution. It is important that the pressure is high enough to disperse 
agglomerates but not as high that it could lead to fragmentation of the primary particles. X10, x50 and x90 
are characteristic values of a particle size distribution. X10 means that 10 % of the particles have a smaller 
diameter than the value x. The span gives an indication of how far the 10 %-value and the 90 %-values 
are apart, normalised with the 50 %-value, i.e., the smaller the span value, the narrower the distribution. 
The pressure that resulted in the smallest span value leads to the narrowest particle size distribution and 
was chosen for the measurements. The particle size distribution was measured above an optical 
concentration of 0.5 %.  








5.2.2.2 Particle size distribution with the SPRAYER module 
Particle size distribution of the nasal formulations was measured using a HELOS laser diffractometer with 
a RODOS module or with a SPRAYER module in combination with a Unit-Dose-System (UDS) powder 
device.  
With the SPRAYER module 20 mg of the formulations were dispersed using the UDS powder device as 
dispersing unit. The distance to the measuring zone was set to 10 cm, the spray angle to 45° [196] and 
the actuator force to 60 N. The particle size distribution was measured for both modules with an R2 lens 
(particle sizes < 87.5 µm) and above an optical concentration of 0.5 %. 
 
Figure 5.5. Schematic picture of the SPRAYER module. 
5.2.2.3 Particle size distribution with the INHALER module 
Particle size distribution of the pulmonary formulations was measured using a HELOS laser 
diffractometer with a RODOS module or with an INHALER module in combination with a Cyclohaler. 
For measurements with the INHALER module 10 mg of the formulations were weighed into a capsule. 
With the aid of a software-controlled vacuum system, which ensured precise volume flow control, it was 
possible to measure formulations in dry powder inhalers that are dispersed by forces comparable to 
respiration. At a maximum adjustable pressure of 138 mbar, a breath of 82.7 L/min (DFM 2000 flow 
meter, Copley Scientific, UK) was simulated. A 90° glass angle imitated the throat and a preseparator 
ensured the separation of large particles. The particle size distribution was measured for both modules 




Figure 5.6. Schematic picture of the INHALER module. 
5.2.3 Protein quantification 
Proteins can be quantified in different ways. UV/Vis spectroscopy is a very simple method for the 
detection of proteins. Aromatic amino acids (tyrosine, tryptophane, phenylalanine) in the protein allow 
to measure the UV absorption at an absorption maximum of 280 nm, although other chromophores can 
easily interfere. Another possibility is to measure an absorption maximum at a wavelength of 190 nm for 
the detection of peptide bonds. Despite of the strong absorption of peptide bonds, oxygen can disturb 
the measurements and therefore lead to falsified results. Moreover, conventional spectrometers just 
show reduced performance at lower wavelengths. Peptide bonds can also absorb at higher wavelengths 
up to approximately 230 nm, whereby the intensity of the absorption decreases with increasing 
wavelength [197].  
As a compromise the protein concentrations were determined at a wavelength of 205 nm in a semi micro 
quartz cuvette (Hellma GmbH & Co. KG, Germany) with a Shimadzu UV-1280 (Shimadzu Corporation, 
Japan) or at a wavelength of 220 nm in a 96-well plate (lumox 96 multiwell, Sarstedt AG & Co. KG, 
Germany) using the FluoStar Omega spectrometer (BMG Labtech GmbH, Germany). Different 
wavelengths were chosen because the lower limit of the adjustable wavelengths in the FluoStar Omega 
spectrometer was 220 nm. Nevertheless, the same results were obtained for 205 nm in the Shimadzu 
UV-1280 and for 220 nm in the FluoStar Omega spectrometer using a calibration curve.  
5.2.3.1 Loading 
Protein content of the spray dried formulations was determined by quantifying ovalbumin at a 
wavelength of 205 nm with a semi micro quartz cuvette. A sample of 2 mg of the nasal formulations was 
suspended in 2 mL phosphate buffer (6.8 mg/mL KH2PO4 in demineralised water) and a sample of 2 mg 
of the pulmonary formulations was suspended in 2 mL water. After the sample was vortexed at 3,000 rpm 
for 30 sec (IKA Vortex 4 basic, IKA-Werke GmbH & Co. KG, Germany), it was centrifuged at 10,000 rpm 
and 25 °C for 10 min (Centrifuge 5430 R, Eppendorf AG, Germany) to remove insoluble components, 
e.g., zinc oxide. Finally, the ovalbumin content in the supernatant was determined. The loading efficiency 
was calculated from the difference between the used ovalbumin amount and the measured 




SDS-PAGE, sodium dodecyl sulphonate polyacrylamide gel electrophoresis, can be used to determine 
the molecular weight of proteins and thus also provide information on fractionation of proteins 
contained in the particles. Polyacrylamide gels are stable and chemically inert. They are formed during 
polymerisation of an acrylamide/bisacrylamide stock solution (60 g acrylamide 2 x, 1.6 g bisacrylamide 
ad 200 mL aqua bidest) by adding ammonium persulphate (500 mg ad 5 mL aqua bidest) and 
tetramethyl ethylenediamine. A clear, transparent gel is obtained. Pore size can be controlled by the 
amount of polyacrylate and crosslinker. 
A combined gel composed of a stacking gel with a concentration of 6 % polyacrylamide and a pH of 6.8 
and a resolving gel with a concentration of 12.5 % polyacrylamide and a pH of 8.8 was prepared. 2 mg 
(nasal formulations) or 1 mg (pulmonary formulations) of the sample were suspended in 1 mL of 
incubation mix and centrifuged for 3 min at 13,000 rpm (Heraeus Biofuge pico, Thermo Fisher Scientific, 
USA). The incubation mix and all buffers contained SDS (Table 5.4), which masked the intrinsic charge of 
the protein and provided a constant negative charge. Thus, after application to the gel, the protein 
migrated in the electric field towards the anode. 3 µL incubation mix and 8 µL sample were loaded per 
well in the stacking gel following Table 5.3. After 8 min and a voltage of 120 V all samples were stacked 
on the interface of stacking gel and resolving gel. At a voltage of 200 V ovalbumin was separated. 
Ovalbumin as raw material and a peqGOLD Protein Marker III (VWR International GmbH, Germany) were 
used as references. After 45 min, the voltage was turned off and the resolving gel was rinsed with 
demineralised water. To stain the protein bands of the proteins the gel was first stained with 
0.2 % coomassie blue (1 g coomassie brilliant blue, 50 mL glacial acetic acid, 125 mL isopropanol ad 
500 mL aqua bidest) and finally silver staining (25 mL silver nitrate solution 2.5 %, 10 µL formaldehyde 
ad 250 mL aqua bidest) followed.  
Table 5.3. Filling scheme of the wells of the SDS-PAGE gel with formulations 1 to 6 (F1 to F6), incubation mix (I), 
ovalbumin (OVA) and marker. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 





Table 5.4. Composition of the buffers and incubation mix used. 
Buffer for the electrophoresis chamber 
25 mmol/L tris-base 15.14 g 
192 mmol/L glycine 72.07 g 
0.1 % SDS 5.0 g 
Aqua bidest ad 5.0 L 
pH 8.3 
Stacking gel buffer 
250 mmol/L tris-base 15.14 g 
0.4 % SDS 2.0 g 
Aqua bidest ad 500 mL 
pH 6.8 
Resolving gel buffer 
750 mmol/L tris-base 45.43 g 
0.4 % SDS 2.0 g 
Aqua bidest ad 500 mL 
pH 8.8 
Incubation mix 
Resolving gel buffer 2.5 mL 
SDS 0.2 g 
Glycerine 1.0 mL 
β-Mercaptoethanol 0.5 mL 
Bromophenol blue 0.2 mL 
Aqua bidest ad 10 mL 
 
5.2.3.3 Size exclusion chromatography 
SEC, size exclusion chromatography, is routinely used for analysis of proteins, often to evaluate the 
aggregation profile of proteins as well as for the separation and quantification of protein mixtures. The 
separation technique [198] of the SEC is based on the molecular size of the components. Very large 
molecules are excluded from the packed column material and elute first. Smaller molecules, depending 
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on their size, can diffuse into the pores to varying degrees, with the smallest penetrating furthest and 
therefore eluting last [199].  
To determine aggregates, molecular weight of ovalbumin in the formulations was measured by size 
exclusion chromatography using Äkta Pure 25 (GE Healthcare, Germany) in combination with multi angle 
light scattering (MALS, DAWN 8+, Wyatt Technology Corporation, Germany). The complete SEC-MALS 
system comprised the UV detector at a wavelength of 280 nm, the SEC column (SuperoseTM 6 Increase 
10/300 GL, GE Healthcare Bio-Sciences AB, Sweden), MALS and the refraction index detector (RI, Optilab 
T-rex, Wyatt Technology Corporation, Germany). The buffer was a solution of 0.15 mol/L NaCl, 
0.025 mol/L NaH2PO4 monohydrate and 0.025 mol/L Na2HPO4 dihydrate (pH 6.85) in demineralised 
water, which was degassed using an ultrasonic water bath for 30 min (Bandelin SONOREX SUPER RK 514 
BH, BANDELIN electronic GmbH & Co. KG, Germany). 40 mg (nasal formulations) or 20 mg (pulmonary 
formulations) of the sample were suspended in 1 mL buffer and filtered to separate undissolved zinc 
oxide particles using Chromafil Xtra PET 45/25 (Macherey-Nagel GmbH & Co. KG, Germany). The final 
ovalbumin concentration was 2 mg/mL. 100 µL of the sample were eluted at a flow rate of 0.7 mL/min. 
The data were analysed with ASTRA version 7.1.2.5 (Wyatt Technology Corporation, Germany) with a 
dn/dc of 0.185 mL/g [200]. 
5.2.4 Adsorption 
Zinc oxide tetrapods and zinc oxide should be capable for being loaded with a protein. The adsorption 
capacity of zinc oxide tetrapods and zinc oxide was tested according to the monograph 
Ph. Eur.: “Hydrated aluminium hydroxide for adsorption” [153] with some modifications. Aluminium 
hydroxide and aluminium phosphate were used as references to ensure that the experimental set-up 
was valid. The substances were weighed or pipetted according to the target concentration of 1 mg/mL, 
i.e., 2 mg zinc oxide tetrapods and zinc oxide, 0.187 mL aluminium hydroxide (10.69 mg aluminium/mL) 
and 400 mg aluminium phosphate (0.5 % (w/w) aluminium). Different proteins were tested in the 
experiment: bovine serum albumin, avidin, ovalbumin, alpha-lactalbumin and lysozyme. After the protein 
solution had been added to the samples with a target concentration of 200 µg/mL, they were exposed 
to a 360° rotation at room temperature for 1 h. During this process the substances were in permanent 
contact with the dissolved protein. To perform the rotation, the adsorption wheel used was rotated at a 
speed of 20 rpm using a friabilator (ERWEKA GmbH, Germany). Finally, the suspensions were centrifuged 
at 10,000 g for 5 min at 25 °C with the Centrifuge 5430 R. The protein content of the supernatant was 
analysed at 205 nm with a calibration curve using a semi micro quartz cuvette. The protein content 
adsorbed at the surface of the samples could be calculated as the difference between the used amount 
of the protein and the measured protein concentration of the supernatant. 
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Figure 5.7. Schematic picture of the adsorption wheel (left) in combination with the friabilator (right). 
5.2.5 Aerodynamic assessment  
5.2.5.1 Next Generation Pharmaceutical Impactor 
The aerodynamic characterisation of aerosols can be carried out using cascade impactors. Impaction 
analysis are methods for analysing in-vitro aerodynamic performances, i.e., aerodynamic diameters, but 
they cannot be seen as a lung model because of a lack of physiological conditions in the human lungs 
[201]. The principle is based on inertia-driven deposition of particles in the airstream. Inertial forces are 
dependent on the particle mass, which leads to heavier particles deposit earlier than comparatively 
lighter ones. 
 




Figure 5.9. Schematic picture showing the principle of the NGI. 
In the Next Generation Pharmaceutical Impactor (NGI, Copley Scientific, UK), a number of seven nozzles 
with decreasing orifice diameters and a terminal micro-orifice collector (MOC) are connected in series. 
In addition, the distance between the orifices and the impact plates is becoming increasingly narrow. As 
a result, the speed of the air increases from stage to stage. The larger the particle, the more likely it is to 
be impacted. Smaller particles, on the other hand, can follow the path further and are separated only at 
higher air speeds [195]. Depending on the flow rate and the nozzle diameter, the cut-off diameter, which 
is an aerodynamic diameter, of each stage is calculated according to Ph. Eur. 2.9.18: “Preparation for 
inhalation: aerodynamic assessment of fine particles” [153] using Table 5.5 and Equation 5.2, whereas  𝑦 
and 𝑥 are factors from the table and 𝑄 is the flow rate in L/min [153]. 
Table 5.5. Parameters for calculating the cut-off diameter of each stage. 
Cut-off diameter y x 
7 (stage 8 = MOC) 0.34 0.67 
6 (stage 7) 0.55 0.60 
5 (stage 6) 0.94 0.53 
4 (stage 5) 1.66 0.47 
3 (stage 4) 2.82 0.50 
2 (stage 3) 4.46 0.52 
1 (stage 2) 8.02 0.54 
 
Equation 5.2. for calculating the cut-off diameter. 








Figure 5.10. Schematic picture of the NGI with the nasal expansion chamber. 
Aerodynamic assessment of the nasal formulations was performed according to 
Ph. Eur. 2.9.18: “Preparation for inhalation: aerodynamic assessment of fine particles” [153] with the NGI 
equipped with a 2 L nasal expansion chamber (NEC). All stages and the NEC were coated with a stage 
coating (isopropanol + 1,2-propanediol, 1 + 1). 20 mg of the formulations were weighed into a UDS 
powder device and the flow rate was set to 15 L/min using a DFM 2000 flow meter. The deposited 
amount of the formulations was calculated by dissolving the powder deposited at each stage in 
phosphate buffer (6.8 mg/mL potassium dihydrogen phosphate; NEC: 15 mL, stage 1 and MOC: 10 mL, 
stage 2 to 7: 5 mL) and analysing the content of ovalbumin using UV spectroscopy (205 nm). Deposition 
in the NEC and fine particle fraction (FPF), i.e., particles with an aerodynamic diameter smaller than 5 µm, 
were calculated using Excel. 
Aerodynamic assessment of the pulmonary formulations was performed according to 
Ph. Eur. 2.9.18: “Preparation for inhalation: aerodynamic assessment of fine particles” [153] with the NGI 
equipped with a preseparator, a throat and a mouthpiece. All stages were coated with a stage coating  
(isopropanol + 1,2-propanediol, 1 + 1) and 15 mL of water were filled in the preseparator. 10 mg of the 
formulations were weighed into a capsule and the flow rate was set to 100 L/min using a DFM 2000 flow 
meter. Two capsules and a Cyclohaler were used per run. The deposited amount of the formulation was 
determined by dissolving the powder deposited at each stage, in the throat, the mouthpiece, the device 
and the capsules in water (device and capsules as combination as well as mouthpiece and throat as 
combination: 15 mL, stage 1 and MOC: 10 mL, stage 2 to 7: 5 mL) and analysing the content of 
ovalbumin of all samples, including the preseparator, using UV spectroscopy (205 nm). Fine particle 




Figure 5.11. Schematic picture of the NGI with the mouthpiece, the throat and the preseparator. 
Particle sizes as aerodynamic diameter of the particles were calculated using the equation described 
above according to Ph. Eur. 2.9.18: “Preparation for inhalation: aerodynamic assessment of fine particles” 
[153]. The aerodynamic diameter is an equivalent diameter, i.e., the measured diameter corresponds to 
the diameter of a sphere with a density of 1 g/cm3 having the same settling velocity as the investigated 
particle. 
5.2.5.2 Precise Inhale 
The Precise Inhale system from Inhalation Sciences, Sweden was used to identify the best formulation 
out of the six spray dried formulations for pulmonary application for the finally planned in-vivo studies 
in terms of their aerodynamic performance.  
The Precise Inhale system is an aerosol generating system for in-vitro, in-vivo and ex-vivo experiments. 
Most aerodynamic characterisation methods, such as the NGI, are used to analyse the in-vitro 
aerodynamic performance, but they cannot be seen as a lung model. By using different exposure 
modules, the Precise Inhale can generate data for the same aerosol in in-vitro, in-vivo and ex-vivo 
experiments. Even small amounts of a sample are sufficient to generate aerosols in precise, repeatable 




Figure 5.12. Schematic picture of the Precise Inhale. A) Aerosol holding chamber, B) Air humidifier, C) Powder 
chamber with impactor nozzle, D) V1 valve, E) Aerosol monitor, F) In-vitro exposure block, G) Vacuum, H) Exposure 
pressure. 
For the tests with the Precise Inhale, 1 mg of each sample was weighed into the powder chamber. A 
high-pressure air jet of 130 bar was used to generate an aerosol from the powder in the 300 mL aerosol 
holding chamber with the aid of the impactor nozzle. This high pressure causes rapid deagglomeration 
of the powder agglomerates. The V1 valve was closed during the aerosol generating step. The resulting 
aerosol cloud rose upwards and was then drawn onto the in-vitro exposure block with the help of a 
vacuum flow with an exposure airflow of 400 mL/min and an exposure time of 90 sec. The V1 valve was 
open for the dispensing step. During the exposure, all data, e.g., particle size distribution and maximum 
aerosol concentration were recorded with the aid of the aerosol monitor. The yield, the maximum aerosol 
concentration and the inhaled aerosol dose were evaluated using the Precise Inhale and calculated using 
Excel. 
The Precise Inhale measurements were assessed in cooperation with the Vaccine Design and Delivery 
group of Prof. Camilla Foged at University of Copenhagen. 
5.2.6 pH and solubility 
In physiology, pH values play an essential role in the activity of enzymes, the permeability of membranes, 
the structure of cells and during the immune reaction.  
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Solubility and pH changes of the formulations were tested in 24-h-solubility studies in various media, 
including phosphate buffers, sodium chloride solutions and simulated biological media for the nose and 
lungs.  
Buffer systems are almost resistant to pH changes and change their pH value only minimally when acids 
or bases are added. Physiological buffer systems, including phosphate buffers, stabilise the pH value in 
the organism and thus serve to balance mainly temporary and minor pH value fluctuations [203].  
Table 5.6. Composition of buffers and solutions [153]. 
Phosphate buffer 
Potassium dihydrogen phosphate (KH2PO4) 6.80 mg/mL 
pH 1.2 – 7.4 
Sodium chloride solution 
Sodium chloride (NaCl) 2.923 mg/mL 
pH 1.2 – 7.4 
Simulated nasal fluid, SNF 
[204,205] 
Sodium chloride (NaCl) 7.45 mg/mL 
Potassium chloride (KCl) 1.29 mg/mL 
Calcium chloride dihydrate (CaCl2 * 2 H2O) 0.32 mg/mL 
pH 6.4 
Simulated lung fluid, SLF 
[206] 
Gamble’s solution 
Magnesium chloride (MgCl2) 0.095 mg/mL 
Sodium chloride (NaCl) 6.019 mg/mL 
Potassium chloride (KCl) 0.298 mg/mL 
Di sodium hydrogen phosphate (Na2HPO4) 0.126 mg/mL 
Sodium sulphate (Na2SO4) 0.063 mg/mL 
Calcium chloride dihydrate (CaCl2 * 2 H2O) 0.368 mg/mL 
Sodium acetate (NaC2H3CO2) 0.574 mg/mL 
Sodium hydrogen carbonate (NaHCO3) 2.605 mg/mL 





In order to simulate the physiological conditions, six phosphate buffers and six sodium chloride solutions 
with different physiological pH values were prepared: pH 1.2 and pH 2.5 (stomach), pH 4.0 (vaginal 
mucosa), pH 5.5 (endosomes), pH 6.4 (nose), pH 7.4 (blood, lungs). Since not all physiological aspects 
could be addressed with a phosphate buffer and hence correlation with in-vivo data was difficult to 
achieve, simulated biological media were used for the nose and lungs [206]. The compositions of all 
media are given in Table 5.6. The pH values were adjusted using a 0.2 mol/L sodium hydroxide solution 
and a 0.2 mol/L hydrochloric acid solution [153].  
A 24-h-solubility study was performed to investigate saturation solubility and pH change of the 
formulations.  
50 mg of the nasal formulations were suspended in 5 mL of the solutions. The samples were placed in 
an orbital shaker (Universalschüttler SM, Edmund Bühler GmbH, Germany) for 24 h. Before adding the 
formulations and after the experiment pH values (WTW Inolab pH 730 in combination with pH-electrode 
SentTix 81, Xylem Analytics Germany Sales GmbH & Co. KG, Germany) were monitored.  
50 mg (pH 1.2) or 5 mg (pH > 1.2) of the pulmonary formulations were suspended in 5 mL of the 
solutions. The samples were placed in an orbital shaker for 24 h. Before adding the formulations and 
after the experiment pH values (Mettler Toledo SevenCompact Benchtop Meter with pH-electrode 
InLab Ultra-Micro-ISM, Mettler Toledo GmbH, Germany) were monitored.  
After 24 h undissolved zinc oxide was separated via centrifugation and the zinc concentration in the 
supernatant was quantified with a zincon assay. 
 
Figure 5.13. Schematic overview of the work flow of the 24-h-solubility study created with BioRender. 
The determination of dissolved zinc ions can be done photometrically using a zincon assay. Zinc ions 
(Zn2+) form a blue coloured complex with zincon in an alkaline environment, which can be measured at 
620 nm. Since heavy metals can also form a coloured complex with zincon, they have to be complexed 
with cyanide before analysis. The addition of cyclohexane ensures the selective release of zinc ions (Zn2+) 
[207]. Since all formulations only contained zinc oxide as a substance detectable by the zincon assay and 
demineralised water was used during the whole experiment the risk of interference factors was 
Methods57 
57 
negligible. 3.6 mL of demineralised water, 1 mL of sodium tetraborate buffer pH 9 (4.76 g 
Na2B4O7 * 10 H2O in 500 mL of water) and 0.1 mL of the sample were mixed with 0.3 mL of zincon 
solution (0.013 g zincon and 0.2 mL of 0.1 mol/L NaOH in 10 mL of water). 200 µL of the mixtures were 
analysed in a 96-well plate (microplate 96 well F, Sarstedt AG & Co. KG, Germany) using the FLUOstar 
Omega spectrometer at 620 nm [208,209]. 
 
Figure 5.14. Reaction equation for the zincon assay. Red zincon (left) reacts with Zn2+ in an alkaline environment to 
a blue colour complex (right). 
5.2.7 Release study 
The release of ovalbumin from the pulmonary formulations was assessed using ThinCerts (Greiner Bio 
One International GmbH, Austria). ThinCerts are cell culture inserts for 12-well plates with a transparent 
membrane of polyethylene terephthalate (PET) and a pore diameter of 1 µm. 10 mg of the dry sample 
were placed on a ThinCert. 1 mg Ovalbumin was used as reference. After 1 mL water was added to the 
well below the ThinCert, the 12-well plate was gently moved at 15 rpm for 6 h at room temperature. 
100 µL were drawn as sample directly at the beginning (0 min) and after 2 min, 5 min, 10 min, 15 min, 
20 min, 45 min, 1 h, 2 h, 4 h and 6 h and replaced by fresh water. After 6 h, the filter was rinsed with the 
water below the ThinCert to determine the total protein content. The ovalbumin concentration was 
determined photometrically at 220 nm in a 96-well plate. 
 




To compare the osmotic activity of the pulmonary formulations the osmolality was measured with the 
Osmomat 030 (Gonotec GmbH, Germany).  
Since both, osmotic pressure and freezing point depression of a solution are colligative properties, 
influenced only by the number of dissolved particles, the freezing point depression of the solution was 
used as measurement principle.  
For this purpose, 1 mg of the sample was dissolved or suspended in 1 mL water and the osmotic activity 
was measured using the Osmomat 030. 
5.2.9 Hygroscopicity 
Hygroscopicity of the pulmonary formulations was measured using dynamic vapour sorption (DVS).  
DVS is a gravimetric technique which measures the mass of a sample as it changes in response to 
alterations in humidity under isothermal conditions at 25 °C.  
The double tree method with two cycles of 0 % - 90 % - 0 % relative humidity was chosen for the 
measurements. 11 mg of the formulations were weighed into the metal basket of the DVS 1 from SMS 
(Surface Measurement System Ltd., UK). After reaching a gravimetric equilibrium at a relative humidity 
of 0 %, where no significant change in mass (< 0.005 %/min for 10 min, but maximum 360 min) was 
noticed, relative humidity was increased or decreased by 10 % to the next stage. When gravimetric 
equilibrium was reached again, the relative humidity was increased or decreased by another 10 % and 
the measurement continued accordingly. 
5.2.10 Crystallinity 
5.2.10.1 X-ray powder diffraction 
Crystallinity of the spray dried formulations was measured with X-ray powder diffraction using a STOE 
STADI P diffractometer built-up with a transmission geometry and equipped with a Cu Kα anode in 
combination with a DECTRIS MYTHEN 1K strip detector (STOE & Cie GmbH, Germany) in the range of 
5° to 50° 2 Theta.  
The principle of X-ray powder diffraction is based on the diffraction of X-rays by electron clouds of 
individual atoms in the sample. The atoms in a crystal are arranged in different lattice planes. They are 
excited to oscillate by the X-ray beam and emit wave fronts of the same wavelength. During the 
measurement, different measuring angles are used. If the lattice planes of a crystal are at a certain angle 
to the direction of the X-ray beam, the path lengths of the emitted wave fronts of the different lattice 
planes can differ by an integer multiple. The diffracted beams, which thus oscillate in phase, intensify 
each other. At intermediate angles, phase-shifted oscillations occur, which weaken or level each other 
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out. This interference condition of the integer multiple can be described with the help of Bragg's 
equation. In a powder sample, crystalline particles are presented in a disordered manner, hence 
diffractions can occur at a multitude of different lattice planes. When the beam hits a powder sample, a 
large number of concentric diffraction cones of different angles are generated, which would produce an 
image of numerous concentric circles with the beam as centre point. The angle position can be 
determined by the intensity maxima of the circles. This makes it possible to differentiate between 
crystalline (sharp diffraction pattern) and amorphous (no sharp diffraction pattern) materials. Due to its 
crystal structure, every crystalline substance has a characteristic diffraction pattern [153,192]. 
5.2.10.2 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) enables the quantitative determination of changes in enthalpy 
and specific heat during heating and cooling of a substance. During a constant heating rate, the 
temperature difference can be analysed. The evaluation is carried out graphically by plotting the energy 
change over the temperature, which, in addition to the quantitative recording of the change, also enables 
the determination of the respective onset temperature of heat-flow related events. This method enables 
the quantitative and qualitative characterisation of a variety of thermal processes, e.g., melting, 
evaporation and recrystallisation. Based on the characteristic thermal processes of a substance, the 
determination or at least an indication of the presence of a substance is also possible with the help of a 
reference substance [195].  
To get an idea about the components of the nasal formulations after spray drying, the Diamond DSC 
(PerkinElmer Inc., USA) was used with a heating rate of 20 °C/min in the range of 60 – 350 °C. Data were 
analysed using the Pyris software (PerkinElmer Inc., USA). Zinc oxide and zinc acetate were used as 
references. 
5.2.11 Density and surface area 
5.2.11.1 Density 
When determining the density of solids, different densities can be distinguished in principle. Bulk density 
and particle density were measured within this work. While particle density determined by gas 
pycnometry already considers parts of the volume of the pores inside the individual particles, the bulk 
density also measures the volume of the voids formed in the powder bed. The bulk density is always 
lower than the particle density.  
The bulk density was determined using a 10 mL cylinder. 10 mL of the zinc oxide tetrapods or the zinc 
oxide were filled into the cylinder. The quotient of the difference between the measured mass and the 
empty mass and the volume resulted in the bulk density.  
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The particle density was determined with the helium gas pycnometer AkkuPyk (POROTEC GmbH, 
Germany). The volume of inert gas displaced by the sample is measured. It does measure the volume of 
open pores, as the gas can penetrate into the open pores, but it does not measure the volume of closed 
pores, as they are not accessible to the gas [153].  
Helium was used as inert gas because it has a high penetration capacity for small, open pores. The 
sample was filled in the measuring vessel and analysed in 10 cycles (zinc oxide) or 20 cycles (zinc oxide 
tetrapods). The mean value of these measurements was used as one measurement, i.e., these 
measurements were repeated two times to obtain a number of three repetitions for statistical evaluation. 
5.2.11.2 Surface area 
The specific surface area of a material can be determined by gas adsorption. A suitable method is the 
equation of Brunauer, Emmett and Teller (BET) with the assumption that the amount of adsorbed gas is 
proportional to the surface area of the sample. The BET theory was developed for the adsorption of N2 
molecules but can also be used for other inert gases. An alternative method for determining the surface 
area is inverse gas chromatography (iGC) which can easily measure BET isotherms at room temperature 
using organic probe molecules. The iGC is a chromatographic characterisation method which analyses 
the surface properties of solid materials. In contrast to gas chromatography, the stationary phase in iGC 
is packed with the unknown solid sample to be characterised and the mobile phase with known gas 
probe molecules is injected. To measure the retention time of the gas, a flame ionisation detector is 
used, which is based on the detection of ions formed during the flame combustion of organic solutes 
[210]. 
The sample was filled into a 30 cm pre-silanised glass column to provide the stationary phase. 
Depending on the expected surface area of the sample different diameters of the glass columns could 
be used. The column was pre-conditioned with helium carrier gas to remove any volatile contamination. 
The specific surface area of zinc oxide and the different zinc oxide tetrapods was determined with 
heptane using the iGC-SEA (inverse gas chromatography surface energy analyser, Surface Measurement 
System Ltd., UK). Heptane adsorption isotherms were measured at 303 K and 0 % relative humidity with 
a constant flow rate. The surface area (BET) was calculated from the corresponding heptane isotherms, 
within the partial pressure range of 5 % to 35 % P/P0 using the SEA analysis software (Surface 
Measurement System Ltd., UK). 
5.2.12 Size exclusion 
Two different methods of sieving were used to separate the zinc oxide tetrapods into different particle 
sizes: wet sieving and air jet sieving. 
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5.2.12.1 Wet sieving 
Two sieves (Retsch GmbH, Germany) with a diameter of 20 cm and different mesh sizes: 45 µm and 
75 µm were used for the wet sieving method. The zinc oxide tetrapods were placed on the sieve, which 
was then placed in a container with an ethanol-water mixture. With the help of a magnetic stirrer on top 
of the sieve, zinc oxide tetrapods smaller than the mesh size of the sieve could be separated at medium 
speed. Both the zinc oxide tetrapods on top of the sieve and those passing through the sieve were 
filtered, washed twice with water and then dried at 60 °C in a drying oven.  
5.2.12.2 Air jet sieving 
The method of air jet sieving was performed with the help of the Alpine Air Jet Sieve e200 LS (Hosokawa 
Alpine AG, Germany). The zinc oxide tetrapods were placed on a sieve. A rotating nozzle with a very 
narrow gap below the sieve ensured that the velocity of the compressed air flows at high speed through 
the sieve and the particles are dispersed at the lid. The individual zinc oxide tetrapods, which are smaller 
than the mesh size of the sieve, can pass through the sieve and were transported into the sample vessel 
by the negative pressure created by a hoover [211]. The three sieves used and the corresponding 
parameters can be seen in the following table (Table 5.7). 
Table 5.7. Parameters of the air jet sieving.  
Sieve Time Pressure 
20 µm 5 min 4,000 Pa 
32 µm 4 min 3,600 Pa 
90 µm 3 min 3,400 Pa 
5.2.13 Rheology 
Rheology is the science that deals with the flow behaviour and deformability of materials. The flow of 
materials can only be achieved if the internal resistance, which is created by the interaction of the 
molecules, is overcome. The theory can be described with the help of Newton’s law. 𝐹 is a force acting 
on the liquid layers, 𝐴 is the area of the liquid layer, 𝜂 is the dynamic viscosity of the liquid, 𝛥𝑣 is the 
difference of the velocity of the liquid layer and 𝛥𝑦 is the distance between the liquid layer under 
consideration and the lowest, stationary layer. The viscosity can therefore be calculated from the shear 
stress 𝜏 = 𝐹/𝐴 and the shear rate 𝐷 = 𝛥𝑣/𝛥𝑦. 












Mucus rheology without and with the nasal formulations was analysed using the Bohlin CVO 120 High 
Resolution rheometer (Bohlin Instruments, Germany) equipped with plate (40 mm diameter). Gap 
distance was fixed at 150 µm. Simulated nasal mucus [204,205] was prepared with simulated nasal fluid 
and 8 % mucin of porcine stomach type II. 20 mg of the sample were added to 500 µL of simulated nasal 
mucus and vortexed for 30 s. After letting the sample rest for 1 min 400 µL of the mixtures were added 
to the rheometer plate and the shear rate dependent viscosity was measured. Apparent viscosity 
measurement was carried out in the range of 1 s-1 to 100 s-1 at a temperature of 32 °C, which is the 
temperature in the nasal cavity during inhalation [212]. Mucus without the nasal formulations was 
handled in the same way. 
Rheology of water without and with the pulmonary formulations was analysed using the Bohlin CVO 120 
High Resolution rheometer equipped with plate (40 mm diameter). Gap distance was fixed at 400 µm. 
60 mg of the sample were added to 1,500 µL of water and vortexed for 30 s. After letting the sample 
rest for 1 min 750 µL of the mixtures were added to the rheometer plate and the shear rate dependent 
viscosity was measured. Apparent viscosity measurement was carried out in the range of 1 s-1 to  
100 s-1. Since these measurements were part of the release experiments, which were carried out at room 
temperature, the rheology of the pulmonary formulations was investigated at 25 °C. Water as reference 
without the pulmonary formulations was handled in the same way. 
Data were analysed with Excel using the resulted viscosity in a range of 60 s-1 to 100 s-1. 
5.3 In-vitro cell experiments 
In order to be able to predict the influence of the formulations in-vivo, various in-vitro cell experiments 
with different cell models were used.  
5.3.1 Calu-3 and RPMI2650 
To investigate pH changes in in-vitro cell experiments and toxicity, nasal formulations were tested with 
RPMI2650, nasal epithelial tumour cells, and pulmonary formulations were tested with Calu-3, 
pulmonary epithelial tumour cells. They were cultivated in a 75 cm2 cell culture flask containing 15 mL 
cell medium (10 % FBS). The media used for the in-vitro cell experiments with Calu-3 and RPMI2650 are 




Table 5.8. Composition of all media used for the in-vitro cell experiments with Calu-3 and RPMI2650.  
Medium Composition 
Medium (10 % FBS) 
Dulbecco’s Modified Eagle’s Medium – high glucose,  
w 4.5 g/L glucose, w L-glutamine, w sodium carbonate, 
w/o sodium pyruvate (Merck KGaA, Germany) 
+ 10 % fetal bovine serum (FBS) 
+ 1 % sodium pyruvate 
+ 1 % penicillin-streptomycin 
+ 1 % non-essential amino acids 
Medium (2 % FBS) 
Dulbecco’s Modified Eagle’s Medium – high glucose 
+ 2 % fetal bovine serum (FBS) 
+ 1 % sodium pyruvate 
+ 1 % penicillin-streptomycin 
+ 1 % non-essential amino acids 
Cell phosphate buffer (PBS) 
Dulbecco's Phosphate Buffered Saline, w/o Ca2+, w/o Mg2+ 
(Merck KGaA, Germany) 
Salt solution 
Hanks’ salt solution – w 0.35 g/L NaHCO3, w Ca2+, w Mg2+, 
w/o Phenol red (Merck KGaA, Germany) 
 
5.3.1.1 Cytotoxicity by MTT assay 
Cytotoxicity was determined using a MTT assay. Viability of cells was estimate after incubation with the 
formulations. 
 
Figure 5.16. Reaction equation for the MTT assay. The yellow tetrazolium salt (left) is going to be reduced to a violet 
crystalline formazan (right). 
This assay is based on the reduction of the yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide or MTT) to a violet crystalline formazan. This reduction is catalysed by the 
mitochondrial succinate dehydrogenase of the cells and can therefore only take place in metabolically 
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active cells. Depending on cell viability, the amount of dye formed varies and can be measured at a 
wavelength of 570 nm [213]. 
100 µL of RPMI2650 nasal epithelial cells (nasal formulations) or Calu-3 pulmonary epithelial cells 
(pulmonary formulations) were seeded in a 96-well plate (TC-plate 96 well, Standard, F, Sarstedt AG & 
Co. KG, Germany) at a density of 1 * 105 cells/mL. After 24 h incubation (HERAcell 150, Thermo Fisher 
Scientific Inc., USA) at 37 °C and 5 % CO2, the medium was removed and 100 µL fresh medium (2 % FBS) 
and 100 µL of different concentrations of the formulations in PBS were added to the cells. The used 
medium (10 % FBS) was replaced by fresh medium (2 % FBS), because the reduced amount of FBS 
guaranteed the survival of the cells but did not distort the experiment by an excessive nutrient content. 
The samples were used as suspensions at final concentrations of 0.005 mg/mL to 10 mg/mL. They were 
prior sonicated with a sonicator (SONOPLUS ultrasonic homogeniser HD 4100 in combination with the 
sonotrode TS 103, BANDELIN electronic GmbH & Co. KG, Germany) with an amplitude of 20 % for 30 s. 
100 µL PBS and 100 µL medium (2 % FBS) were used as negative control, 50 µL Triton-X (1 % in PBS) and 
100 µL medium as positive control. After 24 h the suspensions were removed and 100 µL fresh medium 
(2 % FBS) and 25 µL MTT (5 mg/mL in PBS) were added to the cells. After another 4 h in the incubator 
the MTT solution was removed gently and 100 µL SDS solution (10 % in dimethylformamide + water, 
1 + 1, pH 4.7) were used as lysis solution. The plate was analysed after 12 h with UV/Vis spectroscopy at 
570 nm (absorbance) and 650 nm (background) using a plate reader (FLUOstar Omega spectrometer). 
To calculate the data, first the difference between absorbance and background was calculated and then 
the corresponding viability could be determined using a two-point calibration over the positive and 
negative control. 
 
Figure 5.17. Schematic overview of the work flow of the MTT assay created with BioRender. 
5.3.1.2 pH and transepithelial electrical resistance 
In-vitro pH studies of the pulmonary formulations with Calu-3 cells were performed to get an idea of 
the behaviour of the cells after incubation with the formulations for 24 h in terms of pH changes.  
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200 µL of Calu-3 pulmonary epithelial cells were seeded at ThinCerts with 1 µm pore diameter at a 
density of 2.5 * 105 cell/mL. 1 mL medium (10 % FBS) was added to the 12-well plate and changed every 
2 days. This ensured that the cells received sufficient nutrients from the medium below the ThinCert and 
could develop an air-liquid interface. After 10 days, the cells and the 12-well plate were cleaned with salt 
solution twice, 1 mL salt solution was added to the well and 500 µL of the formulations were added to 
the cells. The formulation concentrations in salt solution were related to the performed toxicity 
experiment. The concentrations used are displayed in Table 5.9. 
Table 5.9. Used concentrations (= LD50) of zinc oxide and the pulmonary formulations. 
 ZnO F1 F2 F3 F4 F5 F6 
Concentration, 
mg/mL 
0.018 0.013  0.010  0.031  0.037 0.049  4.720  
 
The pH levels were monitored after 0.5 h, 1 h, 2 h, 4 h, 8 h and 24 h using a pH meter (Mettler Toledo 
SevenCompact Benchtop Meter with pH-electrode InLab Ultra-Micro-ISM). Before and after the 
experiments, the cells were visually inspected and transepithelial electrical resistance (TEER) was 
determined using EVOM (World Precision Instruments, USA) to check whether the cells showed a 
significant change in their viability or functionality of their tight junctions. 
 
Figure 5.18. Schematic overview of the in-vitro pH studies of the pulmonary formulations created with BioRender. 
5.3.2 Murine bone marrow-derived dendritic cells 
As the isolation of sufficient numbers of dendritic cells for ex-vivo studies is challenging and requires 
expertise, the immunological cell experiments were performed with the Vaccine Design and Delivery 
group of Prof. Camilla Foged at the University of Copenhagen. Murine bone marrow-derived dendritic 
cells (BMDC) were isolated and cultured according to the following protocol. The media used for the  




Table 5.10. Composition of all media used for the in-vitro cell experiments with BMDC. 
Medium Composition 
Complete RPMI 
Gibco RPMI 1640 Medium, GlutaMAX Supplement, 
w GlutaMAX, w/o sodium pyruvate (Thermo Fisher Scientific 
Inc., USA) 
+ 10 % fetal bovine serum (FBS) 
+ 1 % penicillin-streptomycin 
Lysis Buffer 
RBC Lysis Buffer (10 x) (BioLegend Inc., USA) diluted 1:10 with 
MilliQ water 
 
5.3.2.1 Isolation and cultivation of murine bone marrow-derived dendritic cells  
The legs of 10 weeks to 12 weeks old CF57BL/6N mice were largely freed from skin, muscle and fat using 
scissors and tweezers as well as ethanol (70 %). To obtain the bone marrow, the femur was separated 
from the tibia and opened on both sides using scissors. The bone marrow was rinsed out with 10 mL 
complete RPMI and collected in a petri dish. After destroying cell agglomerates by passing the cells 
repeatedly through a syringe with a needle, the cell suspension was filtered through a 40 µm filter. To 
lyse any red blood cells, 1 mL of lysis buffer was added to the cell pellet obtained after centrifugation 
for 5 min at 400 g. After 5 min, the lysis was stopped with complete RPMI and the suspension was 
centrifuged again with the same conditions. The resulting pellet was redispersed in complete RPMI and 
4.25 * 105 cells were added to a 175 cm2 tissue culture flask containing 30 mL complete RPMI and 
20 ng/mL recombinant murine GM-CSF (PeproTech Inc., USA). The cells were incubated for a total of 
10 days at 37 °C and 5 % CO2. After 3 days and 8 days, 30 mL complete RPMI supplemented with 
20 ng/mL recombinant murine GM-CSF were added, and the complete medium was changed once after 
day 6 by removing approximately 60 mL and adding 30 mL complete RPMI supplemented with 20 ng/mL 
recombinant murine GM-CSF. On day 10, the cells were harvested and 600 µL of a cell suspension were 
seeded in a 24-well plate (Cellstar 24-well plates, Greiner Bio One International GmbH, Austria) at a 
density of 1 * 106 cells/mL complete RPMI supplemented with 20 ng/mL recombinant murine GM-CSF.  
5.3.2.2 Cell activation experiment 
After incubating the cells for two hours at 37 °C and 5 % CO2, the immunological in-vitro cell 
experiments were started. Complete RPMI was used as negative control, 10 ng lipopolysaccharide (LPS) 
as positive control and 5 µg ovalbumin as antigen. Pulmonary formulation 2 was applied in three 
different concentrations: 50 µg, 25 µg and 10 µg. After 16 h to 18 h incubation at 37 °C and 5 % CO2, 
the samples were analysed using flow cytometry. Flow cytometry enables the counting and 
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characterisation of cells in a liquid flow. One of the main applications is fluorescence activated cell sorting 
(FACS), where fluorescent dyes are used to examine labelled cells. FACS is a method which allows sorting 
a heterogeneous sample of cells based on specific light scattering and fluorescence properties of each 
cell. The cell suspension is entrained in a liquid stream. A vibrating mechanism causes the cell stream to 
break up into individual droplets. Just before the stream breaks into droplets, the fluorescence properties 
of each cell are measured. An electric charge ring is placed at the exact point where the stream breaks 
into droplets. Based on the immediately preceding measurement of fluorescence intensity, a charge is 
placed on the ring and the opposite charge is trapped on the droplet as it breaks from the stream. The 
charged droplets fall into a container according to their charge due to the influence of an electrostatic 
deflection system [214].  
Fluorescence staining is based on the antigen-antibody reaction, whereby antibodies labelled with 
fluorescent dye are used for the analysis. The suspended and partially labelled cells are passing a focused 
laser beam with a suitable wavelength. The electrons of the fluorescent dye are lifted to a higher energy 
level with exact excitation. When the electrons fall to the original level, the dye fluoresces and can be 
detected. The resulting emitted photon concentration is proportional to the amount of bound antibody. 
A significant advantage is that several fluorescent dyes can be detected in parallel, since the dyes used 
are excited at a common wavelength but show different characteristic emission spectra [215].  
For analysing the immunological reaction and the expression of CD40, CD80, CD86 und MHC-II after 
16 h to 18 h incubation cells were incubated for 15 min with 0.0125 µg FVS510 (fixable viability stain 
510, BD Biosciences, Denmark) per well to discriminate viable from non-viable cells. After the treatment 
with Fc-block (BD Biosciences, Denmark) to ensure that solely antigen-specific binding can be observed 
the cells were stained with 1 µg anti-CD11c-BUV737 (HL3, BD Biosciences, Denmark), anti-CD40-PE (3.23, 
BD Biosciences, Denmark), anti-CD80-APC (16-10A1, BD Biosciences, Denmark), anti-CD86-FITC (GL1, 
BD Biosciences, Denmark) and anti-MHC-II-eF450 (M5/114.15.2, eBioscience, Thermo Fisher Scientific 
Inc., USA) per well. The fluorescent dye labelled samples were then measured using BD LSRFortessa  
(BD Corporation, USA) and FACSDiva software (BD Corporation, USA) and analysed using FlowJo 
software v 10 (Tree Star, USA). 
5.4 Statistics 
Various statistical methods were used to evaluate and present the data. Mean value and standard 
deviation were calculated according to Equation 5.4 and Equation 5.5, whereas ?̅? is representing the 
mean value, 𝑠 the standard deviation, 𝑛 the sample size and 𝑥 individual measured values. Results are 
expressed as mean value ± standard deviation (n > 2), mean value ± min/max (n = 2) or individual value 
(n = 1). In the diagrams, either the mean value and the standard deviation or min/max as positive and 
negative error bars are displayed or individual values without error bars. 
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Equation 5.4. for calculating the mean value. 







Equation 5.5. for calculating the standard deviation. 
𝑠 = √





The results include a t-test to compare the means of two samples. Prerequisites for performing a t-test 
are the normal distribution of a population, no differences in the variances and a sample size that is not 
too small. If equality of variance is assumed although the variances are not equal, a serious error can 
occur. However, due to the robustness of the t-test, it can be performed appropriately without the 
assumption of equality of variances, i.e., it should be checked beforehand whether the variances are 
equal. Most results were based on a sample size of three samples. Even though the sample size was 
included in the calculations, this aspect should be taken into account when looking at the diagrams and 
evaluations. Since the sample size was the same for the mean values studied, the following equation can 
be applied (Equation 5.6). The variables correspond to the definitions of the previous equations.  





𝑥𝐴̅̅ ̅ − 𝑥𝐵̅̅ ̅
?̅?
 
A t-test can be performed double- or one-sided. The t-test is performed in each case with a confidence 
interval of 95 % and a probability of error of 5 %. The t-value can be used to calculate the p-value, which 
is a statistical probability value. A p-value < 0.05 indicates a significant difference (*), a p-value < 0.01 
indicates a very significant difference (**) and a p-value < 0.001 indicates a highly significant 
difference (***). Excel was used to calculate the equality of variances (F-test) and the corresponding  
p-values (t-test). 
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6 Results and discussion 
6.1 Adsorption of proteins to different zinc oxides 
In April 2016, Antoine and colleagues published the results of their study investigating zinc oxide 
tetrapods for their immunoprotective properties against genital herpes [151]. Herpes simplex virus 2 
(HSV 2) can be transmitted not only through sexual contact, but also from mothers to newborns. The 
research group was able to show in in-vivo experiments with HSV 2-infected female mice that zinc oxide 
tetrapods could be used both to treat and prevent the infection.  
During the treatment of HSV 2-infected female mice, zinc oxide tetrapods acted as a biocide when 
applied vaginally. They suppressed the infection and also intercepted the viruses due to their high affinity 
to the zinc oxide tetrapods. Trapping the virus significantly and effectively reduced animal mortality. 
Furthermore, zinc oxide tetrapods showed great promise regarding immunisation and thus prevention 
of HSV 2 infection. HSV 2 virions bound to zinc oxide tetrapods were presented more effectively by 
antigen-presenting cells, thereby enhancing the T cell and antibody responses and thus suppressing 
reinfection, than HSV 2 virions alone. In addition, zinc oxide tetrapods were found to have strong 
adjuvant properties comparable to alum. 
Based on these positive results, the idea of using zinc oxide tetrapods as an alternative adjuvant for 
mucosal immunisation had emerged. In order to investigate whether the properties of zinc oxide 
tetrapods were related to the tetrapodial morphology or to zinc oxide itself, normal zinc oxide was also 
used for the experiments in addition to zinc oxide tetrapods. 
6.1.1 Morphology and particle size distribution 
Zinc oxide tetrapods were formed during flame transport synthesis in a muffle furnace as white to 
yellowish white powder. The zinc oxide tetrapods used were harvested at the top of the muffle furnace. 
In Figure 6.1 representative images of zinc oxide tetrapods derived from this process are shown. Image A 
shows the typical three-dimensional tetrapodial structure. All four arms of the tetrapods have the same 
length and the angles between the arms are almost identical. Image B shows the hexagonal shape of an 
individual arm of typical zinc oxide tetrapods. It can also be observed in these pictures that defects of 
the typical structure can occur during production and harvesting, e.g., different morphologies of an arm. 
These minimal differences and the production of completely different structures were possible during 
flame transport synthesis and post-processing.  
As already mentioned above, the zinc oxide tetrapods used were harvested at the top of the muffle 
furnace. The morphology is strongly dependent on the position of the material to be harvested. Each 
scientist develops his own technique and the individual varieties of zinc oxide tetrapods change 
according to the position harvested. Thus, other forms were harvested in addition to the typical 
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tetrapodial morphology. In Figure 6.2 some structures are shown that were found during the project 
with the scanning electron microscope. The structural diversity ranges from narrow and thick arms, 
through various structures of the arms to the complete loss of the tetrapodial structure.  
 
Figure 6.1. Representative scanning electron microscope images showing zinc oxide tetrapods with different 
magnifications. 
 
Figure 6.2. Representative scanning electron microscope images showing some different structures of zinc oxide 
tetrapods with different magnifications. 
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There are differences in morphology of the tetrapods and in particle size. The particle size of the zinc 
oxide tetrapods was measured by scanning electron microscopy based on the Feret diameter. With an 
average arm length of 47.0 µm ± 21.5 µm and a diameter of 81.4 µm ± 38.8 µm, the particle size of the 
zinc oxide tetrapods is highly variable. While the particles could not be classified regarding morphology, 
they could probably be classified with regard to particle size, by sieving. 
With the help of air jet sieving, the zinc oxide tetrapods were divided into different particle size classes 
through different sieves and different applied pressures. In Figure 6.3 representative images of zinc oxide 
tetrapods after air jet sieving are shown. Almost no tetrapodial structures are visible. The particle size 
was measured by scanning electron microscopy on the basis of the Feret diameter. On the sieve with a 
mesh size of 20 µm (A) the “zinc oxide tetrapods” have an average particle size of 31.2 µm ± 9.9 µm, on 
the sieve with a mesh size of 32 µm (B) they have an average particle size of 50.0 µm ± 14.6 µm and on 
the sieve with a mesh size of 90 µm (C) they have an average particle size of 86.1 µm ± 21.9 µm. 
 
Figure 6.3. Representative scanning electron microscope images showing zinc oxide tetrapods after air jet sieving. 
A) sieve: 20 µm, time: 5 min, pressure: 4,000 Pa; B) sieve: 32 µm, time: 4 min, pressure: 3,600 Pa; C) sieve: 90 µm, 
time: 3 min, pressure: 3,400 Pa. 
Air jet sieving led to the destruction of the tetrapodial structures due to its functional principle. Because 
of the high pressure of the air passing through the sieve, agglomerates can be destroyed on the lid and 
thus a separation into different particle sizes should be possible. The high mechanical stress destroyed 
the zinc oxide tetrapods, i.e., individual arms broke off. These arms can pass the sieve lengthwise. Hence, 
it was neither possible to achieve sieve fractions according to the sieve size nor to maintain the 
tetrapodial structure. For this reason, another gentler method was tested to classify the zinc oxide 
tetrapods: wet sieving.  
Wet sieving was performed in a liquid, in this case, in an ethanol-water mixture. In Figure 6.4 the sieve 
passage and the sieve residue are shown. After sieving, tetrapodial structures are visible. Nonetheless, a 
difference can be seen between the sieve passage containing less intact zinc oxide tetrapods, and sieve 
residue containing more intact zinc oxide tetrapods, and between the sieves with different mesh sizes. 
The particle size was measured by scanning electron microscopy on the basis of the Feret diameter. With 
a particle size of 68.9 µm ± 28.2 µm, the sieve residue of the sieve with the mesh size of 75 µm (B, right) 
shows the highest number of visible tetrapodial structures, followed by the sieve passage of the same 
Results and discussion 72 
72 
sieve (B, left) with a particle size of 55.8 µm ± 25.4 µm. The sieve residue of the sieve with the mesh size 
of 45 µm (A, right) shows less tetrapodial structures with a particle size of 60.9 µm ± 35.4 µm. Least 
tetrapodial structures are visible in the sieve passage of the same sieve (A, left) with 30.8 µm ± 15.7 µm. 
 
Figure 6.4. Representative scanning electron microscope images showing sieve passage (left) and sieve residue 
(right) of zinc oxide tetrapods after wet sieving. A) sieve: 45 µm; B) sieve: 75 µm. 
The ethanol-water mixture had lower surface tension compared to water and thus ensured that the zinc 
oxide tetrapods formed less agglomerates. Thus, the tetrapodial structure was retained despite the use 
of a magnetic stirrer which supported the passage of the particles through the sieve. Both the sieve 
passage and the residue had to be washed with water afterwards to remove ethanol sufficiently from 
the surface of the zinc oxide tetrapods. This should ensure that the reactivity of the oxygen vacancies 
was not additionally influenced by ethanol. The presence of the oxygen vacancies, their influence on the 
reactivity of the zinc oxide and their generation have been investigated for years [216]. The generation 
and the influence of oxygen defects on the adsorption of proteins is discussed in more detail in chapter 
6.1.2. Filtering, washing and drying of the zinc oxide tetrapods required a lot of work and time and 
resulted in a low yield. 
Neither by air jet sieving nor by wet sieving it was possible to divide the zinc oxide tetrapods into particle 
size classes while maintaining both their tetrapodial structure and sufficient yield. For the adsorption 
experiments, the zinc oxide tetrapods were therefore crushed with defined parameters to ensure the 
extent to which the tetrapodial structure influences the adsorption of proteins. A total of three different 
zinc oxide tetrapod qualities were used: zinc oxide tetrapods with a tetrapodial structure, short milled 
and long milled zinc oxide tetrapods. 
Zinc oxide can be produced by various methods as explained in chapter 4.2. It was not known which 
method was used to produce the zinc oxide used. The material used was a white to pale yellowish white 
powder. Figure 6.5 shows a representative image of zinc oxide. It can be seen that the used zinc oxide 
consists of needle-shaped particles in the nanometre range, whereby individual particles cannot be 
recognised. A closer look at the zinc oxide particles shows that miniature tetrapodial structures are 
sometimes also visible. 
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Figure 6.5. Representative scanning electron microscope image showing zinc oxide. 
The particle size distribution of the zinc oxide particles was determined by laser diffraction and is shown 
in Figure 6.6 with a logarithmic x-axis. The zinc oxide particles show an almost monomodal distribution. 
On closer inspection, it is noticeable that also particles in both the smaller and the larger particle size 
ranges are present. With an x10 of 4.03 µm ± 0.14 µm, an x50 of 9.17 µm ± 0.23 µm and an x90 of 
24.16 µm ± 4.67 µm, a span value of 2.19 ± 0.45 results.  
 
Figure 6.6. Particle size distribution using laser diffraction (HELOS) in combination with the RODOS module. n = 3, 
error bars = standard deviation.  
Contrary to the expectations of measurements with the scanning electron microscope, the zinc oxide 
particles had a particle size in the lower micrometre range and not in the nanometre range. Due to the 
small particle size and the resulting large surface area, the zinc oxide particles tended to form 
agglomerates. This could already be seen in the scanning electron microscope image. Based on this, it 
could be assumed that the used pressure of 3 bar to determine the particle size distribution with the 
RODOS module was not sufficient to destroy these agglomerates. This can be seen in the diagram, 
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showing a peak at higher particle sizes as well as a high span value of 2.19. An increase in pressure, 
which would have led to further destruction of the agglomerates, was not possible with the available 
measuring instrument. As already described, small tetrapodial structures had been detected in addition 
to the needle-shaped structures. The optical models of laser diffraction are based on spherical particles. 
For non-spherical particles a particle size distribution equivalent to the spherical one is obtained. Due to 
the morphology of the zinc oxide particles the particle size distribution can be distorted. Based on the 
two findings above, too low dispersion pressure and non-spherical shape, the particle size distribution 
determined by laser diffraction appears to be too large in relation to the individual zinc oxide particles 
seen in scanning electron microscope images.  
To ensure adsorption properties can be attributed to differences in tetrapodial morphology, XRPD had 
been carried out. The resulting diffraction pattern allows conclusions on the crystallinity of the sample, 
as well as on the identity, based on the unique diffraction pattern. 
 
Figure 6.7. Representative diffractograms of X-ray powder diffraction showing the degree of crystallinity of zinc 
oxide (ZnO, top) and zinc oxide tetrapods (ZnOT, bottom). n = 1. 
Figure 6.7 shows representative diffractograms of zinc oxide and the zinc oxide tetrapods. The sharp 
diffraction pattern shows that both zinc oxide tetrapods and zinc oxide are crystalline substances. When 
comparing the X-ray diffraction pattern of the zinc oxide tetrapods with the X-ray diffraction pattern of 
zinc oxide, it is noticed that they are identical. The different intensities merely indicate different sample 
weights and therefore different zinc oxide amounts. Measurements confirm that zinc oxide tetrapods 
consists of pure zinc oxide. 
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6.1.2 Adsorption 
Four different materials were investigated in the adsorption tests: zinc oxide, zinc oxide tetrapods, short 
milled and long milled zinc oxide tetrapods. Zinc oxide and zinc oxide tetrapods were studied to 
investigate whether the tetrapodial structure influences the adsorption of proteins. Milled zinc oxide 
tetrapods were used to compare different particle sizes. As discussed above, it was not feasible to classify 
the tetrapods while maintaining their structure. Hence, to compare different particle sizes nevertheless, 
zinc oxide tetrapods were milled for either a shorter (5 min) or a longer period (60 min). For these 
experiments, a ball mill was used. Like the zinc oxide tetrapods themselves, the milled zinc oxide 
tetrapods were prepared by the working group “Functional Nanomaterials” headed by Prof. Rainer 
Adelung.  
Figure 6.8 shows images of the zinc oxide (ZnO), zinc oxide tetrapods (ZnOT), short milled (ZnOT 5 min) 
and long milled (ZnOT 60 min) zinc oxide tetrapods as well as representative scanning electron 
microscope images of all materials. The same magnification was used for all materials to ensure 
comparability of the particle sizes. As it was not possible to determine particle size distribution with the 
same method for all materials, the particle size was not analysed.  
 
Figure 6.8. Representative scanning electron microscope images (bottom) and images of the dry powders (top) 
showing zinc oxide (ZnO), zinc oxide tetrapods (ZnOT), short milled (ZnOT 5 min) and long milled (ZnOT 60 min) 
zinc oxide tetrapods. 
First, the images of the dry powders are studied. Zinc oxide is a white to pale yellowish white compact 
powder with agglomerates. The zinc oxide tetrapods form a white to yellowish white powder. As the 
bulk density is very low due to the tetrapodial structure, the powder is rather fluffy. Even though the 
bulk density of the two materials is highly significantly different (ZnO = 0.596 g/cm3 ± 0.007 g/cm3, 
ZnOT = 0.023 g/cm3 ± 0.0002 g/cm3, p-value < 0.0001), the particle density of the zinc oxide tetrapods 
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with 4.98 g/cm3 ± 0.16 g/cm3 and of zinc oxide with 5.52 g/cm3 ± 0.04 g/cm3 hardly differs, although 
this difference is very significantly different with a p-value of 0.0050. The short milled zinc oxide 
tetrapods are a slightly yellowish powder and the long milled zinc oxide tetrapods are an ochre yellow 
powder. Both materials form a rather compact powder with agglomerates. 
The yellow colouring caused by the milling process can be explained by increasing oxygen vacancies 
during the milling process. Milling generated heat, which led to an increase in oxygen defects on the 
surface [217]. This phenomenon is not only observed with zinc oxide tetrapods, but also with zinc oxide. 
If zinc oxide gets in contact with a flame, its white colour turns into yellow. This yellow colour disappears 
after the zinc oxide is removed from the flame due to the saturation of the oxygen defects with oxygen 
from the environment. Oxygen defects are surface trapped holes which are caused by released oxygen. 
These defects narrow the band gap, which shifts the absorption into the visible violet area. The zinc oxide 
tetrapods or the zinc oxide therefore turn yellow. Oxygen vacancies could be measured with the help of 
Raman spectroscopy and X-ray photoelectron spectroscopy. As oxygen vacancies are charged defects, 
a change in material adsorption properties is possible [217]. Both a positive and a negative charge of 
the oxygen vacancies are described in literature [150,152]. 
In Figure 6.8 at the bottom, representative scanning electron microscope images of the materials are 
shown. Zinc oxide and zinc oxide tetrapods show the form described above. In the milled zinc oxide 
tetrapods almost no tetrapodial structure is visible. While in the short milled zinc oxide tetrapods 
individual arms of the zinc oxide trapods are still visible, in the long milled zinc oxide tetrapods no 
structures are visible reminding of the original morphology. The long milled zinc oxide tetrapods are 
slightly larger than zinc oxide and the short milled zinc oxide tetrapods are considerably larger. Due to 
their shape, zinc oxide tetrapods are many times larger than zinc oxide. 
For the adsorption tests, zinc oxide, zinc oxide tetrapods, short milled and long milled zinc oxide 
tetrapods as well as aluminium hydroxide and aluminium phosphate as references were used. Aluminium 
hydroxide is positively charged and served as a reference for binding negatively charged proteins and 
aluminium phosphate is negatively charged and served as a reference for binding positively charged 
proteins. The adsorption properties of the afore-mentioned materials were tested with five different 
proteins. Electrostatic interaction is often described as the primary adsorption mechanism between 
antigen and adjuvant [165]. Hence, two different protein groups with varying isoelectric points (IEP) were 
used. BSA (IEP = pH 4.9), OVA (IEP = pH 4.5) and alpha-lactalbumin (IEP = pH 4.4) are characterised by 
an isoelectric point in the acidic pH range and were negatively charged in the almost neutral pH range 
of water. They should therefore tend to electrostatic interactions with aluminium hydroxide. Avidin 
(IEP = pH 10.5) and lysozyme (IEP = pH 11.0) have isoelectric points in the basic pH range and were 
positively charged in the pH range used. They should therefore be prone to electrostatic interaction with 
aluminium phosphate. Besides the isoelectric point other factors, such as molecular weight, the use of 
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phosphate buffer or the size of the aluminium particles could also have an influence on the adsorption 
[165]. To take this crucial factor into account, the choice of model proteins was also based on their 
molecular weight. BSA and avidin have a molecular mass of 66 kDa, OVA has a molecular mass of 44 kDa 
and alpha-lactalbumin and lysozyme have a molecular mass of 14 kDa. 
In Figure 6.9 and Table 6.1 the results of the adsorption of proteins with an isoelectric point in the basic 
pH range on the above-mentioned zinc oxide, zinc oxide tetrapods, short milled and long milled zinc 
oxide tetrapods and the reference materials are shown. The adsorption studies on the materials with 
zinc oxide will be discussed in more detail below, the adsorption on the two reference substances 
aluminium hydroxide and aluminium phosphate is of particular interest in this diagram. In the adsorption 
studies, they were used to check whether the adsorption test has worked in principle. As already 
described, the proteins used in this experiment were positively charged and should therefore adsorb to 
aluminium phosphate due to the electrostatic interactions. With a binding of 
103.34 µg/mg ± 0.04 µg/mg (avidin) and 95.32 µg/mg ± 1.08 µg/mg (lysozyme), approximately 100 % 
of the used proteins adsorb to aluminium phosphate. As these two proteins served as positive control, 
the experiment is valid and the results can be used for further evaluation. 
 
Figure 6.9. Adsorption studies of proteins with an isoelectric point in the basic pH range (IEP avidin = pH 10.5, 
IEP lysozyme = pH 11.0) and zinc oxide (ZnO), zinc oxide tetrapods (ZnOT), short milled (ZnOT 5 min) and long 
milled (ZnOT 60 min) zinc oxide tetrapods, aluminium hydroxide and aluminium phosphate. n = 3, error 
bars = standard deviation, p-value < 0.001 = highly significant difference (***). 
If the adsorption is assumed to be based on electrostatic interactions, only a negligible part of the 
proteins should adsorb on aluminium hydroxide, which is positively charged like the proteins. With 
1.52 µg/mg ± 2.63 µg/mg, almost no lysozyme binds to aluminium hydroxide. With 
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83.91 µg/mg ± 0.48 µg/mg, however, a considerable part of the avidin adsorbs to aluminium hydroxide, 
even if the adsorbed amount is highly significantly different from the adsorbed amount of aluminium 
phosphate (p-value = 0.0002).  
Another mechanism than electrostatic interaction had to be responsible for this high adsorption. This 
other mechanism might be ligand exchange, which is also an important mechanism of adsorption. 
Ligand exchange leads to strong protein adsorption, it can occur even in the presence of a repulsive 
electrostatic force between antigens and aluminium salts. It is assumed that the ligands present in the 
proteins, e.g., phosphoryl groups [165], interact with the hydroxyl group in aluminium hydroxide. Avidin 
is being investigated in numerous studies because of its high ligand binding activity [218]. For a more 
detailed study of the adsorption mechanism of the proteins on the aluminium hydroxide, e.g., the 
amount of phosphorus per mole of protein could be determined. However, this is not part of the work. 
Adsorption to aluminium hydroxide is described as a stronger interaction than adsorption to aluminium 
phosphate and dependent on the molecular mass of the proteins. While aluminium phosphate has an 
amorphous structure, aluminium hydroxide is a crystal colloid gel. The resulting crystal form offers a 
uniform surface for the adsorption of proteins. In addition, it creates a kind of lattice structure, i.e., larger 
proteins are bound more strongly than proteins with a smaller molecular mass, comparable to a sieve. 
Particles smaller than the mesh size of the sieve could pass through the sieve and larger particles would 
be retained. Huang and Wang also described a linear relationship between molecular mass and 
adsorption. They investigated the adsorption of different proteins with different isoelectric points and 
molecular masses on aluminium hydroxide and aluminium phosphate [165]. In contrast to aluminium 
hydroxide, aluminium phosphate showed no correlation between the molecular mass of the proteins 
and the adsorption. 
In Figure 6.10 and Table 6.1 the results of the adsorption of proteins with an isoelectric point in the acidic 
pH range on the above-mentioned zinc oxide, zinc oxide tetrapods, short milled and long milled zinc 
oxide tetrapods and the reference materials are shown. The adsorption studies on the materials with 
zinc oxide will be discussed in more detail below, the adsorption on the two reference substances 
aluminium hydroxide and aluminium phosphate is of particular interest in this diagram. With an 
adsorbed amount of 95.10 µg/mg ± 10.90 µg/mg (BSA), 99.14 µg/mg ± 0.56 µg/mg (OVA) and 
96.50 µg/mg ± 0.56 µg/mg (alpha-lactalbumin), approximately 100 % of the used proteins bind on 
aluminium hydroxide. With 7.69 µg/mg ± 0.42 µg/mg (BSA), 3.46 µg/mg ± 0.88 µg/mg (OVA) and 
5.20 µg/mg ± 11.25 µg/mg (alpha-lactalbumin), almost no protein adsorbs to aluminium phosphate. 
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Figure 6.10. Adsorption studies of proteins with an isoelectric point in the acidic pH range (IEP BSA = pH 4.9, 
IEP OVA = pH 4.5, IEP alpha-lactalbumin = pH 4.4) and zinc oxide (ZnO), zinc oxide tetrapods (ZnOT), short milled 
(ZnOT 5 min) and long milled (ZnOT 60 min) zinc oxide tetrapods, aluminium hydroxide and aluminium phosphate. 
n = 3, error bars = standard deviation. 
Table 6.1. Summary of amounts being adsorbed to the test materials (proteins with an isoelectric point in the basic 
pH range (IEP avidin = pH 10.5, IEP lysozyme = pH 11.0) and in the acidic pH range (IEP BSA = pH 4.9, 
IEP OVA = pH 4.5, IEP alpha-lactalbumin = pH 4.4) and zinc oxide (ZnO), zinc oxide tetrapods (ZnOT), short milled 
(ZnOT 5 min) and long milled (ZnOT 60 min) zinc oxide tetrapods, aluminium hydroxide and aluminium phosphate. 
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The proteins used were negatively charged in the almost neutral pH range of water. Aluminium 
hydroxide was positively charged, so all proteins were able to build an electrostatic bond, and aluminium 
phosphate was negatively charged, so the negative charges repel each other and negligible adsorption 
can be observed. These results can be well explained by adsorption through electrostatic interactions.  
In the following section, the results of the adsorption of the proteins on zinc oxide, zinc oxide tetrapods, 
short milled and long milled zinc oxide tetrapods are discussed.  
Due to the different bulk density, shape and particle size of the materials, it was not easy to compare 
the adsorption of proteins, as the mass of the materials in this context was not a reliable reference value. 
To enable the comparison of all materials, the BET surface of the materials was determined by iGC. With 
a surface area of 0.3113 m2/g the short milled zinc oxide tetrapods show the lowest surface area, 
followed by the zinc oxide tetrapods with 0.3730 m2/g. This was contrary to the general expectation that 
the surface increases with milling. By analysing the milling process and the harvesting after the milling 
process of the material it became clear where this difference came from. While the zinc oxide tetrapods 
were not processed and all arms, however thin, were included in the surface measurement, the milled 
zinc oxide tetrapods had to be harvested from the ball mill at the end of the milling process. Due to the 
increased surface area of small fragments and the energy contribution, these components in particular 
could not be quantitatively removed from the ball mill. This led to a reduction of the surface, because 
the small fragments with the large surface area could not be detected in the measurement as they were 
remaining in the mill. The long milled zinc oxide tetrapods have a surface area of 1.0919 m2/g and zinc 
oxide has a surface area of 3.6609 m2/g.  
The surface areas of zinc oxide, zinc oxide tetrapods, short milled and long milled zinc oxide tetrapods 
and the molecular weights of the proteins were included in the calculations. The amount of adsorbed 
protein was calculated in mmol per m2 surface area. 
In Figure 6.11 and Table 6.2 the adsorbed amounts in mmol of BSA and avidin on a m2 surface area of 
zinc oxide and zinc oxide tetrapods are shown. The aim was to determine whether zinc oxide and the 
zinc oxide tetrapods were also able to adsorb proteins due to electrostatic interactions or whether there 
was no discernible trend with regard to the charge. BSA served as a negatively charged protein and 
avidin as a positively charged one. In the experiments with the aluminium hydroxide, avidin presumably 
also showed adsorption due to ligand exchange in addition to electrostatic interactions. Since the zinc 
oxide tetrapods and zinc oxide are only made of zinc oxide, avidin was nevertheless used as an example. 
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Figure 6.11. Adsorption studies of proteins with a molecular weight of 66 kDa and different isoelectric points 
(IEP BSA = pH 4.9, IEP avidin = pH 10.5) and zinc oxide (ZnO) and zinc oxide tetrapods (ZnOT). n = 3, error 
bars = standard deviation, p-value < 0.001 = highly significant difference (***). 
0.08 mmol/m2 ± 0.008 mmol/m2 BSA and 0.07 mmol/m2 ± 0.016 mmol/m2 avidin adsorb to zinc oxide. 
There is no significant difference. 0.07 mmol/m2 ± 0.034 mmol/m2 BSA and 
0.24 mmol/m2 ± 0.012 mmol/m2 avidin adsorb to the zinc oxide tetrapods. The binding of the positively 
charged avidin is therefore very significantly higher (p-value = 0.0005) than the binding of the negatively 
charged BSA. 
Table 6.2. Adsorption studies of proteins with a molecular weight of 66 kDa and different isoelectric points 
(IEP BSA = pH 4.9, IEP avidin = pH 10.5) and zinc oxide (ZnO) and zinc oxide tetrapods (ZnOT). n = 3, ± = standard 
deviation. 
 BSA, mmol/m2 Avidin, mmol/m2 
ZnO 0.08 ± 0.008 0.07 ± 0.016 
ZnOT 0.07 ± 0.034 0.24 ± 0.012 
 
While there is no difference in the adsorption of negatively and positively charged proteins in zinc oxide, 
zinc oxide tetrapods tend to adsorb positively charged proteins. In other words, zinc oxide tetrapods 
appears to be negatively charged under experimental conditions. Theoretically, this negative charge 
could be confirmed, e.g., with the help of the zeta potential or atomic force microscopy. Due to the 
special morphology of the zinc oxide tetrapods, the measurement of the zeta potential did not seem to 
make any sense, as in theory the potential is measured on the surface of a sphere. The measurement 
with the help of atomic force microscopy was also not possible because the cantilever, which is used to 
measure the charge on the surface, could not measure the surface charge of an intact zinc oxide tetrapod 
due to its tetrapodial structure. But it was already published in 2012 by Antoine and colleagues that the 
surface of zinc oxide tetrapods could also exhibit a negative charge [150]. Their paper addressed the 
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virus trapping ability of zinc oxide tetrapods when investigating their prophylactic, therapeutic and 
neutralising effects against herpes viruses. The negatively charged surface of the zinc oxide tetrapods 
generated during the synthesis was able to adsorb the positively charged virus. They also investigated 
the change of the surface by UV radiation. Zinc oxide tetrapods treated with UV radiation could increase 
the number of oxygen vacancies and thus increased the negative charge of the surface. During the 
photoreaction, photogenerated holes and electrons were produced. Oxygen at an oxygen lattice 
position absorbed two of these photogenerated holes and was released. This creates an oxygen vacancy, 
which is negatively charged due to the electrons created in the photoreaction [219]. Analogous to these 
experiments mentioned before, long milled zinc oxide tetrapods should adsorb more protein due to the 
higher number of oxygen defects and therefore the higher negative charge of the surface. Furthermore, 
they had the largest surface area of the zinc oxide tetrapods which in turn should lead to a further 
increase in adsorption.  
For zinc oxide, the adsorption capacity of all proteins and for the zinc oxide tetrapods, short milled and 
long milled zinc oxide tetrapods the adsorption capacity of proteins with an isoelectric point in the basic 
pH range was investigated.  
In Figure 6.12 and Table 6.3 the results of the adsorption of proteins with an isoelectric point in the basic 
pH range and different molecular weights on zinc oxide tetrapods, short milled and long milled zinc 
oxide tetrapods are shown. For avidin, the short milled zinc oxide tetrapods with 
0.33 mmol/m2 ± 0.021 mmol/m2 show the highest adsorption capacity and the long milled zinc oxide 
tetrapods with 0.11 mmol/m2 ± 0.012 mmol/m2 the lowest one. With 0.24 mmol/m2 ± 0.012 mmol/m2 
the zinc oxide tetrapods are very significantly (p-value = 0.0033) different from the short milled zinc 
oxide tetrapods and highly significantly (p-value = 0.0002) different from the long milled zinc oxide 
tetrapods. The difference between the two milled zinc oxide tetrapods is also highly significant with a  
p-value < 0.0001. 
A similar trend is observed for lysozyme. With 0.83 mmol/m2 ± 0.303 mmol/m2 the short milled zinc 
oxide tetrapods show the highest adsorption capacity, followed by the zinc oxide tetrapods with 
0.63 mmol/m2 ± 0.260 mmol/m2 and the lowest adsorption capacity is shown by the long milled zinc 
oxide tetrapods with 0.23 mmol/m2 ± 0.127 mmol/m2. However, the differences are not significant. 
The adsorption of the lysozyme with a molecular mass of 14 kDa is higher but not significantly higher 
than the adsorption of the avidin with a molecular mass of 66 kDa for all zinc oxide tetrapod variants. 
For simplification, explanation is just based on molecular weight. In this sense, more small lysozyme 
molecules can be placed on the same surface compared to avidin molecules, where one molecule 
occupies much more space due to its larger molecular weight.  
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Figure 6.12. Adsorption studies of proteins with an isoelectric point in the basic pH range and different molecular 
weight (avidin: IEP = pH 10.5, 66 kDa; lysozyme: IEP = pH 11, 14 kDa) and zinc oxide tetrapods (ZnOT), short milled 
(ZnOT 5 min) and long milled (ZnOT 60 min) zinc oxide tetrapods. n = 3, error bars = standard deviation,  
p-value < 0.01 = very significant difference (**), p-value < 0.001 = highly significant difference (***). 
Table 6.3. Adsorption studies of proteins with an isoelectric point in the basic pH range and different molecular 
weight (avidin: IEP = pH 10.5, 66 kDa; lysozyme: IEP = pH 11, 14 kDa) and zinc oxide tetrapods (ZnOT), short milled 
zinc oxides tetrapods (ZnOT 5 min) and long milled zinc oxide tetrapods (ZnOT 60 min). n = 3, ± = standard 
deviation. 
 Avidin, mmol/m2 Lysozyme, mmol/m2 
ZnOT 0.24 ± 0.012 0.63 ± 0.260 
ZnOT 5 min 0.33 ± 0.021 0.83 ± 0.303 
ZnOT 60 min 0.11 ± 0.012 0.23 ± 0.127 
 
Contrary to expectations, the short milled zinc oxide tetrapods with the smallest surface area and the 
medium number of oxygen defects showed the highest adsorption capacity and the long milled zinc 
oxide tetrapods with the largest surface area and the highest number of oxygen defects the lowest one. 
While the surface area had already been included in the calculations and therefore all materials should 
show the same adsorption, only the number of oxygen vacancies should show an influence on 
adsorption. If the zinc oxide tetrapods and the short milled zinc oxide tetrapods are considered, the 
increase in adsorption of the short milled zinc oxide tetrapods can be explained by the increase in the 
number of oxygen defects compared to the unmilled material. A further increase would be expected for 
the long milled zinc oxide tetrapods. However, the long milled zinc oxide tetrapods show the lowest 
adsorption.  
A possible explanation could be the measured surface area, which was larger than for the short milled 
zinc oxide tetrapods and zinc oxide tetrapods. As a result, the nominator in the calculation of the 
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adsorbed amount was larger and thus the result in mmol/m2 would be smaller. If it is assumed that 
adsorption and surface area increase proportionally, however, this should not make any difference 
compared to the short milled zinc oxide tetrapods and the zinc oxide tetrapods. If the long milled zinc 
oxide tetrapods were suspended in water, the individual smaller particles formed agglomerates due to 
the larger surface area and the entire surface area was not available for adsorption of the protein. The 
real surface available in the experiment was therefore smaller than the measured surface and the 
calculated value for the adsorbed protein amount was accordingly too low as the nominator, which was 
the surface area, was too high. 
Another possible explanation for the lower-than-expected adsorption of the long milled zinc oxide 
tetrapods could be the nature of the surface. While the surfaces of the zinc oxide tetrapods and the 
short milled zinc oxide tetrapods were uniformly formed by the existing arms of the zinc oxide tetrapods, 
whether in the form of a tetrapod or individually, the long milled zinc oxide tetrapods formed an irregular 
surface due to the formation of agglomerates. As a result, an organised and uniform adsorption of the 
proteins was not possible resulting in a decrease of adsorbed proteins.  
 
Figure 6.13. Adsorption studies of all proteins with different molecular weight and different isoelectric points 
(BSA: IEP = pH 4.9, 66 kDa; OVA: IEP = pH 4.5, 44 kDa; alpha-lactalbumin: IEP = pH 4.4, 14 kDa; 
avidin: IEP = pH 10.5, 66 kDa; lysozyme: IEP = pH 11, 14 kDa) and zinc oxide. n = 3, error bars = standard deviation, 
p-value < 0.05 = significant difference (*), p-value < 0.01 = very significant difference (**). 
In Figure 6.13 and Table 6.4 the results of the adsorption of all proteins with different isoelectric points 
and different molecular weights on zinc oxide are shown. With 0.20 mmol/m2 ± 0.043 mmol/m2 the 
adsorption of alpha-lactalbumin is very significantly higher than the adsorption of BSA 
(0.09 mmol/m2 ± 0.008 mmol/m2, p-value = 0.0059) and significantly higher than OVA 
(0.07 mmol/m2 ± 0.005 mmol/m2, p-value = 0.0199). Lysozyme shows a very significantly higher 
adsorption with 0.21 mmol/m2 ± 0.038 mmol/m2 than avidin with 0.07 mmol/m2 ± 0.016 mmol/m2  
(p-value = 0.0020).  
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Like zinc oxide tetrapods and milled zinc oxide tetrapods, the proteins with the low molecular weight of 
14 kDa (alpha-lactalbumin and lysozyme) show higher adsorption than the proteins with higher 
molecular weights. OVA shows no significant difference to BSA in adsorption on zinc oxide. These results 
lead to the assumption that there is an upper limit to the loading of zinc oxide particles in terms of 
molecular weight similar to aluminium phosphate in the study of Huang and Wang, where aluminium 
phosphate showed no correlation between the molecular weight of the proteins and the adsorption 
[165]. In order to confirm this hypothesis, further experiments with other proteins with different 
molecular weights have to be performed but this is not part of this work. 
Table 6.4. Adsorption studies of all proteins with different molecular weight and different isoelectric points 
(BSA: IEP = pH 4.9, 66 kDa; OVA: IEP = pH 4.5, 44 kDa; alpha-lactalbumin: IEP = pH 4.4, 14 kDa; 
























There was no clear difference between the proteins with varying isoelectric points, i.e., the adsorption of 
the proteins was not only due to electrostatic interactions. Like many other metal oxides, zinc oxide is 
hydrolysed in the presence of water and forms hydroxide layers on the surface. Water molecules are 
physically or chemically adsorbed on the surface of the dispersed zinc oxide. Due to their amphoteric 
character, the surface can be either positively charged by the reaction with H+ ions or negatively charged 
by the reaction with OH- ions [220]. The adsorption of the proteins could be described by formation of 
hydrogen bonds or van der Waals forces [221]. The strengths of these two bonds are far below the 
strength of covalent bonds or electrostatic interactions. Hydrogen bonds are formed between a bound 
hydrogen atom and a free electron pair. The hydrogen atom is bound to small, very electronegative 
atoms. This hydrogen atom and a pair of electrons on the electronegative atom of another molecule 
attract each other and form a hydrogen bond [222]. They also occur, e.g., as weak bonds in proteins and 
thus lead to the formation of the secondary structure of proteins [223]. Van der Waals forces are 
intermolecular forces like the hydrogen bonds just described. The electron cloud of a molecule can be 
deformed at a certain point in time due to the movement of the electrons. As a result, one side of the 
molecule is temporarily more negatively charged than the other, but the orientation of the dipole will 
already be changed again the next moment. The dipole development takes place synchronously in 
neighbouring molecules, which ultimately leads to an attraction of the current dipoles [222]. 
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6.1.3 Summary and conclusion 
Zinc oxide tetrapods were produced using flame transport synthesis, resulting in a three-dimensional 
tetrapodial structure with the same arm length within a tetrapod and equal angles between these arms. 
The tetrapods showed large differences in particle size and the morphology was strongly dependent on 
the harvested position. The separation into defined particle sizes was neither successful with the help of 
air jet sieving nor with the help of wet sieving, because either almost no tetrapodial structure remained 
or a high work and time effort was necessary, which resulted in a low yield. Therefore, the zinc oxide 
tetrapods were crushed with defined parameters. Three different types of zinc oxide tetrapods could be 
used for adsorption: zinc oxide tetrapods, short milled and long milled zinc oxide tetrapods.  
Zinc oxide can be produced using various processes and had been used in commercial quality. The zinc 
oxide used showed small needle-shaped particles with a resulting large surface area and a tendency to 
form agglomerates.  
Both materials, i.e., the zinc oxide tetrapods and the zinc oxide, were crystalline substances consisting of 
zinc oxide. The adsorption experiments investigated to what extent the production method, shape and 
particle size had an influence on the adsorption of different proteins.  
Five different proteins with varying isoelectric points and different molecular weights were tested for 
their adsorption on the materials consisting of zinc oxide: BSA, OVA, alpha-lactalbumin, avidin and 
lysozyme. Aluminium hydroxide was used as a reference for adsorption of negatively charged proteins, 
and aluminium phosphate as a reference for adsorption of positively charged proteins. 
Zinc oxide and the zinc oxide tetrapods showed the structure just described. Almost no tetrapodial 
structure was visible in the milled zinc oxide tetrapods. Individual arms of the tetrapods were still visible 
in the short milled zinc oxide tetrapods. Long milled zinc oxide tetrapods showed no structure reminding 
of the original morphology. The BET surface determined by iGC increased in the following order: short 
milled zinc oxide tetrapods < zinc oxide tetrapods < long milled zinc oxide tetrapods < zinc oxide. 
In a comparison of the adsorption of avidin and BSA on zinc oxide and the zinc oxide tetrapods, zinc 
oxide showed no difference in the adsorption of negatively and positively charged proteins. The zinc 
oxide tetrapods adsorbed very significantly higher amounts of positively charged proteins. Therefore, 
the following experiments investigated the adsorption capacity of all proteins on zinc oxide and the 
adsorption capacity of proteins with an isoelectric point in the basic pH range on the zinc oxide tetrapods 
and the milled zinc oxide tetrapods. The molecular weight of the proteins and the surface area of the 
zinc oxide, the zinc oxide tetrapods and the milled zinc oxide tetrapods were included in the calculation 
of the adsorption. This calculation resulted in the unit mmol/m2 for the adsorption capacity. 
For the zinc oxide tetrapods and the milled zinc oxide tetrapods, short milled zinc oxide tetrapods 
showed the highest adsorption capacity for avidin and lysozyme. The uniformly formed surface, as in the 
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case of the arms of the zinc oxide tetrapods, and the increase in the number of oxygen defects, as in the 
case of the long milled zinc oxide tetrapods, resulted in the optimum adsorption of positively charged 
proteins on short milled zinc oxide tetrapods. Lysozyme showed higher adsorption than avidin. As the 
calculation of the adsorption capacity included the molecular weight, it indicated a higher loading due 
to a smaller particle size. 
Similar to the zinc oxide tetrapods and milled zinc oxide tetrapods, zinc oxide also showed a higher 
adsorption of smaller proteins due to numerically higher loading. However, as already mentioned, there 
was no difference between the proteins with varying isoelectric points.  
A comparison of the zinc oxide tetrapods with the zinc oxide revealed a clear difference with regard to 
the adsorption of proteins. While the zinc oxide tetrapods were able to adsorb mainly positively charged 
proteins due to their negatively charged surface, there was no discernible difference in the case of zinc 
oxide. The assumption was that the difference in adsorption was related to the production method. Zinc 
oxide tetrapods and the milled zinc oxide tetrapods were then investigated only with the positively 
charged proteins and the adsorption capacity of zinc oxide with all the proteins used. A clear advantage 
of the short milled zinc oxide tetrapods and the small proteins was found in the investigations. 
Comparing the adsorption capacity of long milled zinc oxide tetrapods in relation to avidin and 
lysozymes with the adsorption capacity of zinc oxide in relation to avidin and lysozymes, almost no 
difference is recognisable. This weakened the assumption made at the beginning that the difference in 
adsorption was due to the production method and strengthens the idea that the tetrapodial structure 
in particular would be a decisive factor in increasing the adsorption capacity.  
In conclusion, it was probably a combination of production method, shape and particle size that gave 
the best adsorption capacity results for the short milled zinc oxide tetrapods.  
The adsorption capacities of the zinc oxide tetrapods, short milled and long milled zinc oxide tetrapods 
and zinc oxide were far below the adsorption capacity of the reference materials aluminium hydroxide 
and aluminium phosphate. Finally, the question would be whether the adsorbed amount of protein or, 
in the case of vaccination of an antigen, might even be sufficient to induce an immune reaction. However, 
since it was difficult to make a general prediction about the required adsorbed amount of protein or 
antigen, the adsorbed amount of protein of aluminium hydroxide and aluminium phosphate was 
considered as a reference value. For this reason, a method was sought for increasing the protein loading. 
In order to achieve maximum protein loading, the protein was spray dried in the following together with 
zinc oxide and other excipients in a formulation. Due to the varying morphology, particle size and 
properties of the zinc oxide tetrapods and the milled zinc oxide tetrapods, they were not considered in 
the further investigations. 
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6.2 Spray dried zinc oxide formulations 
Spray drying is a very fast drying method where large amounts of solvents can be dried. It is widely used 
in the food and pharmaceutical industry, e.g., as production method for dry powders for inhalation. With 
different process parameters it was possible to spray dry large particles (> 10µm) for nasal application 
as well as small particles (< 5 µm) for pulmonary application.  
6.2.1 Spray dried zinc oxide for nasal application 
Zinc oxide is already used in various areas. Due to its small particle size in the nanometre range and the 
associated larger surface area, zinc oxide particles tend to form undefined agglomerates. By spray drying, 
it is possible to produce particles with a defined particle size > 10 µm for nasal application. Since the 
aim of the work is to use zinc oxide as an alternative adjuvant in a formulation, it was spray dried together 
with hyaluronic acid, ovalbumin and mannitol. Acetic acid (2 %) was used as liquid medium.  
The six spray dried formulations are all white dry powders independent of the different compositions. 
They were characterised in a pharmaceutical view and finally examined for their properties in in-vitro cell 
experiments. Besides the assessment of morphology, particle size distribution and aerodynamic 
behaviour, 24-h-solubulity studies, mucus rheology and various protein characterisation methods were 
carried out. 
6.2.1.1 Morphology and particle size distribution 
Six different formulations with different concentrations of zinc oxide and mannitol as mentioned in 
Table 5.1 were spray dried. The amount of ovalbumin, as model antigen, and hyaluronic acid, as 
penetration enhancer and adhesive between the single zinc oxide particles, remained constant. The 
formulations were visualised with scanning electron microscopy.  
Figure 6.14 shows representative images of the six different formulations in two different magnifications, 
whereby image A shows formulation 1 with the highest amount of zinc oxide (100 %) and image F shows 
formulation 6 without zinc oxide (0 %). From formulation 1 to formulation 6 the zinc oxide concentration 
decreases and the mannitol concentration increases. The images show wide particle size distributions, 
as both small and large particles are visible in the smaller magnification (right). Nevertheless, it is 
noticeable that all formulations seem to have a similar mean diameter, visible in the higher magnification 
(left). The cut-off diameter for nasal application is 10 µm. Particles larger than 10 µm [102] (aerodynamic 
diameter) are deposited in the nose. Particles smaller than 10 µm are separated in the throat. Particles 
smaller than 5 µm [109] (aerodynamic diameter) can be inhaled into the lungs. 
While almost no difference in particle size was visible, there is a difference in morphology. Formulation 6 
(Figure 6.14, image F) and formulation 1 (Figure 6.14, image A) show the typical uniform spherical shape 
[191] of a spray dried powder. The surface of these formulations however is slightly different. While 
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particles of formulation 6 show a smooth surface, particles of formulation 1 are slightly indented. All the 
other formulations have clearly wrinkled particles (Figure 6.14, images B to E). The different morphology 
can be explained by the particle forming process.  
The initially high amounts of solvent in the drop are removed at the beginning of the drying process. 
The drop becomes smaller and the concentration of dissolved or suspended components increases. As 
long as the surface of the drop is covered with solvent, both the drying speed and the temperature on 
the surface of the drop are constant. As drying progresses, the saturation solubility is exceeded. Shell 
formation occurs due to the concentrated solids on the surface. At the beginning of the shell forming 
process the solvent molecules inside the particle diffuse through the shell and evaporate. The drying 
speed becomes slower and slower. The diameter of the particle does not decrease further [191]. The 
temperature in the particle therefore continues to rise, as finally the solvent cannot evaporate further. 
As a result, the internal pressure also continues to rise. On the one hand, this leads to a stabilisation of 
the spherical form, on the other hand, the solvent vapour is pressed through small pores. As the process 
continues, the solvent inside the particle condenses, which leads to an enormous reduction in volume. 
The applied vacuum can cause the particles shell to collapse [224]. 
Mannitol was initially dissolved in the drop produced by the two-fluid nozzle. Due to the evaporation of 
the solvent on the surface, the particle initially became smaller and the mannitol concentration on the 
surface of the drop increased. When the saturation concentration was exceeded, mannitol precipitated 
and a shell was formed. The particle no longer changed its size. Due to the low glass transition point 
(approximately 10 °C) [225] and the low outlet temperature, a crystalline, uniform and smooth particle 
was formed. The solvent vapour inside the particles could not diffuse though the shell, which increased 
the pressure. However, as the lower outlet temperature caused the pressure inside the particle to 
increase only slightly and then decrease only slightly in the further process, the particle did not collapse. 
Small holes could be formed to release the solvent vapour. 
Since acetic acid (2 %) was used as solvent, zinc oxide was initially partially dissolved and partially 
suspended in the drop produced by the two-fluid nozzle. By removing the solvent, an outer layer of the 
individual zinc oxide particles was formed. These were combined into a shell by the precipitation of the 
dissolved zinc oxide in acetic acid (2 %) as zinc acetate. A crystalline, uniform, almost spherical particle 
was formed whose matrix consisted of individual zinc oxide particles in combination with zinc acetate. 
This allowed the solvent vapour inside the particle to diffuse though the shell and they retained their 
shape.  
When mannitol and zinc oxide were processed together as a matrix, mannitol and zinc oxide were 
partially dissolved and a part of zinc oxide was suspended. The drying of the solvent led to a higher 
concentration of a mixture of mannitol, zinc oxide and the dissolved zinc oxide on the surface of the 
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drop. Crystalline and spherical particles were formed. As this was a suspension, the shell was formed 
more quickly than in a solution. The solvent vapour inside the particles, which was now exposed to higher 
temperatures, created a higher pressure. When the solvent vapour condensed, decreasing volume 
created a vacuum and the shell collapsed.  
The different compositions are clearly visible in the SEM images. The colour of the particles becomes 
darker and darker with the appropriate setting of contrast and brightness, starting with formulation 1 
(Figure 6.14, image A). Small particles and areas in a lighter grey represent zinc oxide particles and areas 
in a darker grey represent mannitol. 
 
Figure 6.14. Representative scanning electron microscope images showing all spray dried powders with different 
amounts of zinc oxide (ZnO) and mannitol and additionally constant concentrations of ovalbumin (10 %) and 
hyaluronic acid (1 %). A) 100 % ZnO and 0 % mannitol; B) 80 % ZnO and 20 % mannitol; C) 60 % ZnO and 
40 % mannitol; D) 40 % ZnO and 60 % mannitol; E) 20 % ZnO and 80 % mannitol; F) 0 % ZnO and 100 % mannitol. 
To make sure that the different compositions of the spray dried particles were not just a visual impression 
but based on the actual composition of the formulation, an elemental analysis was performed. Energy 
dispersive X-ray spectroscopy was the method of choice for the detection of elements in the scanning 
electron microscope. An electron beam was used to excite the samples to emit X-rays. This enabled the 
detection of substance quantities of less than 0.1 pg [194].  
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In Figure 6.15 the atomic concentrations of the four most significant contained elements: zinc (Zn), 
oxygen (O), carbon (C) and nitrogen (N) are plotted against the individual formulations. Hydrogen 
(atomic number too low) and sulfur (concentration too low) were not considered because the detection 
is too unspecific. Table 6.5 contains the corresponding numerical values. As can be seen very clearly in 
the diagram (Figure 6.15), there are differences in the composition of the formulations. While the atomic 
zinc concentration decreases with increasing number of formulation (F1 = 35.34 % ± 2.89 %, 
F2 = 28.87 % ± 2.26 %, F3 = 20.34 % ± 1.88 %, F4 = 21.33 % ± 1.71 %, F5 = 16.41 % ± 6.65 %, 
F6 = 0.03 % ± 0.03 %), the atomic carbon concentration increases (F1 = 4.72 % ± 1.17 %, 
F2 = 7.12 % ± 1.63 %, F3 = 15.84 % ± 3.05 %, F4 = 20.62 % ± 2.18 %, F5 = 28.57 % ± 1.91 %, 
F6 = 48.92 % ± 0.97 %). This can be explained by the different amounts of the starting materials and 
their atomic composition. The matrix of formulation 1 consists of 100 % zinc oxide, which contains the 
atomic elements zinc and oxygen, and the matrix of formulation 6 consists of 100 % mannitol, which 
contains the atomic elements carbon and oxygen. From formulation 1 to formulation 6 the zinc oxide 
concentration and thus also the atomic zinc concentration decreases. In formulation 1, a not 
inconsiderable amount of carbon (F1 = 4.72 % ± 1.17 %) can be seen, even if no mannitol is present. 
This can be explained by the other components, ovalbumin and hyaluronic acid, because they also 
contain the element carbon. Additionally, they have the elements oxygen and nitrogen. Since oxygen is 
present in all starting materials, the atomic concentration of oxygen is similar in all formulations 
(F1 = 59.64 % ± 3.70 %, F2 = 63.64 % ± 1.83 %, F3 = 62.72 % ± 1.03 %, F4 = 56.55 % ± 4.34 %, 
F5 = 52.77 % ± 4.36 %, F6 = 46.27 % ± 0.78 %).  
 
Figure 6.15. Elemental identification of all formulations with energy-dispersive X-ray spectroscopy. 1) 100 % ZnO 
and 0 % mannitol; 2) 80 % ZnO and 20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 
60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard 
deviation. 
The concentrations of ovalbumin and hyaluronic acid, the two ingredients that contain nitrogen, are 
identical in all formulations. Nonetheless, the concentration of nitrogen in the particles increases with 
increasing amount of mannitol and decreasing amount of zinc oxide, which is remarkable. When 
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evaluating the results, it should be considered that a quantitative analysis of elements with low atomic 
numbers is problematic and only possible with an atomic number higher than four [226]. Carbon has an 
atomic number of six, nitrogen of seven, oxygen of eight and zinc of 30. The quantitative elemental 
analysis of zinc is therefore more precise due to the higher atomic number. Thus, a higher concentration 
of zinc oxide in the formulation interferes with the detection of the other elements, especially if they are 
present in low atomic concentration. The increasing amount of nitrogen with increasing formulation 
number could be the result of a measurement problem in the method. Further variations of the 
measurements could be caused by the measuring principle. For optimal detection the surface should be 
smooth. Since the formulations were wrinkled spheres, elemental analysis using EDS should only be used 
to get a first idea of the composition. An absolute statement was not possible. 
Table 6.5. Atomic concentration in % of all formulations using energy dispersive X-ray spectroscopy. F1) 100 % ZnO 
and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 
60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 
 N, % C, % O, % Zn, % 
F1 0.30 ± 0.17 4.72 ± 1.17 59.64 ± 3.70 35.34 ± 2.89 
F2 0.38 ± 0.14 7.12 ± 1.63 63.64 ± 1.83 28.87 ± 2.26 
F3 1.10 ± 1.09 15.84 ± 3.05 62.72 ± 1.03 20.34 ± 1.88 
F4 1.50 ± 0.79 20.62 ± 2.18 56.55 ± 4.34 21.33 ± 1.71 
F5 2.25 ± 1.11 28.57 ± 1.91 52.77 ± 4.36 16.41 ± 6.65 
F6 4.77 ± 0.31 48.92 ± 0.97 46.27 ± 0.78 0.03 ± 0.03 
 
As already mentioned, particle size or particle size distribution plays an important role in nasal 
application. For nasal spray products, the FDA requires a particle size larger than 10 µm (aerodynamic 
diameter) for most of the particles. For nasal dry powders, Hickey [58,102] recommends a particle size 
of 50 µm (aerodynamic diameter) to ensure deposition in the nose. The particle size distribution of all 
formulations was determined by laser diffraction (volume-based diameter). 
In Figure 6.16 and Table 6.6, the x50 and the span values from the measurements with the RODOS 
module of all formulations are shown. With an x50 of 8.75 µm ± 0.13 µm (F1), 7.85 µm ± 0.57 µm (F2), 
8.67 µm ± 0.29 µm (F5) and 7.13 µm ± 0.34 µm (F6), 50 % of the particles of formulations 1, 2, 5 and 6 
are smaller than 10 µm. With 10.56 µm ± 0.15 µm (F3) and 12.59 µm (F4) the x50 of formulations 3 and 
4 is higher than 10 µm. 
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Figure 6.16. Particle size distribution using laser diffraction (HELOS) in combination with the RODOS module,  
x50 (primary axis) and span (secondary axis) of all formulations; 1) 100 % ZnO and 0 % mannitol; 2) 80 % ZnO and 
20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 
6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation; F3 RODOS: n = 2, error bars = min/max;  
F4 RODOS: n = 1. 
The span value describes the distribution width and is especially useful, when the distribution is not 
normally distributed. Spray drying is a fast process with a resulting logarithmic normally particle size 
distribution. In the logarithmic graph (x-axis), the curves of formulations 1, 2, 5 and 6 showed a 
monomodal distribution with a small shoulder in the direction of the smaller particle sizes. 
Formulations 3 and 4 had a bimodal distribution with a second smaller peak at larger particle sizes, which 
could be generated from potential agglomerations. This is also reflected in the span values of 
formulation 3 with 1.94 ± 0.20 and especially of formulation 4 with 3.49. As it was not possible to 
measure formulations 3 and 4 three times, no statistical analysis of the data was performed. 
Table 6.6. x10, x50, x90 and span of all formulations using the HELOS in combination with the RODOS module. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard 
deviation; F3: n = 2, ± = min/max; F4: n = 1. 
 x10, µm x50, µm x90, µm Span 
F1 3.23 ± 0.08 8.75 ± 0.13 16.02 ± 0.23 1.46 ± 0.01 
F2 2.09 ± 0.22 7.85 ± 0.57 15.90 ± 0.40 1.76 ± 0.11 
F3 3.77 ± 0.02 10.56 ± 0.15 24.27 ± 2.38 1.94 ± 0.20 
F4 3.49 12.59 47.42 3.49 
F5 2.84 ± 0.12 8.67 ± 0.29 17.95 ± 0.88 1.74 ± 0.10 
F6 1.58 ± 0.08 7.13 ± 0.34 14.71 ± 0.41 1.84 ± 2.25 
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Figure 6.17. Particle size distribution using laser diffraction (HELOS) in combination with the SRAYER module 
(> 10 µm) and the UDS powder device, cumulative distribution of all formulations; 1) 100 % ZnO and 0 % mannitol; 
2) 80 % ZnO and 20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 
80 % mannitol; 6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
In Figure 6.17 and Table 6.7, the results of the measurements with the SPRAYER module in combination 
with the UDS powder device are shown. Since only the device contributed to the dispersion, the HELOS 
with the SPRAYER module rather provided data about the realistic particle size distribution than the 
HELOS with the RODOS module. Nevertheless, a similar trend can be seen. Illustrated is the cumulative 
distribution of particles larger than 10 µm (volume-based diameter). Formulations 3 and 4 also show the 
highest values with 93.65 % ± 1.94 % and 93.59 % ± 2.31 % of particles larger than 10 µm. For 
Formulations 1, 2 and 5 more than 50 % (F1 = 62.77 % ± 3.83 %, F2 = 57.42 % ± 5.60 %, 
F5 = 72.43 % ± 3.20 %) of the particles are larger than 10 µm and for formulation 6 almost 50 % 
(F6 = 49.49 % ± 9.11 %). The amount of particles larger than 10 µm in formulation 3 is very significantly 
different to formulation 6 (p-value = 0.0012) and highly significantly different to formulations 1  
(p-value = 0.0002), 2 (p-value = 0.0005) and 5 (p-value = 0.0006). Formulation 4 has a very significantly 
different percentage of particles above 10 µm than formulation 6 (p-value = 0.0012) and a highly 
significantly different percentage than formulations 1 (p-value = 0.0003), 2 (p-value = 0.0005) and 5  
(p-value = 0.007). Formulation 5 shows a significant difference to formulations 1 (p-value = 0.0284), 2 
(p-value = 0.0157) and 6 (p-value = 0.0147). 
Table 6.7. Cumulative distribution (> 10 µm) of all formulations using the HELOS in combination with the SPAYER 
module and the UDS powder device. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, ± = standard deviation. 
 F1 F2 F3 F4 F5 F6 
Particle size 
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6.2.1.2 Aerodynamic assessment using the NGI 
The deposition in the nose of a spray dried powder for nasal application could not be assessed by using 
laser diffraction and a geometric diameter. Aerodynamic performance with the help of an NGI took 
different parameters of the formulation into account, e.g., density and morphology and can measure the 
aerodynamic diameter.  
In Figure 6.18 and Table 6.8, deposition profiles of all formulations using the NGI in combination with 
the NEC and the UDS powder device are shown. A similar trend to the laser diffraction measurements is 
obtained. Formulations 3, 4 and 5 have the highest deposition in the NEC (F3 = 84.82 % ± 6.43 %, 
F4 = 87.54 % ± 2.24 %, F5 = 81.64 % ± 2.21 %). Formulations 1, 2 and 6 have a nasal fraction below 80 % 
(F1 = 73.00 % ± 4.13 %, F2 = 73.36 % ± 8.98 %, F6 = 75.56 % ± 7.55 %). There is a very significant 
difference between formulation 1 and formulation 4 (p-value = 0.0058) and a significant difference 
between formulation 1 and formulation 5 (p-value = 0.0330). There is also a significant difference 
between formulation 4 and formulation 5 (p-value = 0.0315) with regard to the deposition in the NEC. 
 
Figure 6.18. Deposition profiles of all formulations using the NGI at 15 L/min in combination with the NEC and the 
UDS powder device. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, error bars = standard deviation, p-value < 0.05 = significant difference (*),  
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Table 6.8. Deposition data of all formulations using the NGI at 15 L/min in combination with the NEC and the UDS 
powder device. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 

































































































































































































As already mentioned, the impaction tests with the NGI were also performed to determine the 
percentage of fine particles in a formulation. According to Ph. Eur. 2.9.18 “Preparation for inhalation: 
aerodynamic assessment of fine particles” [153], the FPF was calculated. The corresponding values can 
be found in Table 6.9. Formulation 3 shows a significant difference to formulation 5 (p-value = 0.0303), 
a very significant difference to formulations 1 (p value= 0.0035), 4 (p-value = 0.0036) and 6  
(p-value = 0.0068). The FPF of formulation 5 is significantly different to formulations 4  
(p-value = 0.0118) and 6 (p-value = 0.0245) and very significantly different to formulation 1  
(p-value = 0.0080).  
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Table 6.9. FPF of all formulations using the NGI at 15 L/min in combination with the NEC and the UDS powder 
device. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; 
F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, 
± = standard deviation. 
 F1 F2 F3 F4 F5 F6 
Fine particle 
fraction, % 
8.91 ± 1.48 5.61 ± 1.65 3.43 ± 0.42 7.46 ± 1.06 4.57 ± 0.43 7.03 ± 1.14 
 
Overall, the NGI measurements and the HELOS measurements gave a similar impression. Formulations 3, 
4 and 5 provided the highest nasal fraction with almost 85 % (F3), 88 % (F4) and 82 % (F5) deposited in 
the NEC, respectively. Looking at the total mucosal deposition in the nose and the lungs, i.e., NEC and 
FPF, the difference of formulations 1, 2, 5 and 6 to formulation 3 is slightly smaller. Formulation 4 stands 
out with almost 95 % of nasal and pulmonary deposition. 
6.2.1.3 pH and solubility 
While particle size and morphology play an important role in the characterisation of nasal formulations 
with respect to nasal deposition, the pH value and solubility of nasal powders for mucosal vaccination 
are also of interest. In order to induce an immune response in the respiratory tract, the antigen has to 
be taken up in a particulate form by antigen presenting cells [35]. A 24-h-solubility study was conducted 
to investigate the amount of soluble zinc oxide, which serves as a protein adsorbent and adjuvant in the 
formulation. In addition, pH changes in different solutions after adding the formulations were measured 
to show the influence of zinc oxide (dissolved or undissolved) on the pH value. Zinc oxide as raw material 
was used as reference. As mentioned above in chapter 5.2.6, different solutions were used: sodium 
chloride solution adjusted to six different pH levels that mimic relevant pH conditions in the human 
body, was the simplest solution. pH levels to mimic relevant pH conditions in the human body. Since 
buffer systems often exist in the body, additional phosphate buffers with different pH values were used. 
Finally simulated nasal fluid (SNF) was used, which took account of the salt and pH conditions in the 
nose. 
In Figure 6.19 and Table 11.1 the results of the 24-h-solubility study of zinc oxide as raw material and in 
formulation 1 are shown. With a solubility between 1 mg/mL and 10 mg/mL, both zinc oxide and 
formulation 1 are slightly soluble at pH 1.2 according to Ph. Eur. classification. The exact values are 
shown in Table 11.1. At pH 2.5, zinc oxide and formulation 1 are very slightly soluble in both the 
phosphate buffer and the sodium chloride solution with a solubility between 0.1 mg/mL and 1 mg/mL. 
Zinc oxide is practically insoluble in all tested pH values above pH 2.5 with a solubility of less than 
0.1 mg/mL. While formulation 1 is practically insoluble in the phosphate buffer at all tested pH values 
above pH 2.5, it is very slightly soluble in the corresponding sodium chloride solutions. It is noticeable 
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that at all pH values of the sodium chloride solution and in the SNF, the differences in solubility between 
zinc oxide as raw material and formulation 1 is similar. This leads to the assumption that a different zinc 
compound was formed in the formulation during spray drying. 
 
Figure 6.19. 24-h-pH- and solubility study showing starting pH (pH 0 h, black bars) and pH change of different 
solutions/suspensions after 24 h with zinc oxide as raw material (ZnO 24 h, black dots) in comparison to 
formulation 1 (F1 24 h, green dots). Saturation solubility after 24 h is shown for zinc oxide (ZnO 24 h, blacks bars) in 
comparison to formulation 1 (F1 24 h, green bars). F1) 100 % ZnO and 0 % mannitol. n = 3, error bars = standard 
deviation. 
In order to exclude the possibility that the differences in solubility of zinc oxide as raw material and 
formulation 1 is merely a phenomenon of formulation 1, the experiment was repeated with all 
formulations and zinc oxide as raw material in SNF at pH 6.4. The results are presented in Figure 6.20. 
For zinc oxide as raw material and formulation 6, as shown in Table 6.10, no dissolved zinc was 
detectable, hence the values are not shown in the diagram. 
Since formulation 6 did not contain zinc oxide and zinc oxide as raw material is practically insoluble at 
pH 6.4 these results are not surprising. However, formulations 1 to 5 show a constant amount of 
dissolved zinc ions, shown in Table 6.10. Even if the values of formulation 1 from the two experiments 
differ slightly, the difference is not significant. In order to explain the phenomenon of differences in 
solubility, the preparation of the formulations is examined in detail. As the very first step in preparing 
the suspension for spray drying, zinc oxide and mannitol were suspended in acetic acid 2 %. It would 
therefore only be obvious if zinc acetate was formed during spray drying. But why was dissolved zinc 
from zinc acetate only detectable in sodium chloride solution? 
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Figure 6.20. 24 h-solubility study showing saturation solubility of zinc oxide as raw material (ZnO) in comparison to 
all formulations in simulated nasal fluid pH 6.4 (SNF) after 24 h. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
Table 6.10. 24 h-solubility study showing saturation solubility of zinc oxide as raw material (ZnO) in comparison to 
all formulations in simulated nasal fluid pH 6.4 (SNF) after 24 h. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 


















To clarify the question whether it is really zinc acetate, measurements of formulation 1 were carried out 
with differential scanning calorimetry (DSC). Formulation 1 was chosen because its matrix consisted of 
only zinc oxide. All other formulations contained mannitol, which might interfere with the measurements. 
Zinc oxide and zinc acetate (dihydrate) were chosen as reference substances. The results are shown in 
Figure 6.21 and Table 6.11.  
For zinc oxide as raw material, no event is detectable during DSC measurements in the observed 
temperature range as zinc oxide melts at 1975 °C. For zinc acetate, two endothermic events are 
detectable: a double peak at 105.20 °C and a peak at 259.41 °C [227]. Hydrate water is an example of 
strongly bound water and since zinc acetate is a dihydrate, a double peak between 80 and 140 °C is an 
indication of the elimination of the dihydrate, the dehydration. The melting point for zinc acetate 
dihydrate is reported to be at 237 °C [228] and for zinc acetate anhydrous at 200 °C [229]. The peak at 
259.41 °C could therefore be explained by the melting of zinc acetate dihydrate. For formulation 1 three 
peaks are visible: a broad peak at 103.8 °C, a peak at 240.54 °C and a peak at 298.03 °C. The first two 
peaks are endothermic events and the latter is an exothermic one. Comparing the values of formulation 1 
with the values of zinc acetate dihydrate, it is noticeable that the curves and values differ only minimally 
Results and discussion 100 
100 
and formulation 1 therefore contains a certain amount of zinc acetate. The small exothermic peak is 
probably an artefact, because no process could be found in literature at this temperature in the context 
with zinc acetate or other components in formulation 1.  
 
Figure 6.21. Representative chromatograms showing differential scanning calorimetry to answer the question of 
composition of formulation 1 after the spray drying process. In the diagram zinc oxide as raw material (ZnO), zinc 
acetate as raw material (Acetate) and formulation 1 (F1) is visible. F1) 100 % ZnO and 0 % mannitol. n = 1. 
Table 6.11. Data table of the differential scanning calorimetry showing peaks of zinc oxide (ZnO), zinc acetate 
(Acetate) and formulation 1 (F1). F1) 100 % ZnO and 0 % mannitol. 
 Weight, mg Onset, °C Peak, °C Area, mJ Delta H, J/g 
ZnO 2.50 - - - - 
Acetate 2.37 
105.20 117.28 759.65 320.53 
259.41 263.91 227.13 95.83 
F1 11.00 
103.08 124.27 380.47 37.59 
240.54 248.34 224.78 20.43 
298.03 298.73 -4.16 -0.38 
 
The question remains, why is dissolved zinc from the zinc acetate formed in formulation 1 only 
detectable in sodium chloride solution? This could be explained by the solubility of the individual salts. 
With 430 g/L, zinc acetate is freely soluble in water. Zinc chloride, which could theoretically be formed 
in sodium chloride, is very soluble in water with 4,300 g/L [230] and is therefore not a problem. In the 
phosphate buffer, zinc phosphate could theoretically be formed from the dissolved zinc acetate, which 
is practically insoluble in water and would therefore precipitate. 
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In order to investigate further influences on solubility in addition to the formation of zinc acetate, the 
following section examines whether all formulations have a similar crystalline state. Zinc oxide as raw 
material serves as a reference (Figure 6.22).  
 
Figure 6.22. Representative diffractogram of X-ray powder diffraction showing the degree of crystallinity of zinc 
oxide as raw material. n = 1. 
In Figure 6.23 representative diffractograms of the formulations are shown. The flat baseline and sharp 
diffraction patterns indicate that the formulations contain crystalline substances. In comparison to the 
reference in Figure 6.22, it can be seen that the diffraction patterns are primarily zinc oxide, which can 
be recognised by the four sharp peaks.  
 
Figure 6.23. Representative diffractograms of X-ray powder diffraction showing the degree of crystallinity of all 
formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; 
F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 1. 
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The decrease in absolute intensity of the peaks from formulations 1 to 4 shows the decreasing amount 
of zinc oxide in the formulations. The broad peak at the beginning of the diffractograms indicates a 
certain amount of amorphous product. As this is particularly noticeable in formulations with a higher 
zinc oxide content, formulations 1 to 4, this indicates the formation of amorphous components from 
zinc oxide. In combination with representative diffractograms of zinc acetate [231], it could be assumed 
that there is again a correlation with the suspension agent used in spray drying and therefore with the 
zinc acetate produced. In formulation 5, the concentration of zinc oxide is too low and formulation 6 
does not contain zinc oxide. Therefore, they do not show any of the corresponding peaks.  
In addition to the characteristic peaks of zinc oxide, further peaks can be identified, especially in the 
formulations with decreasing amount of zinc oxide. Mannitol was not measured as a reference because 
sufficient data on the polymorphism of mannitol is already available. A comparison with the diagrams 
of the different forms of mannitol in the study of Fronczek and coworkers [232] and the increase in the 
absolute intensity of the peaks with increasing amount of mannitol clearly indicates that these peaks are 
caused by mannitol. A closer look at the diffractograms revealed that the spray dried mannitol was the 
β-modification which is the thermodynamically most stable one.  
Coming back to the 24-h-solubility study, not only the solubility but also the change of the pH value of 
the solutions after adding the formulations was investigated. The pH value is plotted on the right-hand 
y-axis of Figure 6.19. The black bars are plotted as the pH value before the start of the experiment, and 
the black (ZnO) and dark green (F1) dots for the pH values after 24 h. The corresponding pH values are 
listed in Table 11.2. 
In the phosphate buffers zinc oxide and formulation 1 lead to similar pH values. The shift of the pH value 
after 24 h shows an increase with different gradients, depending on the initial pH value. In the sodium 
chloride solutions, both zinc oxide and formulation 1 reach a plateau of the pH value after 24 h. For zinc 
oxide, this plateau is approximately pH 7.6, independent of the initial value, and for formulation 1 it is 
pH 6.9. Only at a pH value of pH 1.2 a lower pH value (ZnO = 6.43 ± 0.11, F1 = 6.08 ± 0.09) was 
measured after 24 h. In order to analyse the influence of the different amounts of zinc oxide in the 
formulations on the pH, the pH values after 24 h of formulations 2 to 6 were also tested. In Figure 6.24 
pH values are shown as a function of the solutions with different pH values. The starting pH is shown in 
black bars and the individual formulations in dots. Again, a similar behaviour of all formulations in SNF 
and the sodium chloride solutions can be seen. 
For the phosphate buffers, the pH value increases in relation to the initial pH value. After combining the 
individual dots of the respective formulation, a higher gradient of the lower pH values (pH 1.2 and 
pH 2.5) and the higher pH values (pH 5.5, pH 6.4 and pH 7.4) is visible. For the pH values in the middle 
pH 2.5, pH 4.0 and pH 5.5 the gradient is rather flat. However, the gradient is similar for all formulations. 
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It can be seen that the zinc oxide content has an influence on the pH change. The higher the zinc oxide 
percentage, the stronger the pH shift. The strongest pH increase shows zinc oxide as raw material, 
followed by formulations 1 and 2. Formulation 3 also leads to an increase of the pH value in the lower 
pH ranges up to pH 4.0. For pH values above pH 5.5 the pH values after 24 h are almost identical to the 
original pH values. For formulations 4 and 5, i.e., the formulations with a higher mannitol amount, a pH 
increase can also be seen for the three lower pH values. For the three higher pH values, however, the pH 
value decreases after 24 h. In formulation 6, after 24 h no difference can be seen from the initial pH 
value. 
For the sodium chloride solutions, a clearly different picture is obtained. Regardless of the starting pH 
except for pH 1.2, the pH value after 24 h of formulations 1 to 5 form a plateau of approximately pH 7 
and of zinc oxide of approximately pH 7.5. As already mentioned, pH 1.2 is an exception, where a 
dependence of the zinc oxide concentration can be seen. While zinc oxide and formulation 1 with a 
matrix of 100 % zinc oxide have a strong increase in pH, the pH of the other formulations does not 
increase as much. The increase gets smaller with lower zinc oxide percentage. After 24 h formulations 5 
and 6 have a similar pH to the starting pH. Formulation 6 shows a special characteristic. While the pH 
values pH 2.5 and pH 4.0 show an increase in pH parallel to the starting pH, a plateau below the starting 
pH of the three higher pH values is reached of approximately pH 4.5.  
 
Figure 6.24. 24 h-pH study showing starting pH (pH 0 h, black bars) and pH change of different 
solutions/suspensions after 24  with zinc oxide as raw material (ZnO) in comparison to all formulations (coloured 
dots and lines). F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, error bars = standard deviation. 
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The behaviour of the formulations in SNF is similar to the behaviour in the sodium chloride solution at 
the corresponding pH value. 
A connection with the production and composition of the formulation is evident. The starting materials 
were dissolved or suspended in acetic acid 2 %. After spray drying, the ions of the acetic acid are still 
present in the formulation. Zinc oxide in the formulation contributes to an increase of the pH value 
independent of the starting pH of the sodium chloride solution. Formulation 6 does not contain zinc 
oxide. This allows the ions of acetic acid to set a corresponding pH value close to the pKa value of acetic 
acid (pKa = 4.76).  
Even if the pH change in the phosphate buffer is somewhat attenuated or buffered, the increase by zinc 
oxide as well as the change by the ions of acetic acid is evident. 
6.2.1.4 Mucus rheology 
Not only the characteristics of the formulation, but also the properties of the nose and their effect on 
nasal formulations must be considered when developing nasal formulations. An essential aspect is the 
mucosal clearance. The ciliary beating ensures the replacement of the nasal mucus on average every 
30 min [233]. To increase the retention time, mucoadhesive or viscosity increasing substances can be 
used. Due to the longer time of the formulation in the nose, the interaction time of the formulation with 
the mucosa is increased and thus fosters the possibility of the antigens being absorbed by the nasal 
mucosa.  
 
Figure 6.25. Rheology studies of simulated nasal mucus without (Mucus, black bar) and with added zinc oxide as 
raw material (ZnO, black bar) or one formulation (F1 – F6, coloured bars). Viscosity ranges at shear rates from 
60 – 100 s-1 are shown. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, error bars = standard deviation.  
Simulated nasal mucus was used as a model in these experiments. To investigate the influence of the 
different formulations and therefore, e.g., the influence of the different zinc oxide concentrations on 
rheology, first the viscosity of the pure artificial mucus at 32 °C was determined. Afterwards, the mucus 
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was mixed with the formulations and after 30 s resting time, the viscosity at 32 °C was measured again. 
The results of the measurements are given in Figure 6.25 and Table 6.12. 
The viscosity of pure mucus at shear rates from 60 s-1 to 100 s-1 ranges from 5.78 mPas ± 0.17 mPas to 
6.36 mPas ± 0.05 mPas. Formulation 6 without zinc oxide shows a similar viscosity from 
5.87 mPas ± 0.07 mPas to 6.32 mPas ± 0.09 mPas. Zinc oxide as a raw material increases the viscosity of 
the mucus to 6.58 mPas ± 0.01 mPas (min) and 7.40 mPas ± 0.09 mPas (max). 
The viscosity of the mucus in combination with formulations 1 to 5 is higher than the viscosity of pure 
mucus and mucus in combination with formulation 6 and zinc oxide as raw material. There is no 
significant difference between formulations 1 to 5. While formulation 5 shows a slightly lower viscosity 
increase, there is almost no difference between formulations 1 to 4. There is no direct correlation 
between the increase of the viscosity and the different concentrations of the components of the 
formulations, e.g., the different zinc oxide concentrations. In a further study (shown in chapter 6.2.2.4) 
to investigate pulmonary formulations, different starting materials were examined for their viscosity 
increasing properties. Water with a viscosity at shear rates from 60 s-1 to 100 s-1 of 
1.29 mPas ± 0.11 mPas to 1.51 mPas ± 0.07 mPas was used as reference material and suspending agent. 
Mannitol (1.32 mPas ± 0.03 mPas to 1.50 mPas ± 0.04 mPas) and ovalbumin (1.32 mPas ± 0.08 mPas to 
1.49 mPas ± 0.04 mPas), in the corresponding concentration in the formulation, showed no increase in 
viscosity, and the addition of zinc oxide slightly increased the viscosity (1.75 mPas ± 0.16 mPas to 
2.02 mPas ± 0.16 mPas). The addition of hyaluronic acid caused an increase in viscosity to a range of 
9.75 mPas ± 0.29 mPas to 12.23 mPas ± 0.35 mPas. 
Table 6.12. Rheology studies of simulated nasal mucus without and with added zinc oxide as raw material or one 
formulation (F1 – F6, coloured bars). Viscosity ranges at shear rates from 60 – 100 s-1 are shown. F1) 100 % ZnO and 
0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 
60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 






































A similar picture can be observed in measurements with simulated nasal mucus. Even if the addition of 
zinc oxide contributes to an increase in the viscosity of the mucus, the increase in viscosity of mucus in 
combination with the formulations can be explained mainly by hyaluronic acid. Hyaluronic acid is 
biodegradable and biocompatible, has a high molecular mass and special viscoelastic properties. It is 
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used in numerous areas of medicine and pharmacy, e.g., in the treatment of arthritis, ophthalmic surgery, 
drug delivery and tissue engineering [234]. In formulation development within this work, it is mainly 
used as an adhesive between individual nanoparticles to produce a microparticle. Furthermore, it serves 
as mucoadhesive excipient and penetration enhancer. The influence of the formulations on rheological 
properties are of great interest in all formulations for nasal application. Since different pH values exist in 
the human body, the pH dependent viscosity change of hyaluronic acid has already been investigated 
in many ways. Maleki and coworkers [234] investigated among other things the effect of the pH value 
on the rheological properties of hyaluronic acid in different diluted aqueous solutions. It was found that 
the effect of the pH value on the viscosity is related to intramolecular rupture of the polymer chain at 
low and high pH values. That means at a very low or very high pH value, irreversible degradation of the 
polymer takes place, which leads to a reduction of viscosity. If the pH value measurements of the 24-h-
solubility study are taken into account, it is noticeable that after 24 h in simulated nasal fluid, a constant 
pH value of pH 4.40 ± 0.03 was reached with formulation 6. As mentioned before, hyaluronic acid is 
known to undergo acid hydrolysis in acidic media, this would explain the lack of viscosity increase of 
formulation 6 [235]. Formulation 6 consists mainly of mannitol, which is also discussed in many papers 
connected with hyaluronic acid. Mannitol has a long-established safety profile and is among other things 
used as an antioxidant and free radical scavenger. With these properties, it protects hyaluronic acid 
against degradation by free radicals. However, even the addition of high concentrations of mannitol 
does not protect hyaluronic acid against the low pH resulting by adding the formulations to the 
simulated nasal fluid. Thus, hyaluronic acid does not increase the viscosity of mucus when adding 
formulation 6 [236]. 
6.2.1.5 Cytotoxicity 
While mannitol did not affect the rheology in-vitro, it can irritate the mucosa in-vivo. Generally, water-
soluble components start dissolving in the nasal mucus. This may result in a concentrated solution of 
high osmolarity and can also cause irritancy and a running nose because of increased water ingression 
to dilute the substance. The influence of the formulations and zinc oxide on nasal cells was evaluated in 
in-vitro cell experiments. Specifically, the toxicity on nasal epithelial cells (RPMI2650) after contact with 
the formulations was studied.  
In Figure 6.26 and Table 6.13, the LD50 of the formulations are shown. The LD50 provides information 
about the toxicity of substances and indicates the dose, where 50 % of the cells die after incubation. It 
should be mentioned that after incubation of the cells with the formulations, the higher concentrated 
formulations could not be completely removed from the cells because zinc oxide had very adhesive 
properties. For this reason, the absorption, and thus apparently the viability, increased again with 
increasing concentrations. This would imply that the viability increased with increasing concentrations. 
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However, visual inspection of the cells after they came into contact with the formulations showed a 
significant decrease in viability. For this reason, the higher concentrations are not shown in Figure 6.27. 
 
Figure 6.26. LD50 of zinc oxide as raw material (ZnO) in comparison to all formulations in a RPMI2650 model. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard 
deviation, p-value < 0.001 = highly significant difference (***). 
With an LD50 of 0.007 mg/mL ± 0.000 mg/mL, zinc oxide as raw material shows the highest toxicity in 
Figure 6.26. With a p-value < 0.0001, the toxicity of formulations 1 (0.020 mg/mL ± 0.001 mg/mL), 2 
(0.021 mg/mL ± 0.001 mg/mL), 3 (0.021 mg/mL ± 0.001 mg/mL) and 4 (0.023 mg/mL ± 0.001 mg/mL) is 
highly significantly lower than the toxicity of zinc oxide. Formulations 5 (0.070 mg/mL ± 0.003 mg/mL) 
with a p-value of 0.0004 and 6 (3.200 mg/mL ± 0.178 mg/mL) with a p-value of 0.0005 are also highly 
significantly less toxic than zinc oxide. 
Table 6.13. LD50 of zinc oxide as raw material (ZnO) in comparison to all formulations in a RPMI2650 model. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard 
deviation. 


















The LD50 increases from formulation 1 to 6 which means that the toxicity decreases. It is hence 
reasonable to assume that there is a correlation between toxicity and zinc oxide concentration.  
For this reason, in Figure 6.27 the viability of all formulations is considered as a function of the zinc oxide 
concentration. If the toxicity depends on the zinc oxide concentration, the resulting curves would overlap 
and be almost identical. As formulation 6 does not contain zinc oxide, it is not considered in Figure 6.27 
and Table 11.3. All curves show a similar trend. While the viability at a zinc oxide concentration of less 
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than 0.005 mg/mL is almost 100 %, it decreases in the range of 0.005 mg/mL to 0.05 mg/mL to finally 
almost 0 % viability at concentrations higher than 0.05 mg/mL. Although the range of the LD50 value, 
i.e., 50 % viability, is between 0.005 mg/mL and 0.05 mg/mL for all formulations, the curves are not 
identical. However, as in-vitro cell experiments are living systems, variability can easily occur.  
 
Figure 6.27. Viability as a function of the zinc oxide concentration in all formulations, to identify whether toxicity is 
dependent on zinc oxide concentrations in the formulation. Zinc oxide as raw material (ZnO) is used as a reference. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol. n = 3, error bars = standard deviation. 
6.2.1.6 Loading 
The main mission of a formulation for vaccination is the effective delivery of the antigen along with the 
adjuvant. In the current work, proteins are considered as safe and effective antigens. For that reason, 
protein loading plays a crucial role. The loading was determined after spray drying via UV spectroscopy 
at 205 nm. 
Protein loading in spray dried particles was dictated by the amount of protein in the feed solution of the 
process, but might further be influenced by the process parameters and reactions via the spray drying 
process. Figure 6.28 shows the found concentration of ovalbumin in all formulations after the spray 
drying process compared to the added concentration of ovalbumin. 0.1 mg ovalbumin per mg 
formulation was added to all formulations, but only 50 % of the used ovalbumin is recovered after spray 
drying (Table 6.14). 
There is no significant difference between individual formulations. The detection of the ovalbumin was 
based on the absorption of the peptide bond at 205 nm. Since numerous interference factors at this 
wavelength could falsify the result, a blank was previously determined with the buffer and the calibration 
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curve was established with the buffer. To ensure that the ovalbumin had not already been lost before 
spray drying, the suspension for spray drying was also assessed. The measured concentrations match 
the added concentrations.  
 
Figure 6.28. Concentration of ovalbumin (coloured bars) in all formulations after the spray drying process in 
comparison to the used amount of ovalbumin (black bars). 1) 100 % ZnO and 0 % mannitol; 2) 80 % ZnO and 
20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 
6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
Table 6.14. Concentration of ovalbumin in all formulations after the spray drying process in comparison to the 
starting concentration of ovalbumin. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, ± = standard deviation. 






















A phosphate buffer instead of water was used to dissolve or suspend the samples to guarantee that no 
zinc oxide or zinc acetate is in solution, since zinc acetate and zinc oxide did not dissolve in phosphate 
buffers with higher pH values (pH > 2.5) as shown in the 24-h-solubility studies in chapter 6.2.1.3, and 
therefore did not disturb the measurements. In principle, interference of the measurements by zinc oxide 
or mannitol can be excluded, since there is no significant difference depending on the different 
concentrations in the formulations. Nevertheless, the question remains why 50 % of the ovalbumin has 
been lost. Too high temperatures, acids or alkalis can denature proteins. When a protein is denatured, 
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its tertiary structure changes, and sometimes the secondary structure is also affected. However, the 
primary structure is usually retained, i.e., the sequence of amino acids and thus also the peptide bonds 
are retained and can be measured at 205 nm. During the spray drying process water was evaporating, 
acetic acid was getting more concentrated and remained in the formulation as acetate and proton. As 
mentioned before, ovalbumin concentrations in the suspension prior to the spray drying corresponded 
the added concentration. It could thus be possible, that denatured material became insoluble and thus 
was removed together with the other undissolved components during sample preparation prior to the 
measurements. 
In Figure 6.29, representative chromatograms of size exclusion chromatography (graphs) and 
representative pictures of SDS-PAGE of ovalbumin as raw material in comparison to formulations 1 and 
6 (left) are shown. The horizontal dotted lines above the peaks show the individual molar mass of the 
molecules that contribute to the formation of the peak. The flatter the slope of this line, the more 
homogeneous is the distribution of the molar masses. Ovalbumin as a raw material was used as a 
reference substance in the SEC measurements and in the SDS-PAGE to see if there is a difference 
between the starting material and the ovalbumin in the formulation. As reference for the analysis of the 
SDS-PAGE a marker with the given molecular weights was used additionally (left, white font).  
 
Figure 6.29. Representative chromatograms of size exclusion chromatography and representative pictures of SDS-
PAGE of ovalbumin (OVA) as raw material in comparison to formulation 1 (F1) and formulation 6 (F6). F1) 100 % ZnO 
and 0 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 1. 
In Table 6.15 the individual peaks of the SEC are analysed from right to left, with peak 1 representing 
the monomer, peak 2 the dimer and peak 3 the trimer. All peaks were used to calculate the total 
molecular weight. 
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In Figure 6.29, there is a large peak (peak 1) for ovalbumin (black), a smaller peak (peak 2) in front of it 
and a shoulder (peak 3) in front of peak 2. The ovalbumin used as starting material consists of 
monomers, dimers and trimers, whereas the distribution of the molar masses is homogeneous. With a 
mass recovery of 67.9 %, the monomer (39.8 kDa) makes up the largest part, followed by the dimer 
(83.1 kDa) with 5.8 % and finally the trimer (127.5 kDa) with 1.0 %. With a total molecular weight of 
44.4 kDa 74.8 % of the used amount could be detected with SEC. This brings up the question why only 
about 75 % of the ovalbumin used could be recovered? For this purpose, the ovalbumin as well as the 
settings on the instrument and the experiment must be considered. Ovalbumin with a purity of at least 
98 % was used for the experiments. As described in the SDS-PAGE results below, the used ovalbumin 
batch contained two different glycosylated forms of ovalbumin. For the determination of the molecular 
mass, the refractive index, among others, was needed. The refractive index is strongly discussed in the 
literature, as it can be influenced by various factors [237]. Besides the glycosylation and folding of a 
protein, pH value and matrix composition are also of interest. All these factors lead to changes in the 
refractive index and thus to inaccuracies in the results. Furthermore, the samples were first weighed, then 
the formulations were suspended and ovalbumin was dissolved, filtered and finally injected with a 
syringe. Since all these steps were performed manually, inaccuracies could have occurred both in the 
equipment and in the procedure. The combination of all these factors could explain the recovery of 
about 75 % of the ovalbumin used. 
Formulation 1 with the highest zinc oxide concentration and no mannitol and formulation 6 with the 
highest mannitol concentration and no zinc oxide were used as representative samples.  
Formulation 6 (blue) shows a similar curve to ovalbumin, i.e., a large peak (peak 1), a larger shoulder 
(peak 2) and a smaller shoulder (peak 3) and thus consists of monomers, dimers and trimers. The slope 
of the dotted line of peak 3 is higher compared to the dotted line of peak 3 of ovalbumin. The 
distribution is therefore somewhat more inhomogeneous in the direction of higher molar masses. This 
indicates the formation of multimers. For peak 1 and peak 2 there is no visible difference to ovalbumin. 
With a mass recovery of 73.1 %, the monomer (36.3 kDa) makes up the largest part, followed by the 
dimer (78.3 kDa) with 2.8 % and finally the trimer (138.9 kDa) with 0.9 %. With a total molecular weight 
of 39.1 kDa 76.8 % of the used amount could be detected. Since the loading of the formulations with 
50 % of the used ovalbumin was already taken into account when weighing the formulation, the same 
amount is detected in relation to ovalbumin as raw material.  
The measurement of formulation 1 was very difficult. The formulations were suspended, filtered and 
then injected into the system. While this was not a problem with ovalbumin and formulation 6, 
formulation 1 precipitated at the start of the stationary phase. Therefore, the ovalbumin in formulation 1 
was no longer dissolved and could not be measured. This can also be seen in Figure 6.29 and Table 6.15. 
Peak 1, which is the largest peak, is shifted towards higher retention times and the dotted line is also 
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shifted towards lower molar masses. The baseline shows a strong noise. With a molecular weight of 
23.2 kDa and a mass recovery of 8.5 % for peak 1, and since it is the only peak for all peaks, formulation 1 
has only one-ninth of the recovery and half of the molecular weight of ovalbumin as raw material.  
Table 6.15. Representative data of size exclusion chromatography of ovalbumin (OVA) as raw material in comparison 
to formulation 1 (F1) and formulation 6 (F6). F1) 100 % ZnO and 0 % mannitol; F6) 0 % ZnO and 100 % mannitol. 
n = 1. 


























OVA 39.8 67.9 83.1 5.8 127.5 1.0 44.4 74.8 
F1 23.2 8.5 n/a n/a n/a n/a 23.2 8.5 
F6 36.3 73.1 78.2 2.8 138.9 0.9 39.1 76.8 
 
Similar difficulties with formulation 1 can be observed in SDS-PAGE. A doublet of ovalbumin as raw 
material is detected between 34 kDa and 50 kDa [238]. Two different glycosylated forms of ovalbumin 
within the purified protein preparation might cause the presence of a doublet. Formulation 6 also shows 
a doublet between 34 kDa and 50 kDa and a weaker band at about 20 kDa. In addition, a veil extends 
from the stronger bands to the weaker band. This could be sign of a disturbing matrix. Formulation 1 
shows a weak band at about 20 kDa, similar to the measurements of formulation 1 with the SEC, and an 
even weaker doublet between 34 kDa and 50 kDa. Ovalbumin might already be denatured before the 
measurement. By centrifugation, the denatured ovalbumin would be separated. With the small amounts 
of ovalbumin in the samples for SDS-PAGE, a pellet of this size would not have been noticed at all.  
If the data from SEC and SDS-PAGE are combined, it could be assumed that ovalbumin was denatured 
due to the acetic acid 2 % and gradually loses its functionality. However, as this was included in both 
formulation 1 and formulation 6, there must be another factor affecting the stability of ovalbumin. In 
this case the composition of the matrix must be considered. While the matrix in formulation 1 consists 
of 100 % zinc oxide, the matrix in formulation 6 consists of 100 % mannitol. Even if the addition of zinc 
oxide led to an increase in pH value and thus to a less acidic environment, the stabilising effect of 
mannitol on proteins during spray drying was probably more pronounced. The ovalbumin in 
formulation 6 was thus stabilised and remained largely intact, while the ovalbumin in formulation 1 is 
denatured by the combination of acetic acid and spray drying. 
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6.2.1.7 Summary and conclusion 
The zinc oxide used showed a needle-shaped morphology with particles in the nanometre range, 
resulting in a large surface area and a tendency to form undefined agglomerates.  
The project aimed to use zinc oxide as an alternative adjuvant. By spray drying, it was possible to produce 
particles with a defined particle size > 10 µm, which is usually the particle size required for nasal 
application. Zinc oxide was spray dried together with hyaluronic acid, ovalbumin and mannitol in acetic 
acid (2 %). Six different formulations were prepared with different concentrations of zinc oxide and 
mannitol. The matrix of formulation 1 consisted of 100 % zinc oxide and the matrix of formulation 6 of 
100 % mannitol. The concentrations of hyaluronic acid and ovalbumin remained constant.  
All formulations resulted in a white powder after spray drying, with differences in morphology. 
Formulations 1 and 6 had the typical uniform spherical shape, with formulation 1 being slightly indented 
and formulation 6 having a smooth surface. Formulations 2 to 5 were all clearly wrinkled particles. The 
difference in composition was not only visible by the decreasing proportion of zinc oxide particles 
present from formulation 1 (100 % zinc oxide) to formulation 6 (0 % zinc oxide), but also measurable 
using EDS. The produced white dry powders had almost no visible differences in particle size. 
Measurements of the particle size distribution with the RODOS module showed an x50 smaller than 
10 µm for formulations 1, 2, 5 and 6 and an x50 higher than 10 µm for formulations 3 and 4. When 
measuring the particle size distribution with the SPRAYER module in combination with the UDS powder 
device, formulation 6 had almost 50 % of particles larger than 10 µm, formulations 1, 2 and 5 had over 
50 % of particles larger than 10 µm and formulations 3 and 4 had over 90 % of particles larger than 
10 µm. 
An NGI was used in combination with the nasal expansion chamber and the UDS powder device for 
aerodynamic characterisation. With more than 80 %, formulations 3, 4 and 5 showed the highest 
deposition percentage in the nasal expansion chamber. For formulations 1, 2 and 6, less than 80 % of 
the delivered dose was deposited in the nasal expansion chamber.  
To stimulate an immune response in the respiratory tract, an antigen has to be taken up in a particulate 
form by antigen presenting cells. For this reason, the amount of dissolved zinc oxide in different media 
was investigated. Sodium chloride solutions and phosphate buffers with different pH levels were 
prepared to mimic relevant pH conditions in the human body. In addition, simulated nasal fluid was 
tested, which took account of the salt and pH conditions in the nose. In addition to the solubility, the 
influence of zinc oxide (dissolved or undissolved) on the pH values after 24 h was also investigated. 
Formulation 1, as representative sample, was slightly soluble in pH 1.2 and very slightly soluble in pH 2.5, 
both in sodium chloride solution and in phosphate buffer. At pH values above pH 2.5, formulation 1 was 
practically insoluble in phosphate buffer, but very slightly soluble in sodium chloride. In simulated nasal 
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fluid, formulations 1 to 5 were very slightly soluble. The difference in solubility in phosphate buffers 
compared to sodium chloride solutions and simulated nasal fluid was due to the formation of zinc 
acetate during spray drying. The pH value after 24 h also showed a difference between phosphate buffer 
and both the sodium chloride solutions and the simulated nasal fluid. After 24 h, the pH value increased 
in relation to the initial pH value in the phosphate buffer, while the zinc oxide content had an influence 
on the pH change: the higher the zinc oxide percentage, the stronger the pH shift. In both the sodium 
chloride solutions and simulated nasal fluid, the pH value reached a plateau of approximately pH 7 after 
24 h for the formulations 1 to 5 and of approximately pH 4.5 for formulation 6.  
Looking at the physiology of the nose, mucosal clearance plays an important role. The ciliary beating 
ensures the replacement of the nasal mucus every 30 min. The retention time increases with increasing 
viscosity of the mucus. Simulated nasal mucus was used for the tests. Formulations 1 to 5 led to an 
increase in the viscosity of the mucus compared to pure mucus, whereby the increase in viscosity was 
mainly due to the hyaluronic acid. At low and high pH values, as for example in formulation 6, there was 
an intramolecular rupture of the polymer chains and thus a loss of the viscosity increasing effect. While 
no dependence on the zinc oxide concentration could be seen in the viscosity experiments, the 
concentration played an important role in the toxicity tests of the formulations. After 24 h incubation of 
RPMI2650 with the formulations, the LD50 increased from formulation 1 to formulation 6, i.e., the toxicity 
decreased from formulation 1 to formulation 6. 
The goal of the spray dried formulation was to increase the protein loading. The loading of the particles 
after spray drying was investigated. Only 50 % of the used ovalbumin was recovered after spray drying. 
SEC and SDS-PAGE were used to investigate the stability of the ovalbumin. Ovalbumin was denatured 
due to acetic acid (2 %) and gradually loses functionality. While in formulation 6 the high mannitol 
concentrations had a stabilising effect on the ovalbumin and thus it remained largely intact, the 
ovalbumin in formulation 1 was mostly denatured. The combination of acetic acid (2 %) and spray drying 
caused denaturation of ovalbumin. 
In conclusion, the increase in protein loading (from 0.013 mg ovalbumin/mg zinc oxide as raw material 
to about 0.05 mg ovalbumin/mg spray dried zinc oxide for nasal application) with ovalbumin was 
generally successful. However, only 50 % of the ovalbumin used was recovered after spray drying and 
the use of acetic acid (2 %) as a medium for dissolving or suspending all materials prior to the spray 
drying caused repeated difficulties during characterisation. To overcome these problems and to achieve 
a higher loading of the particles, for further investigations the formulations were spray dried using water 
as medium. Using the same concentrations as for the production of the nasal particles would lead to 
clogging of the two-fluid nozzle during spray drying of an aqueous suspension. By using lower 
concentrations, pulmonary formulations were prepared, which had the great advantage that they could 
subsequently be used in in-vivo experiments to investigate pulmonary immunisation in mice. 
Results and discussion 115 
115 
6.2.2 Spray dried zinc oxide for pulmonary application 
By spray drying, it is not only possible to produce particles for nasal application, but also for pulmonary 
administration with a defined particle size < 5 µm. Zinc oxide as an alternative adjuvant was spray dried 
together with hyaluronic acid, ovalbumin and mannitol. The composition of the six pulmonary 
formulations was the same as the composition of the six nasal formulations, but with water as a liquid 
medium for spray drying instead of acetic acid (2 %) as mentioned in chapter 5.1. However, to obtain 
smaller particles, a lower concentration of the components in the suspension to be dried was used, since 
in spray drying, among other things, the concentration of the feed liquid influences the particle size 
[189]. 
The six spray dried formulations are all dry white powders independent of their composition. They were 
physiochemically characterised, i.e., morphology, particle size distribution, aerodynamic behaviour,  
24-h-solubulity and dissolution. Moreover, various protein characterisation methods were evaluated and 
the behaviour of the formulations in in-vitro cell experiments were assessed. 
6.2.2.1 Morphology and particle size distribution 
Six formulations with different concentrations of zinc oxide and mannitol as matrix were spray dried. The 
amounts of ovalbumin and hyaluronic acid remained constant. The formulations were visualised with 
scanning electron microscopy.  
Figure 6.30 shows representative pictures of the six formulations in two different magnifications. 
Image A depicts formulation 1 with the highest amount of zinc oxide (100 %) and image F formulation 6 
without zinc oxide (0 %). From formulation 1 to formulation 6, the zinc oxide concentration decreases 
and the mannitol concentration increases. Both the particle size, better visible in the smaller 
magnification (left), and the particle size distribution, better visible in the higher magnification (right), 
are similar for all formulations. With geometric diameters of approximately 10 µm, the particles seem to 
be too large for pulmonary application, since, as already mentioned, an aerodynamic diameter smaller 
than 5 µm is required. However, geometric and aerodynamic diameters cannot be compared directly. 
The aerodynamic diameter also considers the morphology and density of a particle, i.e., aerodynamic 
diameter assumes a sphere with a density of 1 g/cm3. Therefore, a porous particle with low density with 
a geometric diameter above 5 µm may still have an aerodynamic diameter below 5 µm. This is the reason 
why both the geometric and the aerodynamic diameter were determined. 
Similar to the spray dried nasal formulations, there was almost no difference in particle size visible 
between the six formulations but there is a difference in morphology. Formulation 6 (Figure 6.30, 
image F), formulation 1 (Figure 6.30, image A) and formulation 2 (Figure 6.30, image B) show the typical 
uniform spherical shape of a spray dried powder [191]. Particles of formulation 6 show a smooth surface. 
Particles of formulation 1 and formulation 2 show an irregular surface. In formulation 1, individual zinc 
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oxide particles are visible which do not contribute to the formation of the spray dried particle. All other 
formulations have wrinkled particles mixed with spherical particles (Figure 6.30, images C to E). The 
different compositions are clearly visible in the SEM images. Small particles and areas in a lighter grey 
represent zinc oxide particles and areas in a darker grey represent mannitol. The different morphology 
can be explained by the particle forming process.  
Mannitol (formulation 6) was, similar to the nasal formulations, dissolved in the drop produced by the 
two-fluid nozzle. During the spray drying process, mannitol precipitated on the surface of the drop and 
a shell was formed. The particle no longer changed its size. Due to the low glass transition point and the 
low outlet temperature, a crystalline, uniform and smooth particle was formed. 
While zinc oxide in the nasal formulations was initially partially dissolved in acetic acid (2%), the zinc 
oxide in the pulmonary formulations (formulation 1) was suspended in the drop produced by the two-
fluid nozzle. By drying the solvent off, a layer of individual zinc oxide particles at the surface of the drop 
was formed. As they would not form stable particles by themselves, hyaluronic acid was added as an 
adhesive between those single zinc oxide particles [169]. In contrast, the spray dried nasal formulations 
formed a shell of precipitated zinc acetate in combination with single zinc oxide particles. A crystalline, 
uniform, almost spherical particle was formed whose matrix consists of individual zinc oxide particles. 
Using 1 % hyaluronic acid was not sufficient to form stable spherical particles in formulation 1, where 
the matrix consisted of 100 % zinc oxide. However, if the matrix consisted of 80 % zinc oxide and 20 % 
mannitol (formulation 2), stable particles could be formed and almost no individual zinc oxide particles 
were visible. 
If mannitol and zinc oxide are processed together as a matrix, mannitol was dissolved and zinc oxide 
was suspended. The drying of water led to a higher concentration of mannitol and zinc oxide on the 
surface of the drop. Crystalline and spherical particles with single zinc oxide particles embedded in the 
continuous mannitol matrix were formed. As this was a suspension, the particle was formed more quickly 
than in a solution. The solvent vapour inside the particles, which was now exposed to higher 
temperatures, created higher pressure. As a consequence, when the solvent vapour condenses, 
decreasing volume created a vacuum and the shell collapsed.  
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Figure 6.30. Representative scanning electron microscope images showing all spray dried powders with different 
amounts of zinc oxide (ZnO) and mannitol and additionally constant concentrations of ovalbumin (10 %) and 
hyaluronic acid (1 %). A) 100 % ZnO and 0 % mannitol; B) 80 % ZnO and 20 % mannitol; C) 60 % ZnO and 
40 % mannitol; D) 40 % ZnO and 60 % mannitol; E) 20 % ZnO and 80 % mannitol; F) 0 % ZnO and 100 % mannitol. 
The particle size distribution of all formulations was determined by laser diffraction (volume-based 
diameter). In Figure 6.31, the x50 and the span of the measurements with the RODOS module of all 
formulations are shown. The corresponding values can be found in Table 6.16. With an x50 of 
1.32 µm ± 0.07 µm (F1), 3.20 µm ± 0.08 µm (F2), 3.64 µm ± 0.25 µm (F3), 3.63 µm ± 0.04 µm (F4), 
3.98 µm ± 0.06 µm (F5) and 4.00 µm ± 0.14 µm (F6) 50 % of the particles of formulations 1 to 6 are 
smaller than 5 µm. Formulation 1 shows with 1.32 µm ± 0.07 µm a highly significantly smaller particle 
size than formulations 2, 3, 4, 5 and 6 (p-value < 0.0001). Formulation 2 is significantly smaller than 
formulation 3 (p-value = 0.0224) and highly significantly smaller than formulations 4 (p-value = 0.0005), 
5 (p-value < 0.0001) and 6 (p-value = 0.0005). Formulation 3 is significantly smaller than formulations 5 
(p-value = 0.0440) and 6 (p-value = 0.0491). Formulation 4 is highly significantly smaller than 
formulation 5 (p-value = 0.0006) and very significantly smaller than formulation 6 (p-value = 0.0057). 
As mentioned above, zinc oxide particles alone could not form a shell. Hyaluronic acid as an adhesive 
between the individual zinc oxide particles was not sufficient and individual zinc oxide particles were not 
involved in the forming of the spherical particles. If the zinc oxide concentration per particle was 
decreased the particles became smaller. If mannitol was added as a continuous matrix, the spray dried 
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particles became larger, because all zinc oxide particles were included in the formation of the particle. 
In addition, the individual zinc oxide particles not involved in the formation of a stable particle formed 
separate agglomerates and as such contributed to the particle size distribution. As a result, the particle 
size distribution was shifted towards smaller particle sizes. This is also reflected in the increased span 
value of 3.47 ± 0.06 for formulation 1. The span value describes the distribution width. Spray drying is a 
fast process usually resulting in a lognormal particle size distribution. 
 
Figure 6.31. Particle size distribution using laser diffraction (HELOS) in combination with the RODOS module, x50 
(primary axis) and span (secondary axis) of all formulations; 1) 100 % ZnO and 0 % mannitol; 2) 80 % ZnO and 
20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 
6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
 
Figure 6.32. Density distribution using laser diffraction (HELOS) in combination with the RODOS module; 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard 
deviation. 
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Curves of all formulations show a bimodal distribution as shown in Figure 6.32. Formulation 1, as the x50 
already suggests, shows a higher maximum at smaller particle sizes. All other formulations show a higher 
maximum at larger particle sizes, with formulations 3 to 6 showing almost identical curves. The higher 
span value of formulation 1 indicates a broader particle size distribution due to the individual zinc oxide 
particles. 
Table 6.16. x10, x50, x90 and span of all formulations using the HELOS in combination with the RODOS module. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard 
deviation. 
 x10, µm x50, µm x90, µm Span 
F1 0.43 ± 0.01 1.32 ± 0.07 5.01 ± 0.32 3.47 ± 0.06 
F2 0.56 ± 0.01 3.20 ± 0.08 7.88 ± 0.07 2.29 ± 0.04 
F3 0.66 ± 0.02 3.64 ± 0.25 8.38 ± 0.34 2.12 ± 0.07 
F4 0.75 ± 0.02 3.63 ± 0.04 8.28 ± 0.12 2.07 ± 0.01 
F5 0.84 ± 0.01 3.98 ± 0.06 9.11 ± 0.19 2.08 ± 0.01 
F6 0.80 ± 0.02 4.00 ± 0.14 9.35 ± 0.29 2.14 ± 0.003 
 
In Figure 6.33 and Table 6.17, the results of the measurements with the INHALER module in combination 
with the Cyclohaler are shown. 
The use of an inhaler and the corresponding settings (simulated inspiration instead of pressurised air 
and a 90° glass pipe bend for the simulation of the throat) led to more meaningful particle size 
distributions related to the lung deposition than the HELOS with the RODOS module. In Figure 6.33 the 
cumulative distribution of particles smaller than 5 µm (volume-based diameter) is illustrated. The trend 
of the measurements with the RODOS module that formulation 1 was highly significantly smaller than 
all the other formulations and therefore had a higher number of particles smaller than 5 µm is not visible. 
For the Cyclohaler, a pressure drop of 4 kPa is recommended, i.e., 0.04 bar. This corresponds to a flow 
rate of 100 L/min. The highest value that could be set for the flow rate in the combination of HELOS and 
INHALER module however was 82.7 L/min. Either way, the pressure responsible for powder dispersion is 
not comparable between the RODOS module and the INHALER module as the principle of these two 
modules differ as mentioned in chapter 5.2.2. With 65.31 % ± 4.76 % (< 5 µm) formulation 6 shows the 
highest percentage of particles smaller than 5 µm. It thus has a significantly higher (p-value = 0.0152) 
percentage of smaller particles than formulation 2 (< 5 µm = 47.49 % ± 8.11 %) and a very significantly 
higher percentage of smaller particles than formulation 1 (p-value = 0.0036, 
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< 5 µm = 35.20 % ± 9.13 %), formulation 3 (p-value = 0.0020, < 5 µm = 45.49 % ± 4.29 %), 
formulation 4 (p-value = 0.0024, < 5 µm = 42.04 % ± 5.25 %) and formulation 5 (p-value = 0.0037, 
< 5 µm = 41.57 % ± 2.48 %). All other formulations do not show significant differences.  
 
Figure 6.33. Particle size distribution using laser diffraction (HELOS) in combination with the INHALER module 
(< 5 µm) and the Cyclohaler, cumulative distribution of all formulations; 1) 100 % ZnO and 0 % mannitol; 
2) 80 % ZnO and 20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 
80 % mannitol; 6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation.  
Table 6.17. Particle size distribution using laser diffraction (HELOS) in combination with the INHALER module 
(< 5 µm) and the Cyclohaler. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, ± = standard deviation. 
 F1 F2 F3 F4 F5 F6 
Particle size 














6.2.2.2 Aerodynamic assessment using the NGI 
In addition to the volume-based diameter via laser diffraction, the aerodynamic particle size distribution 
was assessed. The aerodynamic diameter is an equivalent diameter, i.e., the measured diameter 
corresponds to that of a sphere with a density of 1 g/cm3 having the same settling velocity as the particle 
under consideration. It also considers the morphology and density of a particle. Therefore, a porous 
particle with low density with a geometric diameter above 5 µm may still have an aerodynamic diameter 
below 5 µm. 
Figure 6.34 and Table 6.18 show deposition profiles of all formulation using the NGI in combination with 
the Cyclohaler, the mouthpiece, the throat and the preseparator.  
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Figure 6.34. Deposition profiles of all formulations using the NGI in combination with the mouthpiece, the throat, 
the preseparator and the Cyclohaler. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, error bars = standard deviation. 
All formulations show a similar trend. Formulations with a higher zinc oxide content, formulations 1 to 
3, and those with a higher mannitol content, formulations 4 to 6, can be grouped together. The emitted 
dose of all formulations is about 90 % (formulation 1 = 87.70 % ± 1.26 %, 
formulation 2 = 88.31 % ± 1.47 %, formulation 3 = 90.06 % ± 1.39 %, formulation 4 = 91.7 % ± 1.39 %, 
formulation 5 = 90.72 % ± 0.12 %, formulation 6 = 91.63 % ± 2.21 %). While approximately 50 % of the 
formulations with the higher zinc oxide content are found in the throat, only 40 % of the formulations 
with the higher mannitol content were found in the throat. This difference could be explained by the 
adhesive properties of zinc oxide, which could be observed in almost all experiments. The high amount 
of the formulations in the throat was due to impaction. The emitted particles could no longer follow the 
air flow at the 90° angle of the throat and impacted at the surface. The higher the speed of the flow and 
the weightier the particle, the higher was the probability of impaction.  
The structure of the lungs is similar to that of a tree. The trachea is the trunk that branches 23 times 
down to the alveoli. The diameter decreases from 12 mm (upper airways) to 410 µm (lower airways), 
while the number of branches increases. The total diameter of all branches of one generation from the 
trachea to the lobe bronchi initially remains constant in comparison to the previous generation but 
increases rapidly from the lobe bronchi onwards. Accordingly, the breathing air speed decreases more 
and more from the upper to the lower airways. The separation of the particles in the lungs is based on 
five different mechanisms: Impaction, sedimentation, diffusion, interception and electrostatic 
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precipitation. Interception and electrostatic precipitation play a secondary role. The impaction described 
above takes place mainly in the upper respiratory tract and depends not only on the speed of the air, 
but also on the diameter, density and shape of the particles. In the lower respiratory tract, sedimentation 
and diffusion are the driving forces for particle separation. Sedimentation follows Stokes' law of 
sedimentation and depends mainly on the diameter and density of the particle as well as on the viscosity 
of the dispersion medium. Particles smaller than 1 µm are exposed to the Brownian molecular movement 
of the surrounding gas molecules and are separated by diffusion. The diffusion rate also depends on the 
size of the particles. While sedimentation and impaction increase with increasing particle size, diffusion 
decreases. Various physiological factors can also further influence particle deposition, e.g., the geometry 
of the respiratory tract and the inhalation technique. The target size for pulmonary application is an 
aerodynamic diameter of 1 µm to 5 µm, as small particles, typically smaller than 1 µm, are exhaled again 
[239]. 
Table 6.18. Deposition data of all formulations using the NGI in combination with the mouthpiece, the throat, the 
preseparator and the Cyclohaler. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO 
and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
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As already mentioned, the target particle size for pulmonary application is an aerodynamic diameter of 
1 µm to 5 µm. According to Ph. Eur. 2.9.18 “Preparation for inhalation: aerodynamic assessment of fine 
particles” [153], the FPF of the emitted dose of all formulations was calculated (Table 6.19). With 
35.03 % ± 2.65 % formulation 4 is significantly different to formulations 2 with 28.76 % ± 2.39 %  
(p-value = 0.0382), 3 with 27.57 % ± 1.83 % (p-value = 0.0160) and 6 with 30.34 % ± 1.13 %  
(p-value = 0.0378). Formulation 5 with 32.00 % ± 0.87 % is significantly different to formulation 3  
(p-value = 0.0194). Formulation 1 with 28.75 % ± 3.17 % has no significant difference to the other 
formulations.  
Table 6.19. Particles with an aerodynamic diameter < 5 µm, < 3 µm and < 1 µm of all formulations using the NGI in 
combination with the mouthpiece, the throat, the preseparator and the Cyclohaler F1) 100 % ZnO and 0 % mannitol; 
F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO 
and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 




3 µm 1 µm 
F1 28.75 ± 3.17 21.87 ± 1.36 14.99 ± 0.76 
F2 28.76 ± 2.39 20.43 ± 1.36 12.09 ± 2.16 
F3 27.57 ± 1.83 19.99 ± 1.23 12.40 ± 1.19 
F4 35.03 ± 2.65 23.55 ± 2.61 12.06 ± 2.81 
F5 32.00 ± 0.87 21.05 ± 1.01 10.11 ± 1.23 
F6 30.34 ± 1.13 18.43 ± 2.24 6.51 ± 3.42 
 
A grouping can be seen for formulations with a higher amount of zinc oxide and a higher amount of 
mannitol. While the deposition of formulations with a higher amount of zinc oxide is higher in the throat, 
the fine particle fraction of the formulations with a higher amount of mannitol is higher. If the particles 
with an aerodynamic diameter below 5 µm are considered, it is noticeable that the formulations with a 
higher mannitol amount are more represented at higher cut-off diameters (> 2.18 µm) than the 
formulations with a higher zinc oxide amount.  
As the target size for pulmonary application is < 5 µm and particles smaller than 1 µm are exhaled again, 
the percentage of particles < 1 µm was calculated. Dendritic cells as immunocompetent cells form a 
bridge between the innate and the adaptive immune system and are specialised in taking up a broad 
spectrum of pathogens to present their antigens on the cell surface [171]. Dendritic cells are also located 
in the lungs, i.e., in the epithelial linings of the conducting airways and in the submucosa and the surface 
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of the alveoli [28]. For targeted uptake of the particles by dendritic cells in the respiratory tract, the 
particle size should be lower than 3 µm [45]. That is why the percentage of the particles < 3 µm was also 
calculated. The calculation of the deposition of particles with an aerodynamic diameter < 3 µm and 
< 1 µm were carried out analogously to the calculation of the fine particle fraction according to 
Ph. Eur. 2.9.18 “Preparation for inhalation: aerodynamic assessment of fine particles” [153]. 
Considering the deposition of particles with an aerodynamic diameter < 1 µm, formulations with a 
higher amount of zinc oxide have a higher percentage of smaller particles. When subtracting the 
percentage of particles with an aerodynamic diameter < 1 µm from the fine particle fraction, the above-
mentioned observation that particles with a higher mannitol amount were more represented at higher 
cut-off diameters below 5 µm is confirmed. Formulation 6 with the highest amount of mannitol shows 
about 24 % of the formulation deposited in the lung. Formulation 1, on the other hand, shows only 
about 14 % of the formulation deposited in the lung.  
As for targeted uptake of particles by dendritic cells in the respiratory tract a particle size below 3 µm is 
recommended, the percentage of particles with an aerodynamic diameter < 3 µm was calculated. With 
no significant differences, all formulations show about 21 % of the formulation with an aerodynamic 
diameter < 3 µm and thus an equal amount of particles that could theoretically be taken up by dendritic 
cells. However, a prediction of in-vivo deposition was not possible using the NGI, as essential factors of 
in-vivo conditions are not considered in the Ph. Eur. method.  
6.2.2.3 pH and solubility 
A 24-h-solubility study as already described in chapter 6.2.1.3 was conducted to investigate the amount 
of soluble zinc oxide. In addition, the pH change after adding the formulations to different environments 
was measured to show the influence of zinc oxide on their pH value. While phosphate buffers and 
sodium chloride solutions with six different pH conditions were used for both the nasal and the 
pulmonary formulations, simulated lung fluid (SLF, pH 7.4) was used for the pulmonary formulations 
instead of simulated nasal fluid used for the nasal formulations. SLF took account of the salt and pH 
conditions in the lungs. 
In Figure 6.35 and Table 11.4, the results of the 24-h-solubility study of zinc oxide as raw material and 
formulation 1 are shown. Zinc oxide and formulation 1 show similar results for the concentration of 
dissolved zinc and pH value in the 24-h-solubility study.  
With a solubility between 1 mg/mL and 10 mg/mL, both zinc oxide and formulation 1 are slightly soluble 
at pH 1.2 according to Ph. Eur. classification. At a pH value of pH 2.5, zinc oxide and formulation 1 are 
very slightly soluble in both the phosphate buffer and the sodium chloride solution with a solubility 
between 0.1 mg/mL and 1 mg/mL. Zinc oxide and formulation 1 are practically insoluble in all tested pH 
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values, including SLF, above pH 2.5 with a solubility of less than 0.1 mg/mL. The exact values are shown 
in Table 11.4.  
Besides the results of the dissolved zinc concentrations, the pH values before and after adding zinc oxide 
and formulation 1 are also shown in Table 11.4. Zinc oxide and formulation 1 result in similar pH values. 
In the phosphate buffers the pH values have increased after 24 h. The extent of the increase is dependent 
on the starting pH value. The lower the starting pH, the higher the increase. An exception to this is 
phosphate buffer at pH 4.0. The pH increase is more distinct than for phosphate buffer at pH 2.5.  
In the sodium chloride solutions, the pH value reaches a plateau at approximately pH 7.5 independent 
of the starting pH (beginning at pH 4). 
In SLF the shift of the pH value after 24 h shows an increase to approximately pH 8.2 for both zinc oxide 
and formulation 1. 
 
Figure 6.35. 24-h-pH- and solubility study showing starting pH (pH 0 h, black bars) and pH after 24 h with zinc oxide 
as raw material (ZnO 24 h, black dots) in comparison to formulation 1 (F1 24 h, green dots). Saturation solubility 
after 24 h is shown for zinc oxide (ZnO 24 h, blacks bars) in comparison to formulation 1 (F1 24 h, green bars). 
F1) 100 % ZnO and 0 % mannitol. n = 3, error bars = standard deviation. 
In order to analyse the influence of different zinc oxide amounts in the formulations on the pH, the pH 
values after 24 h of formulations 2 to 6 were also tested. In Figure 6.36, pH values are shown as a function 
of the solutions with different pH values. The starting pH is shown as black bars and the formulations as 
coloured dots. The exact values are shown in Table 11.5. 
In phosphate buffers, as seen for formulation 1 before, the pH increases after 24 h for all formulations 
containing zinc oxide. After combining the individual dots of the respective formulation, it can be seen 
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that the zinc oxide content has an influence on the extent of the pH change. While zinc oxide and 
formulations 1 and 2 show almost identical trends, the change in pH value decreases with decreasing 
zinc oxide content. Formulation 6 containing no zinc oxide shows an almost similar curve with the 
starting pH. The trend observed for formulation 1 can also be observed for all other formulations. The 
extent of the increase is dependent on the starting pH value. The lower the starting pH, the higher the 
increase. An exception to this is phosphate buffer at pH 4. The pH increase is more distinct than for 
phosphate buffer at pH 2.5.  
 
Figure 6.36. 24 h-pH study showing starting pH (pH 0 h, black bars) and pH change of different 
solutions/suspensions after 24 h with zinc oxide as raw material (ZnO) in comparison to all formulations (coloured 
dots and lines). F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, error bars = standard deviation. 
For the sodium chloride solution, a different picture is obtained. Zinc oxide and all formulations reach a 
plateau of the pH value after 24 h. Zinc oxide and all formulations with a higher zinc oxide amount, 
formulations 1 to 3, show almost identical graphs. Formulations 4 to 6 however behave differently. At 
pH 1.2 the difference to the starting pH depends on the zinc oxide content in the formulation. 
Formulation 6, without zinc oxide, shows a pH value similar to that of the starting solution, formulation 5, 
including 20 % zinc oxide, increases the pH value to pH 1.72 ± 0.01 and formulation 4, 40 % zinc oxide, 
to pH 5.81 ± 0.36. At pH 2.5 all formulations except formulations 5 (pH 6.57 ± 0.07) and 6 
(pH 2.58 ± 0.02) show an almost identical pH value of about pH 6.9. From the starting pH of 4.0, 
formulations 1 to 5 reach a plateau of approximately pH 7.5. From pH 5.5 onwards, formulation 6 shows 
only a slight change in the difference of pH value after 24 h to starting pH from pH 6.5 to pH 6.9 (starting 
pH 7.4).  
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In SLF zinc oxide and the formulations with a higher zinc oxide amount, formulations 1 to 3, increase the 
initial pH to about pH 8.3. The formulations with a lower zinc oxide content, formulations 4 to 6, increase 
the pH value even more to approximately pH 9.1. 
A correlation of the pH value with the composition of the formulation is obvious. The starting materials 
were dissolved or suspended in water. Zinc oxide as raw material and zinc oxide in the formulations 
contributed to an increase of the pH value after spray drying in the phosphate buffers, which was 
dependent on the initial pH value and in the sodium chloride solutions, which was independent of the 
initial pH value in higher pH values. The pH increase of the zinc oxide in the buffer solutions (phosphate 
buffer) was not as pronounced as in the simple salt solutions (sodium chloride solution). This reflected 
the ability of the buffer to attenuate slight pH changes. Formulation 6 contained no zinc oxide and 
therefore showed almost no change compared to the initial pH and all other formulations. 
In order to investigate further influences on solubility, representative diffractograms of X-ray powder 
diffraction of all formulations are shown in Figure 6.37. The diffractogram of zinc oxide as reference was 
shown in Figure 6.22. The flat baseline and sharp diffraction patterns indicate that the formulations 
contain crystalline substances. By comparison with the reference, it is clear that the diffraction patterns 
can be primarily assigned to zinc oxide, which can be recognised by the four sharp peaks. In addition to 
the characteristic peaks of zinc oxide, further peaks can be identified, especially in the formulations with 
decreasing amount of zinc oxide. As already mentioned in chapter 6.2.1.3, mannitol was not measured 
as a reference because sufficient data on the polymorphism of mannitol is already available.  
 
Figure 6.37. Representative diffractograms of X-ray powder diffraction showing the degree of crystallinity of all 
formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; 
F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 1. 
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6.2.2.4 Release study 
The release of the model antigen ovalbumin from the spray dried pulmonary formulations was evaluated 
using ThinCert cell culture inserts. The dry formulations and pure ovalbumin as reference were placed 
on the ThinCert and the released ovalbumin content in the medium was analysed. As the amount of 
ovalbumin in the solution at the end of the dissolution or the release study with maximum 1 mg/mL 
does not exceed 10 % of the saturation concentration of the used ovalbumin in water (saturation 
concentration = 40 mg/mL [176]), it could be assumed that perfect sink conditions exist. In Figure 6.38 
and Table 6.20, the released ovalbumin quantities are plotted in % against time.  
 
Figure 6.38. Release curves of the formulations and ovalbumin as reference. F1) 100 % ZnO and 0 % mannitol; 
F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO 
and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
The black curve shows the dissolution of pure ovalbumin as a reference. It shows a steep increase at first 
and reaches a plateau after 60 min showing only a weak increase afterwards. The initially undissolved 
ovalbumin was located on the ThinCert and could not pass the membrane with a pore size of 1 µm. If 
the insert was now placed in the 12-well plate with the release medium water, the ovalbumin dissolved 
and could freely diffuse through the membrane. In order to match the amount of pure ovalbumin to the 
amount of ovalbumin in the formulations, only 1 mg was used in the test. The amount released at a 
certain time was related to the total amount recovered at the end of the experiment. After 6 h, 
75.0 % ± 8.5 % of the total amount of ovalbumin has been released, i.e., 25 % of the ovalbumin is not 
released into the release medium. Due to the structure of the ThinCert, some material might have stuck 
in the contact well of the membrane and the insert, which would only be detected at the end. Ovalbumin 
shows a first-order release kinetic, which is typical for an uncontrolled release, respectively, since 
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ovalbumin was present as single substance, this is correctly not a release, but rather a dissolution. Due 
to a high difference in concentration between the active pharmaceutical ingredient and the medium, the 
release starts quickly. The smaller this difference in concentration becomes, the slower the release takes 
place.  
Equation 6.1 shows the corresponding mathematical function. 
Equation 6.1. Mathematical function of a first-order release kinetic. 
𝑀𝑡 =  𝑀0 ∗ (1 −  𝑒
−𝑘 ∗ 𝑡) 
𝑀𝑡 stands for the released drug amount at time 𝑡, 𝑀0 for the initial amount of the drug and 𝑘 is the 
reaction rate constant of the release.  
The coloured curves show the formulations with different release profiles. The different release profiles 
depend on the composition of the matrix of the formulations.  
Formulations 1 to 3 with the higher zinc oxide content show the same release profile with a delayed start 
and more continuous release compared to ovalbumin. Subsequently, the release speed increases until 
approximately 120 min and slows down again with time. This release kinetic can best be described with 
the Higuchi release kinetic. The release is initially fast and then slows down. Although this law was first 
described for the release of suspended drugs from semi-solid preparations, it could also be used, for 
example, to describe the release of drugs from non-erodible matrix tablets. In the case of a non-erodible 
matrix tablet the drug substance has to move further and further over time. Within the experiment, it is 
not possible to say whether the particles remained intact or not. Since the dry formulation was placed 
on the ThinCert and only had contact with liquid on one side, the experiments were not directly similar 
to the common examples of the release kinetics, but had to be considered with a slightly different 
perspective. 
Equation 6.2 shows the corresponding mathematical function. 
Equation 6.2. Mathematical function of a Higuchi release kinetic. 
𝑀𝑡
𝐴
=  √2 ∗ 𝑐0 ∗ 𝐷 ∗  𝑐𝑠 ∗ 𝑡 
𝑀𝑡 stands for the released drug amount at time 𝑡, 𝐴 for the effective diffusion surface, 𝐷 is the diffusion 
coefficient, 𝑐0 describes the initial concentration in the carrier matrix and 𝑐𝑠 is the saturation 
concentration in the matrix material. The simplified form of the Higuchi release kinetics is shown in 
Equation 6.3 with 𝑘 as reaction rate constant of the release.  
Equation 6.3. Simplified mathematical function of a Higuchi release kinetic. 
𝑀𝑡 = 𝑘 ∗ √𝑡 
Linearisation can be achieved by using the square root of time as x-value instead of time.  
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With a coefficient of determination of R2 = 0.9702 (F1), R2 = 0.9575 (F2) and R2 = 0.9836 (F3), 
formulations 1 to 3 closely follow a Higuchi release kinetic. The formulations consisted mainly of zinc 
oxide, which is practically insoluble in water. First the ovalbumin located on the surface of the particle at 
the bottom of the ThinCert was dissolved. The water penetrates further and further into the particle and 
the dry formulation on the ThinCert and dissolved the ovalbumin, which had to travel an increasingly 
longer way to pass through the membrane of the insert, as the zinc oxide matrix did not dissolve. The 
increasing amount of mannitol from formulation 1 to formulation 3 did not seem to influence the release 
kinetics as long as the zinc oxide content is predominant. 
If the formulations with the lower proportion of zinc oxide and the higher proportion of mannitol 
(formulations 4 and 5) are considered, a clear difference to formulations 1 to 3 can be seen. The 
formulations with a higher mannitol content show an almost uniform release, which can best be 
described with the zero-order release kinetic (Equation 6.4). As long as undissolved ovalbumin was in 
the formulations, the same amount of ovalbumin was dissolved and released in each time interval, i.e., 
the rate is constant. Equation 6.4 can be used to describe the drug release from an erodible matrix. In 
this model, the drug substance always has to overcome the same distance to be released. The matrix is 
continuously degraded, while the release medium, which is responsible for dissolving the drug, 
penetrates further and further into the inner part of the particle.  
Equation 6.4. Mathematical function of a zero-order release kinetic. 
𝑀𝑡 =  𝑘 ∗ 𝑡 
𝑀𝑡 stands for the released drug amount at time 𝑡 and 𝑘 is the reaction rate constant of the release.  
If the amount of the drug released in formulations 4 and 5 is plotted against time, a straight line can be 
seen. With a coefficient of determination of R2 = 0.9945 (F4) and R2 = 0.9799 (F5), formulations 4 and 5 
closely follow a zero-order release kinetic. The formulations consisted mainly of mannitol, which is easily 
soluble in water. Both formulations also contained zinc oxide, which is practically insoluble in water. The 
mannitol was thus dissolved during the experiment, but the zinc oxide was not, i.e., the matrix and the 
amount of dry formulation on the ThinCert decreased further and further up to a certain point and the 
ovalbumin was released steadily. It should be noted that at the end of the experiment, approximately 
100 µL of a viscous suspension was formed on the insert of formulation 4 and 250 µL on the insert of 
formulation 5. The higher volume of the viscous suspension and therefore the lower volume of release 
medium would explain why formulation 5 shows a slower release than formulation 4. The viscous 
suspension led to a longer diffusion path for the ovalbumin in formulation 5 than in formulation 4, i.e., 
the release was slower.  
If formulation 6 with a matrix of 100 % mannitol is considered, it is noticeable that the release after 1 h 
is more similar to the formulations with the higher zinc oxide content, but then exceeds the plateau of 
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the reference ovalbumin. Finally, after 6 h, 84.2 % ± 4.2 % of the total ovalbumin is released. With a 
coefficient of determination of R2 = 0.9926 this release corresponds to a first-order kinetic (Equation 
6.1). The difference of almost 10 % to ovalbumin could be explained by the fact that the weighed amount 
of ovalbumin was only 10 % of formulation 6, i.e., the amount of ovalbumin stucking in the contact weld 
of the membrane and the insert was much more relevant for ovalbumin as single material than for 
formulation 6 as formulation 6 consisted of mannitol, ovalbumin and hyaluronic acid.  
Table 6.20. Release study of the formulations and ovalbumin (OVA) as reference with the released amount of 
ovalbumin in %. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 3, ± = standard deviation. 
 OVA F1 F2 F3 F4 F5 F6 
2 min 14.8 ± 13.2 1.5 ± 1.9 0.5 ± 0.4 -0.1 ± 1.0 0.0 ±0.7 0.0 ± 0.5 0.4 ± 0.3 
5 min 18.8 ± 12.5 4.7 ± 2.7 1.9 ± 0.3 2.4 ± 1.1 1.4 ± 1.1 1.2 ± 1.3 0.9 ± 0.6 
10 min 32.3 ± 6.8 8.2 ± 1.9 5.2 ± 0.7 7.4 ± 2.1 2.9 ± 0.9 2.2 ± 0.8 2.4 ± 1.1 
15 min 37.4 ± 8.3 10.0 ± 1.0 7.1 ± 1.5 8.6 ± 2.3 2.9 ± 1.7 2.2 ± 0.6 3.2 ± 1.0 
30 min 48.4 ± 6.6 17.4 ± 2.0 14.0 ± 5.9 14.5 ± 2.0 6.2 ± 1.7 3.1 ± 0.5 9.6 ± 2.8 
45 min 55.6 ± 8.9 29.9 ± 3.7 26.2 ± 10.6 24.9 ± 3.8 9.5 ± 2.0 4.0 ± 0.7 23.6 ± 4.5 
60 min 60.2 ± 13.9 34.5 ± 1.4 33.6 ± 9.9 27.7 ± 2.4 11.2 ± 2.2 5.2 ± 0.7 31.4 ± 4.6 
120 min 62.4 ± 8.6 51.1 ± 9.8 51.3 ± 9.6 47.5 ± 5.4 20.9 ± 4.3 9.5 ± 1.0 58.3 ± 7.1 
240 min 67.0 ± 8.8 59.5 ± 8.0 61.4 ± 5.1 62.2 ± 4.7 37.7 ± 6.5 27.3 ± 6.7 79.1 ± 5.1 
360 min 75.0 ± 8.5 70.7 ± 2.6 67.5 ± 4.7 71.9 ± 5.4 52.6 ± 2.5 46.9 ± 5.1 84.2 ± 4.2 
 
The question of why a viscous suspension has formed on the inserts in formulations 4 and 5 needs to 
be clarified. In addition to the hygroscopicity and osmolality of the formulations, the viscosity of the 
formulations was also considered. 
DVS was used to determine the hygroscopicity of all formulations and thus the ability to absorb water 
from the environment. In Figure 6.39 the change in mass is plotted for both cycles against the 
formulations. The corresponding values can be found in Table 6.21. All formulations show an almost 
identical characteristic curve in cycle 1 and cycle 2, i.e., the mass increases gradually as relative humidity 
increases and decreases gradually as relative humidity decreases. In both, cycle 1 and cycle 2, no specific 
events during water sorption and desorption can be seen. With over 2 % mass change at 80 % relative 
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humidity, all formulations are hygroscopic according to Ph. Eur. classification. In cycle 2 the change in 
mass for formulations 2 to 5 is smaller than in cycle 1. For formulation 1, change in mass increases 
minimally from 2.14 % to 2.16 %. Amorphous hydrophilic materials can adsorb water on their surface 
and absorb water inside. Crystalline materials, on the other hand, adsorb water only on their surface. 
Therefore, the recrystallisation of a material is accompanied by water loss in the sample and leads to a 
smaller mass change [240–242]. Since the water loss was usually fast and relatively strong, it could only 
be a recrystallisation of small percentages in the respective formulations. The diffractograms of X-ray 
powder diffraction (Figure 6.37) of all formulations were examined again and it is noticeable that only 
very small amorphous proportions can be involved.  
 
Figure 6.39. Hygroscopicity of all formulations at 80 % relative humidity with two bars showing the change in mass 
for cycles 1 and cycle 2 of the DVS double tree method. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 1. 
Table 6.21. Hygroscopicity of all formulations at 80 % relative humidity showing the change in mass for cycle 1 and 
cycle 2 using the DVS double tree method. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 1. 
 
The hygroscopicity probably only had a minor influence on the formation of the viscous suspension in 
the case of formulations 4 and 5 because the hygroscopic behaviour was very similar in all formulations. 
The formulations differed slightly in their change in mass during the absorption of water. 
 F1 F2 F3 F4 F5 F6 
Change in mass 
(Cycle 1), % 
2.14 2.83 2.61 2.92 3.04 2.69 
Change in mass 
(Cycle 2), % 
2.16 2.53 2.25 2.59 2.71 2.55 
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Osmolality of all formulations and thus the possibility to pull water through the membrane of the insert 
was evaluated. With very significant (F3: p-value = 0.0012, F4: p-value = 0.0039, F5: p-value = 0.0063) or 
highly significant (F2: p-value < 0.0001, F6: p-value = 0.0009) differences in osmolality, all formulations 
show an increase in osmolality compared to the previous formulation, e.g., formulation 2 is highly 
significantly different from formulation 1.  
The osmolality depends on the number of osmotically active particles in a certain mass of solvent. Zinc 
oxide as a component of the matrix of the formulations is practically insoluble in water. Mannitol as a 
component of the matrix of the formulations is dissolved in water and is therefore osmotically active. 
Ovalbumin and hyaluronic acid were present in all formulations in the same quantity and therefore have 
only a negligible effect on the different osmolalities of the various formulations. The observation of 
increasing osmolality can be seen in Figure 6.40 and Table 6.22, the higher the mannitol concentration, 
the higher the osmotic activity.  
 
Figure 6.40. Osmolality of all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, error bars = standard deviation, p-value < 0.01 = very significant difference (**),  
p-value < 0.001 = highly significant difference (***). 
These differences in osmolality might explain the viscous residues found during the release experiment 
for formulations 4 and 5. At the beginning of the experiment, the particles were undissolved and there 
was no osmotic activity. With progressing time, the mannitol components of the matrix dissolved and 
the osmolality increased. In the formulations 1 to 3, the zinc oxide portion, which is practically insoluble 
in water, predominated. In formulations 4 to 6, water soluble mannitol predominated and the osmotic 
activity increased with increasing mannitol content. In formulation 6 the osmolality was the highest. And, 
as no insoluble material was present, the dissolved mannitol could diffuse through the membrane and 
no residue was formed on the insert. In formulations 4 and 5, zinc oxide was present in the matrix. This 
means that the dissolved mannitol did not immediately diffuse through the membrane, as undissolved 
zinc oxide blocked the membrane and a viscous suspension could form on the insert. Formulation 4 
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contained 40 % zinc oxide and 60 % mannitol in the matrix, the osmotic activity was less and the 
insoluble amount higher than for formulation 5 with 20 % zinc oxide and 80 % mannitol. As a result, 
there were finally approximately 100 µL on the insert of formulation 4 and 250 µL on the insert of 
formulation 5. 
Table 6.22. Osmolality of all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; 
F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, ± = standard deviation. 
















To check whether viscosity also influences the release, the viscosity of all formulations and the starting 
materials, in the maximum concentrations present in the formulations, dissolved or suspended in water 
were tested. The results of the rheology studies of all formulations in water are shown in Figure 6.41 and 
Table 6.23. All samples show a pseudoplastic flow behaviour, i.e., the viscosity decreases with increasing 
shear rate. The initially disordered molecules align themselves with increasing shear rate, which reduces 
the internal resistance, i.e., a decreased viscosity. Once the orientation process is complete, the viscosity 
remains constant and a plateau is formed. In order to be able to compare the formulations, the viscosity 
at the plateau was used for evaluation.  
While mannitol and ovalbumin do not lead to an increase in viscosity, and zinc oxide only leads to a 
minimal increase in viscosity, hyaluronic acid has a strong influence on viscosity. With regard to viscosity, 
the formulations with higher mannitol content (formulations 4 to 6) have a slightly higher viscosity 
compared to the formulations with higher zinc oxide content (formulations 1 to 3). However, there is 
neither a trend in terms of concentrations nor is the difference significant. As observed in the previous 
experiment with the pure starting materials, there was no correlation between increasing viscosity and 
differences in the concentrations of mannitol and zinc oxide in the matrix. Hyaluronic acid led to strong 
increases in viscosity compared to the other starting materials.  
Since different pH values exist in the human body, the pH value dependent viscosity change of 
hyaluronic acid has already been investigated in many ways. As already mentioned in chapter 6.2.1.4, 
Maleki and coworkers investigated the effect of the pH value on the hyaluronic acid behaviour in 
different diluted aqueous solutions [234]. If the pH value measurements of the 24-h-solubility study are 
taken into account, it was noticeable that after 24 h in a sodium chloride solution a constant pH value 
almost independent of the starting pH was reached with approximately pH 7.6 for the 
formulations 1 to 5. Formulation 6 showed no plateau, but a slight increase from pH 6.5 to pH 6.9. These 
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pH values were rather in the neutral than in the low or high pH range. Therefore, the different viscosity 
of the formulations due to the pH dependent viscosity of hyaluronic acid could not only be explained 
by the pH value of the solutions. 
Burger und coworkers investigated the formation of a zinc (II) complex of hyaluronic acid [243]. Among 
other things, the viscosity of an aqueous solution of sodium hyaluronate and the corresponding zinc 
complex was investigated. They found that sodium hyaluronate has a six times higher viscosity than the 
zinc complex of hyaluronic acid. Zinc (II) ions in the aqueous solution bound to the oxygen-containing 
donor groups of hyaluronic acid in the pH range between pH 6.0 and pH 6.5. As a result, the random 
coil structure that led to the formation of a gel could no longer be formed and the viscosity decreased. 
At pH values starting from pH 4.0 the solubility of zinc oxide in the 24-h solubility study was only 
0.01 mg/mL. Nonetheless, this small amount of dissolved zinc might already led to a change in the 
structure, but had to be investigated further to be confirmed. Furthermore, formulation 6 did not contain 
zinc oxide, but showed a viscosity similar to all the other formulations. 
It can be assumed that both the composition of the formulations and the pH value had the effect that 
hyaluronic acid could not form its complete random coil structure. Therefore, hyaluronic acid in the 
formulations did not lead to the same viscosity increase as the pure hyaluronic acid. The formulations 
have a lower viscosity increase. However, it is less a question of the type and quantity of the different 
components than of the presence of other substances in much higher concentrations than the hyaluronic 
acid itself. 
 
Figure 6.41. Rheology studies of all formulations in water. H2O, ZnO, Mannitol, OVA and HA are used as references. 
Viscosity ranges at shear rates from 60 s-1 – 100 s-1 are shown. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
Formulations 4 and 5 have, as all the other formulations, a higher viscosity than water. The difference in 
viscosity between formulation 4 and 5 was only small and not significant. If the detected volume was 
taken into account, the higher volume of formulation 5 (250 µL) resulted in a lower viscosity compared 
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to formulation 4 (100 µL), because the amount of hyaluronic acid was the same, but the higher volume 
reduced the concentration. The small differences in viscosity and concentration would probably 
compensate each other and there would be no significant difference in the viscosity of the suspension 
on the insert between formulations 4 and 5. 
Table 6.23. Rheology studies of all formulations in water. H2O, ZnO, Mannitol, OVA and HA are used as references. 
Viscosity ranges at shear rates from 60 – 100 s-1 are shown. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 











































































The influence of the formulations and zinc oxide on pulmonary cells was evaluated in an in-vitro cell 
experiment. Specifically, the toxicity on pulmonary epithelial cells (Calu-3) after contact with the 
formulations was studied. Calu-3 were incubated for 24 h with the formulations as suspensions in 
different concentrations. In Figure 6.42 and Table 6.24, the LD50 of the formulations are shown. It should 
be mentioned that after incubation of the cells with the formulations, the formulations in the higher 
concentrations could not be completely removed from the cells because zinc oxide had very adhesive 
properties. For this reason, the higher concentrations are not shown and considered for the evaluation 
of LD50.  
With an LD50 of 0.018 mg/mL ± 0.006 mg/mL (zinc oxide), 0.013 mg/mL ± 0.005 mg/mL (F1) and 
0.010 mg/mL ± 0.000 mg/mL (F2), zinc oxide as raw material, formulations 1 and 2 show the highest 
toxicity with no significant difference. With a p-value of 0.0236 (F3) and a p-value of 0.0102 (F4), the 
toxicity of formulation 3 with 0.031 mg/mL ± 0.005 mg/mL and of formulation 4 with 
0.037 mg/mL ± 0.006 mg/mL are significantly lower than the toxicity of zinc oxide. Formulation 5 
(0.049 mg/mL ± 0.025 mg/mL) shows no significant differences in toxicity to zinc oxide as raw material. 
Formulation 6 (4.720 mg/mL ± 0.570 mg/mL) is very significantly less toxic than zinc oxide with a p-value 
of 0.0024.  
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Figure 6.42. LD50 of zinc oxide as raw material (ZnO) in comparison to all formulation in a Calu-3 model. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard 
deviation, p-value < 0.05 = significant difference (*), p-value < 0.01 = very significant difference (**). 
Table 6.24. LD50 of zinc oxide as raw material (ZnO) in comparison to all formulation in a Calu-3 model. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard 
deviation. 


















The LD50 values of zinc oxide and formulations 1 and 2 are not significantly different and increases from 
formulation 2 to 6, which means that the toxicity decreases. Therefore, the following section will examine 
whether there is a correlation between toxicity and zinc oxide concentration in the formulations.  
For this reason, in Figure 6.43 and Table 11.6 the viability of formulations is considered as a function of 
the zinc oxide concentration. If the toxicity depends on the zinc oxide concentration, the resulting curves 
would be similar. As formulation 6 did not contain zinc oxide, it is not included in the graph. All curves 
show similar graphs. While the viability at a zinc oxide concentration of less than 0.005 mg/mL is almost 
100 %, it decreases in the range of 0.005 mg/mL to 0.05 mg/mL to finally almost 30 % viability at 
concentrations of approximately 0.05 mg/mL. The toxicity is thus mainly dependent on the zinc oxide 
concentration. However, as in-vitro-cell experiments are living systems, variability can easily occur. 
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Figure 6.43. Viability as a function of the zinc oxide concentration in all formulations, to identify whether toxicity is 
dependent on zinc oxide concentrations in the formulation. Zinc oxide as raw material (ZnO) is used as a reference. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol. n = 3, error bars = standard deviation. 
6.2.2.6 pH – cell culture 
After determining the LD50 of each formulation and of zinc oxide, these concentrations of 50 % viability 
should be used to test the reaction, resulting pH values, of the cells in the air-liquid interface. As shown 
in the 24-h-solubility study, the zinc oxide concentration had a partial influence on the pH value of a 
solution or buffer. In order to see whether the formulations and thus the zinc oxide concentration also 
have an influence on the cells and thus on the resulting pH and whether the reaction of the cells 
influences the resulting pH, the pH value in in-vitro cell experiments was examined. To ensure that a 
Calu-3 monolayer had been formed, the TEER was determined at the beginning of the experiments. 
Measurement of TEER provides a value for the formation of tight junctions and is often used as a marker 
of disruption [244]. A Calu-3 monolayer usually show a plateau of a TEER value of 300 Ω/cm2 between 
day 10 and day 13 in an air-liquid interface [244–246]. After 10 days of growing the Calu-3 monolayer 
was used. They showed a TEER value of 140.9 Ω/cm2 ± 89.9 Ω/cm2, which was a little lower than usually 
shown. The formulations (formulations 1 to 3) with higher zinc oxide amount and zinc oxide as raw 
material are shown in Figure 6.44. The formulations with lower zinc oxide content (formulations 4 to 6) 
and cells without formulation are shown in Figure 6.45. The exact values can be found in Table 6.25. 
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Figure 6.44. The influence of formulations 1, 2 and 3 on pH values in a Calu-3 model. Zinc oxide as raw material is 
used as reference. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol. n = 3, error bars = standard deviation. 
 
Figure 6.45. The influence of formulations 4, 5 and 6 on pH values in a Calu-3 model. Calu-3 cells without a 
formulation are used as reference. F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO 
and 100 % mannitol. n = 3, error bars = standard deviation. 
The formulations with a higher amount of zinc oxide show a plateau at the beginning of the 
measurement until 4 h, while zinc oxide as raw material creates the highest pH value. The starting pH 
decreases with decreasing zinc oxide amount. The pH value decreases from 4 h to 24 h for all 
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formulations. Even after 24 h the pH value is dependent on the zinc oxide concentration, i.e., 
formulation 3 has the lowest pH value with pH 6.50 ± 0.10. Formulations 2 with pH 6.61 ± 0.02 and 1 
with pH 6.68 ± 0.06 follow. The highest pH value is shown by Calu-3 cells with zinc oxide as raw material 
(pH 6.75 ± 0.08). 
The formulations with a lower content of zinc oxide and the cells without a formulation show a totally 
different behaviour from formulations with higher zinc oxide content as well as pure zinc oxide. While 
the pH value is decreasing at the beginning, a plateau is reached after 4 h. Again, the pH value is 
dependent on the zinc oxide concentration. Formulation 4 has the highest pH value at the beginning 
(pH 7.24 ± 0.03) and after 24 h (pH 6.73 ± 0.01). Formulation 5 show a lower pH value at the beginning 
(pH 7.12 ± 0.03) and after 24 h (pH 6.71 ± 0.05). The lowest pH value at the beginning (pH 7.03 ± 0.01) 
and after 24 h (pH 6.66 ± 0.04) is shown by formulation 6. 
Table 6.25. The influence of formulations 1 to 6 on pH values in a Calu-3 model. Calu-3 with zinc oxide as raw 
material as well as Calu-3 without formulation are used as references. F1) 100 % ZnO and 0 % mannitol; 
F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO 
and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 
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To make sure that these changes in pH were not due to the toxicity of the formulations, the viability was 
determined visually and the disruption of the monolayer by measuring the TEER. As mentioned before, 
the Calu-3 monolayer showed a start TEER value of 140.9 Ω*cm2 ± 89.9 Ω*cm2. To avoid including the 
TEER of the insert in the TEER of the cells, the value of the inserts without the cells 
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(290.0 Ω*cm2 ± 10.0 Ω*cm2) was also determined at the beginning and had already been included in the 
calculations. 
A trend in the TEER measurements after 24 h could be assumed and is shown in Figure 6.46 and 
Table 6.26. While zinc oxide as raw material and formulations 1 to 3 with a higher zinc oxide amount 
increase the TEER values compared to the starting TEER, the formulations with a higher mannitol amount 
and the Calu-3 monolayer without a formulation decrease the TEER values compared to the starting 
TEER. There are also significant differences of the TEER values of the Calu-3 monolayer after 24 h with 
or without the formulations and with zinc oxide as raw material to the starting TEER. 
 
Figure 6.46. Confluency of Calu-3 cell monolayer, measured as TEER value. Calu-3 with zinc oxide as raw material as 
well as Calu-3 without formulation after 24 h as well as inserts without cells and Calu-3 without formulation at the 
beginning of the experiment are used as references F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
After 24 h without a formulation, the Calu-3 monolayer shows a significantly different TEER with 
64.6 Ω*cm2 ± 51.6 Ω*cm2 and a p-value of 0.0465 compared to the starting TEER. Also, formulations 4 
with 48.3 Ω*cm2 ± 32.0 Ω*cm2 (p-value = 0.0177) and 5 with 58.4 Ω*cm2 ± 36.1 Ω*cm2  
(p-value = 0.0196) show a significant difference. Formulation 6 with 33.3 Ω*cm2 ± 25.4 Ω*cm2  
(p-value = 0.0068) and zinc oxide as raw material with 290.6 Ω*cm2 ± 81.5 Ω*cm2 (p-value = 0.0021) 
show a very significantly different TEER to the starting TEER. Formulation 2 with 
268.4 Ω*cm2 ± 59.3 Ω*cm2 (p-value = 0.0008) and the starting TEER are highly significantly different. 
Formulations 1 with 185.7 Ω*cm2 ± 102.2 Ω*cm2 and 3 with 139.4 Ω*cm2 ± 101.9 Ω*cm2 show no 
significant difference. 
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Table 6.26. Confluency of Calu-3 cell monolayer, measured as TEER value. Calu-3 with zinc oxide as raw material as 
well as Calu-3 without formulation after 24 h as well as inserts without cells and Calu-3 without formulation at the 
beginning of the experiment are used as references F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 




F1 24 h F2 24 h F3 24 h F4 24 h F5 24 h F6 24 h 
w/o 
24 h 






















Even if a trend in the data was visible, the visual observation and also the toxicity measurements in 
chapter 6.2.2.5 would not indicate a toxic effect. The statistical differences in the TEER values after 24 h 
compared to the TEER values at the beginning indicated rather a disruption of the Calu-3 monolayer 
when incubating the cells with the formulations with a higher mannitol amount (formulation 4 to 6) and 
without formulation. It should be mentioned that the start TEER value was relatively low with 
140.9 Ω*cm2 ± 89.9 Ω*cm2. The TEER values after 24 h of the Calu-3 monolayer incubated with the 
formulation with a higher zinc oxide amount (formulations 1 to 3) and with zinc oxide would indicate a 
further formation of the Calu-3 monolayer as the TEER values increased and the cells with zinc oxide 
reached the TEER value of 300 Ω*cm2 described for the Calu-3 monolayer. 
Calu-3 as an epithelial cell model produces in-vivo characteristics similar to native airways epithelium in 
terms of differentiation, morphology, polarisation and TEER. The Calu-3 model is investigated in 
numerous experiments, e.g., to study toxicological effects or transport mechanisms. Ong et al. [247] 
investigated the effect of mannitol on the transport of ciprofloxacin across respiratory epithelia. They 
also studied the change in pH on the surface of the Calu-3 monolayer 1 h after adding mannitol. It was 
shown that the deposition of mannitol increased osmolarity. This in turn increased the transepithelial 
water flow and lowers the pH value. Furthermore, the stress caused by the increased osmolarity was 
mentioned as an influencing variable of the ion response of the epithelial cells.  
When comparing these results with the pH changes of pulmonary formulations with a higher mannitol 
content (formulations 4 to 6), certain similarities could be seen. Formulation 6 had the highest mannitol 
content and showed the lowest pH after 1 h with a pH value of pH 7.02 ± 0.03. Formulation 4, with a 
mannitol content of 60 %, had the lowest mannitol content of the three tested formulations, but the 
highest pH value of pH 7.20 ± 0.07. An explanation could be found in the increasing osmolality by higher 
mannitol content. However, the cells without formulation in the same diagram (Figure 6.45) showed an 
even lower pH value (pH 6.94 ± 0.02) in comparison to cells incubated with formulation 6. Regardless of 
the formulation used, all Calu-3 monolayers showed a pH value of about pH 6.7 after 24 h incubation. 
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In a review of Fischer et al. [248] different mechanism of acid and base secretion by the airway epithelium 
are summarised. Among other things, it was found that both acid and carbonates are permanently 
secreted in considerable quantities in the airways. Investigations of different acid transporters were 
carried out using different molecular and functional approaches. However, a more detailed 
understanding of the individual acid transporters for the regulation of acidification of the air-liquid 
interface is still missing.  
Looking at the pH changes of the Calu-3 monolayer of the formulations with a higher mannitol amount 
and without a formulation, a decrease in pH due to acidic metabolic products can nevertheless not be 
ruled out. 
But what causes the differences in cells incubated with the pulmonary formulations? A possible 
explanation could again be the different amounts of zinc oxide. If the Calu-3 monolayer was alkalised to 
a higher pH value by zinc oxide, the cells tried to equalise the pH value again and acidify. In the 24-h-
solubility tests, the formulations increased the pH value almost independently of the initial pH value and, 
depending on the system used, almost independently of the zinc oxide concentration, if zinc oxide was 
present in the formulation. The Calu-3 air-liquid interface is a living model and not a static experiment 
in the laboratory. The amount of zinc oxide exposed to the Calu-3 cells affects both the cells and the pH 
value. The formulations with the higher zinc oxide amount (formulations 1 to 3) led to longer 
maintenance of the alkaline pH value, because the acidification of the cell did not initially compensate 
the alkaline effect of the zinc oxide. Again, a connection with the zinc oxide concentration could be seen. 
While zinc oxide as raw material and formulation 1 with 100 % zinc oxide as matrix show a similar pH 
value with pH 7.02 ± 0.01 (ZnO) and pH 6.98 ± 0.04 (formulation 1), the pH value of formulation 3 drops 
to pH 6.83 ± 0.05. As the experiment progressed, the acidification progresses and hence the cells and 
consequently also the medium was acidified to a pH value suitable for the cells. Even if a pH value of 
pH 7.4 is assumed in the lung, the literature reports a repeatable and consistent pH value of about pH 6.6 
for the air-liquid interface [248]. Even with small deviations in the experiments, the pH value of 
approximately pH 6.6 could be recognised as the pH value after 24 h. 
6.2.2.7 Loading 
The main mission of vaccination is to deliver a certain concentration of the antigen. In order to verify the 
exact loading of the particles with the antigen, the loading was determined after spray drying via UV/Vis 
spectroscopy at 205 nm. 
Figure 6.47 shows the found concentration of ovalbumin in all formulations after the spray drying 
process compared to the added concentration of ovalbumin. 0.1 mg ovalbumin per mg formulation was 
added to all formulations as starting concentration and almost 100 % of the used ovalbumin is recovered 
after spray drying (Table 6.27). There is no significant difference between individual formulations. 
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Figure 6.47. Concentration of ovalbumin (coloured bars) in all formulations after the spray drying process in 
comparison to the used amount of ovalbumin (black bars). 1) 100 % ZnO and 0 % mannitol; 2) 80 % ZnO and 
20 % mannitol; 3) 60 % ZnO and 40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 
6) 0 % ZnO and 100 % mannitol. n = 3, error bars = standard deviation. 
Table 6.27. Concentration of ovalbumin in all formulations after the spray drying process in comparison to the used 
amount of ovalbumin. 1) 100 % ZnO and 0 % mannitol; 2) 80 % ZnO and 20 % mannitol; 3) 60 % ZnO and 
40 % mannitol; 4) 40 % ZnO and 60 % mannitol; 5) 20 % ZnO and 80 % mannitol; 6) 0 % ZnO and 100 % mannitol. 
n = 3, ± = standard deviation. 

































Besides loading, the stability of the protein after spray drying is also of interest. In Figure 6.48, 
representative chromatograms of size exclusion chromatography (graphs) and representative pictures 
of SDS-PAGE of pure ovalbumin in comparison to all formulations are shown. 
The horizontal dotted lines above the peaks show the individual molar mass of the molecules that 
contributes to the formation of the peak. Pure ovalbumin was used as a reference substance in the SEC 
measurements and in the SDS-PAGE to see if there is a difference between the starting material and the 
ovalbumin in the formulation. As reference for the analysis of the SDS-PAGE a marker with the given 
molecular weights was used additionally (left, white font).  
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Figure 6.48. Representative chromatograms of size exclusion chromatography and representative pictures of SDS-
PAGE of ovalbumin (OVA) as raw material in comparison to all formulations. F1) 100 % ZnO and 0 % mannitol; 
F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO 
and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 1. 
In Table 6.28 the individual peaks of the SEC are analysed from right to left, with peak 1 representing 
the monomer, peak 2 the dimer and peak 3 the trimer. All peaks are used to calculate the total molecular 
weight. In Figure 6.48, there is a large peak (peak 1) for ovalbumin (black), a smaller peak (peak 2) in 
front of it and a shoulder (peak 3) in front of peak 2. The ovalbumin used as starting material consists of 
monomers, dimers and trimers, whereas the distribution of the molar masses is homogeneous as there 
is almost no slope visible in the dotted black lines. With a mass recovery of 67.9 %, the monomer 
(39.8 kDa) makes up the largest part, followed by the dimer (83.1 kDa) with 5.8 % and finally the trimer 
(127.5 kDa) with 1.0 %. With a total molecular weight of 44.4 kDa 74.8 % of the used amount could be 
detected with SEC. The question why only 75 % of the ovalbumin could be recovered is already discussed 
in chapter 6.2.1.6. 
All formulations show a curve similar to ovalbumin, i.e., a large peak (peak 1), a smaller peak with a 
slightly different height (peak 2) and a small shoulder (peak 3) and thus consist of monomers, dimers 
and trimers. The dotted lines of peak 1 and peak 2 of all formulations are similar to the dotted lines of 
ovalbumin. The slope of the dotted line of peak 3 of the formulations is higher compared to the dotted 
line of peak 3 of ovalbumin and varies within the formulations depending on the composition of the 
formulation. The slope becomes steeper the higher the zinc oxide concentration in the formulation, i.e., 
the slope is highest for formulation 1 and becomes flatter and flatter until finally the dotted line of 
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formulation 6 is almost identical to the dotted line of ovalbumin. The distribution is therefore fairly more 
inhomogeneous in the direction of higher molar masses. This indicates the formation of multimers.  
Table 6.28. Representative data of size exclusion chromatography of ovalbumin (OVA) as raw material in comparison 
to all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 1. 


























OVA 39.8 67.9 83.1 5.8 127.5 1.0 44.4 74.8 
F1 38.4  44.0 79.7 4.8 118.0 1.1 44.2 50.0 
F2 39.2 45.6 82.1 5.5 132.1 1.5 46.4 52.8 
F3 39.7 44.0 87.4 4.7 189.5 0.9 47.0 49.6 
F4 39.2 49.6 83.9 5.9 146.5 1.2 46.2 56.9 
F5 39.4 59.2 84.7 6.5 153.4 1.5 46.4 67.3 
F6 39.1 50.9 85.8 4.5 175.5 0.8 44.9 56.4 
 
For all formulations, with a mass recovery of 44.0 % to 59.2 %, the monomer (38.4 kDa to 39.7 kDa) 
makes up the largest part, followed by the dimer (79.7 kDa to 87.4 kDa) with 4.5 % to 6.5 % and finally 
the trimer (118.0 kDa to 189.5 kDa) with 0.8 % to 1.5 %. With a total molecular weight of 44.2 kDa to 
47.0 kDa 49.6 % to 67.3 % of the used amount could be detected. However, a trend in the molecular 
weights and the mass recovery of the formulations depending on the composition cannot be seen, but 
all formulations show less mass recovery than pure ovalbumin.  
In addition to the SEC graphs, representative pictures from the SDS-PAGE can also be seen in Figure 6.48. 
Pure ovalbumin shows a doublet between 34 kDa and 50 kDa [238]. All formulations show a similar 
doublet between 34 kDa and 50 kDa with varying intensities depending on the composition of the 
matrix. The irregular shape of the doublet of formulation 6 is due to the position in the gel of SDS-PAGE. 
While the doublet is palest in formulation 1 with the highest content of zinc oxide and without mannitol, 
the intensity continues to increase until formulation 6 with the highest amount of mannitol and without 
zinc oxide. Ovalbumin might already be denatured before the measurements. By centrifugation, the 
denatured ovalbumin would have been separated and can hence not be detected by SDS-PAGE.  
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If the data from SEC and SDS-PAGE are combined, it became obvious that the composition of the matrix 
had an influence on the denaturation of the ovalbumin in the formulations. As the amount of mannitol 
increased, the stabilising effect on ovalbumin during spray drying also increased. The ovalbumin in 
formulation 6 was thus stabilised and remained largely intact, while the ovalbumin in formulation 1 was 
denatured. 
6.2.2.8 Aerodynamic assessment using the Precise Inhale 
To identify the best formulation of the six spray dried formulations for pulmonary application for the 
finally planned in-vivo studies, the yield, the maximum aerosol concentration and the inhaled aerosol 
dose was assessed using the Precise Inhale. 
Figure 6.49 shows the yield, which is the amount of formulation found on the filter in the in-vitro 
exposure block after the experiment in relation to the weighed quantity. Figure 6.50 shows the maximum 
aerosol concentration shown as coloured bars as well as the inhaled aerosol dose shown as dots of all 
formulations using the Precise Inhale in combination with an impactor nozzle. The same trend can be 
seen in both diagrams. 
 
Figure 6.49. Yield of the aerodynamic assessment using the Precise Inhale of zinc oxide as raw material in comparison 
to all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 
40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 
100 % mannitol. n = 5, error bars = standard deviation, p-value < 0.05 = significant difference (*),  
p-value < 0.01 = very significant difference (**), p-value < 0.001 = highly significant difference (***). 
Formulation 2 shows the highest yield (35.6 % ± 3.3 %) as well as the highest maximum aerosol 
concentration (1.87 mg/L ± 0.26 mg/L) and inhaled aerosol dose (0.488 mg ± 0.063 mg). Formulation 2 
has no significantly higher yield compared to zinc oxide as raw material, a significantly higher yield 
compared to formulation 1 (p-value = 0.0218), a highly significantly higher yield compared to 
formulations 3 (p-value < 0.0001) and 4 (p-value < 0.0001) and a very significantly higher yield 
compared to formulations 5 (p-value = 0.0025) and 6 (p-value = 0.0023). 
Results and discussion 148 
148 
 
Figure 6.50. Max. aerosol concentration (primary axis) and inhaled aerosol dose (secondary axis) of the aerodynamic 
assessment using the Precise Inhale of zinc oxide as raw material in comparison to all formulations. F1) 100 % ZnO 
and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 
60 % mannitol; F5) 20 % ZnO and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 5, error bars = standard 
deviation. 
Formulation 2 shows no significantly higher maximum aerosol concentration compared to zinc oxide as 
raw material, but a significantly higher maximum aerosol concentration than formulation 1  
(p-value = 0.0409) and highly significant higher values compared to formulations 3 (p-value < 0.0001), 
4 (p-value = 0.0001), 5 (p-value < 0.0001) and 6 (p-value < 0.0001). A similar picture is visible for the 
inhaled aerosol dose. Formulation 2 also has no significantly higher amount compared to zinc oxide as 
raw material and formulation 1, but highly significantly higher values compared to formulations 3  
(p-value = 0.0002), 4 (p-value < 0.0001), 5 (p-value < 0.0001) and 6 (p-value < 0.0001).  
Table 6.29. Yield, max. aerosol concentration and inhaled aerosol dose of the aerodynamic assessment using the 
Precise Inhale of zinc oxide as raw material in comparison to all formulations. F1) 100 % ZnO and 0 % mannitol; 
F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO 
and 80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 5, ± = standard deviation. 
 Yield, % 
Max. aerosol concentration, 
mg/L 
Inhaled aerosol dose, mg 
ZnO 27.7 ± 10.9 1.37 ± 0.34 0.337 ± 0.168 
F1 25.5 ± 8.8 1.36 ± 0.52 0.357 ± 0.149 
F2 35.6 ± 3.3 1.87 ± 0.26 0.488 ± 0.063 
F3 9.7 ± 4.2 0.40 ± 0.16 0.085 ± 0.137 
F4 18.0 ± 1.4 0.59 ± 0.06 0.120 ± 0.015 
F5 21.2 ± 7.7 0.70 ± 0.31 0.155 ± 0.087 
F6 23.1 ± 6.4 0.81 ± 0.23 0.192 ± 0.073 
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Since the yield as well as the maximum aerosol concentration and the inhaled aerosol dose should be 
as high as possible for the final in-vivo experiments, formulation 2 was further investigated in the 
following immunological in-vitro cell experiments. A maximum yield of approximately 35 % for 
formulation 2 was not really a high yield, which could lead to problems, i.e., too low concentrations of 
the formulation deposited in the lungs or too many experiments for the right dose in in-vivo 
experiments. This would not only lead to insufficient immunisation but also to an unacceptable stress 
for the animals. A production of smaller spray dried particles for pulmonary application increased the 
yield for formulation 2 from 35.6 % ± 3.3 % to 51.4 % ± 15.5 %, again showing the best performance. 
However, since the formulations had to be suspended anyway for the immunological in-vitro cell 
experiments and the composition of the particles is the same regardless of the particle size, 
formulation 2 could be used in the following cell activation experiments in the particle size of the results 
shown. 
6.2.2.9 Cell activation experiment 
Since formulation 2 showed the highest yield as well as the maximum aerosol concentration and the 
inhaled aerosol dose, the cell activation experiments were performed with formulation 2. BMDC 
obtained from female CF57BL/6N mice were evaluated after incubation with a negative control (RPMI), 
a positive control (10 ng LPS), the antigen (5 µg ovalbumin) and formulation 2. Formulation 2 was tested 
in three different concentrations: 50 µg, 25 µg and 10 µg per well. 50 µg per well was chosen as the 
highest concentration, as this amount contains 4.5 µg ovalbumin and thus approximately corresponded 
to the concentration of ovalbumin used as pure antigen control. The up-regulation of four different 
markers (CD40, CD80, CD86 and MHC-II) and thus the stimulation of the dendritic cells was examined 
after staining with fluorescent dyes using flow cytometry.  
CD40 is known as a marker for B cell activation, CD86 for early DC maturation and CD80 for late DC 
maturation. In general, dendritic cells only have the ability to take up antigens in tissues. Once they have 
migrated into the lymphatic system, they lose this property and begin to mature and activate T cells. 
CD80 and CD86 are two important costimulatory molecules in this process. They are induced in response 
to contact with pathogens. They interact with receptors on the T cells, e.g., the best known costimulatory 
receptor CD28. To be activated, a naive T cell has to recognise both the antigen and a costimulatory 
ligand on the same antigen presenting cell. The signals from CD28 then support antigen dependent 
activation of T cells primarily by promoting T cell proliferation, cytokine production and cell survival. 
While CD28 is the primary costimulatory receptor for naive T cells, CD40 is the primary receptor for naive 
B cells. CD40 activates both the NFκB and PI-3 kinase pathways after receptor stimulation. NFκB 
activation enhances cell survival and PI-3 kinase shows a wide range of effects on B cell physiology. 
Generally speaking, the function of CD28 for the T cells corresponds to the function of CD40 on the 
B cells [171].  
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While CD80 and CD86 are expressed during DC maturation, the number of MHC molecules on the cell 
surface is increased. MHC-I molecules and MHC-II molecules are found on different cell types, but both 
are found on dendritic cells in lymphoid tissue. While MHC-I molecules present peptides from pathogens 
to the cytotoxic CD8 T cells and therefore all cells with these peptides are killed, CD4 T cells recognise 
the peptides presented by MHC-II molecules and thereby activate other effector cells of the immune 
system [171]. The stimulated CD4 T cells induce the development of IgA bound B cells in the lymphoid 
follicle. After maturation, these B cells migrate from the MALT to the regional cervical lymph nodes. 
Finally, antigen-specific CD4 T cells and IgA-positive B cells migrate to the effector sites [26]. 
Figure 6.51 and Table 6.30 show the results of the cell activation experiments. Based on the negative 
and positive control, it can be seen that the experiments are valid for all markers, since the negative 
control is lower than the positive control.  
 
Figure 6.51. Immunological in-vitro cell experiments of formulation 2 in a BMDC model; F2) 80 % ZnO and 
20 % mannitol. RPMI, LPS, OVA: n = 2, error bars = min/max; F2: n = 1. 
Ovalbumin as antigen shows values comparable to the positive control, although the concentration used 
is many times higher. The different immunological markers give different values for the negative control, 
the positive control and the antigen. The fluorescent markers used for the immunological markers were 
excited at the same wavelength, but showed different fluorescence strengths, which explained the 
different MFI values of the controls. If formulation 2 is now examined in different concentrations with 
the different markers, differences can be seen. The different concentrations of formulation 2 do not show 
any increase in CD40 compared to the negative control. For CD86, formulation 2 at 25 µg and 50 µg 
shows similarly high values as the positive controls and the antigen and at 10 µg comparable values with 
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the negative control. Also, for CD80, the lowest concentration of formulation 2 shows comparable values 
with the negative control and the two higher concentrations of 25 µg and 50 µg show higher values than 
the negative control but lower values than the positive control and the antigen. For MHC-II, 
formulation 2 at the lowest concentration of 10 µg shows slightly higher values than the negative control 
and the two higher concentrations of 25 µg and 50 µg show higher values than the positive control and 
the antigen. It is important to note that the measured values of formulation 2 are only a single 
determination and therefore only a tendency could be identified from the data and not an absolute 
statement. 
Table 6.30. Immunological in-vitro cell experiments of formulation 2 in a BMDC model; F2) 80 % ZnO and 
20 % mannitol. RPMI, LPS, OVA: n = 2, ± = min/max; F2: n = 1. 
 
CD11c+ x+ MFI 
CD40 CD86 CD80 MHC-II 
RPMI 763.5 ± 3.5 826.0 ± 43.0 2,930.5 ± 63.5 5,005.5 ± 329.5 
LPS 10 ng 2,041.0 ± 36.0 1,567.5 ± 33.5 9,589.0 ± 306.0 7,180.0 ± 245.0 
OVA 5 µg 1,883.0 ± 127.0 1,605.0 ± 110.0 9,449.5 ±324.5 8,150.0 ± 725.0 
F2 50 µg 731.0 1,687.0 7,282.0 1,0056.0 
F2 25 µg 826.0 1,812.0 7,071.0 9,717.0 
F2 10 µg 637.0 728.0 2,881.0 5,863.0 
 
As already mentioned, zinc oxide has many different applications. Roy and coworker investigated the 
immunomodulating effect of zinc oxide in their study [249]. The effect of zinc oxide was investigated in 
mice sensitised with ovalbumin. In addition to the increased proliferation of T cells compared to the 
control, a high expression of MHC-II molecules could also be observed. Transferring the results of the 
study to in-vitro cell experiments, the adjuvant effect of zinc oxide would be based on the increase of 
CD80 and CD86 and thus a theoretically increased proliferation of T cells and the high expression of 
MHC-II molecules. These expectations are reflected by the results of the in-vitro cell experiments. While 
MHC-II shows an increased expression compared to the antigen when using formulation 2, an increase 
is seen for CD80 and CD86 compared to the negative control. Thus, an activation of the dendritic cells 
can be observed for MHC-II as well as for CD80 and CD86. It is striking that there is almost no difference 
between 25 µg and 50 µg. For this purpose, the composition of formulation 2 had to be considered. The 
matrix consisted of 80 % zinc oxide and 20 % mannitol. Furthermore, it contained additional 10 % 
ovalbumin and 1 % hyaluronic acid. While 50 µg of formulation 2 per well contained approximately 
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36 µg zinc oxide and 4.5 µg ovalbumin, 25 µg of formulation 2 per well contained approximately 18 µg 
zinc oxide and 2.25 µg ovalbumin. On the one hand, the different concentrations of zinc oxide had 
different toxic effects on the dendritic cells and on the other hand, the basic level of activation of the 
dendritic cells by the antigen varied. While for 50 µg of formulation 2 5 µg ovalbumin could be 
considered as the reference concentration, for 25 µg of formulation 2 the reference concentration of the 
antigen has to be lower. In addition, as already shown in the toxicity studies, zinc oxide had a toxic effect 
at higher concentrations. Of course, the toxicity studies of the Calu-3 cells could not be applied one-to-
one to the BMDC, but the trend was similar, i.e., toxicity increases or viability decreases with increasing 
concentration, i.e., 37.5 % viability for 50 µg and 45.8 % viability for 25 µg of formulation 2 per well. If 
the data are examined more closely, the adjuvant effect is probably higher at 25 µg per well than at 
50 µg per well, since the toxic effect of the zinc oxide is higher at the higher concentration and thus the 
possibly higher immune response is masked by the higher toxicity. No adjuvant effect or activation of 
the BMDC is observed with CD40.  
An adjuvant effect of the zinc oxide in formulation 2 can be assumed on the basis of the cell activation 
experiments through the expression of CD80, CD86 and MHC-II. However, a final statement is only 
possible when the formulations are tested in in-vivo studies. These studies had already been planned, 
but could not be carried out within the context of this thesis due to the COVID-19 pandemic. 
Nevertheless, the in-vitro experiments are a first indication for an adjuvant effect. 
6.2.2.10 Summary and conclusion 
By spray drying, it was not only possible to produce particles for nasal application, but also for pulmonary 
administration with a defined particle size < 5 µm. Zinc oxide was spray dried together with hyaluronic 
acid, ovalbumin and mannitol in water. A total of six different formulations was prepared with different 
concentrations of zinc oxide and mannitol. The matrix of formulation 1 consisted of 100 % zinc oxide 
and that of formulation 6 of 100 % mannitol. The concentrations of hyaluronic acid and ovalbumin 
remained constant. 
All formulations formed dry white powder after spray drying with almost no visible differences in particle 
size and particle size distribution, but visible differences in morphology. Formulations 1, 2 and 6 showed 
the typical spherical shape of spray dried particles, with formulations 1 and 2 showing an irregular and 
formulation 6 a smooth surface. All other formulations had wrinkled particles in a mixture with spherical 
particles. The difference in composition was visible by the decreasing proportion of zinc oxide particles 
present from formulation 1 (100 % zinc oxide) to formulation 6 (0 % zinc oxide). Measurements of the 
particle size distribution with the RODOS module showed an x50 smaller than 5 µm for all formulations 
and an x90 of almost 5 µm for formulation 1. When measuring the particle size distribution with the 
INHALER module in combination with the Cyclohaler, formulation 6 had almost 65 % of the particles 
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smaller than 5 µm, formulations 2, 3, 4 and 5 had 40 % to 50 % of particles smaller than 10 µm and 
formulation 1 had almost 35 % of the particles smaller than 5 µm. 
With more than 30 %, formulations 4, 5 and 6 showed higher fine particle fraction compared to 
formulations 1, 2 and 3 with less than 30 % of the delivered dose smaller than 5 µm (aerodynamic 
diameter). An NGI was used in combination with the mouthpiece, the throat, the preseparator and the 
Cyclohaler for aerodynamic characterisation.  
To stimulate an immune response in the respiratory tract, an antigen has to be taken up in a particulate 
form by antigen presenting cells. For this reason, the amount of dissolved zinc oxide in different media 
was investigated. Sodium chloride solutions and phosphate buffers with different pH levels were 
prepared to mimic relevant pH conditions in the human body. In addition, simulated lung fluid was 
tested, which took account of the salt and pH conditions in the lungs. In addition to the solubility, the 
influence of zinc oxide (dissolved or undissolved) on the pH values after 24 h was also investigated. 
Formulation 1, as representative sample, was slightly soluble in pH 1.2, very slightly soluble in pH 2.5 
and practically insoluble in pH values above pH 2.5, both in sodium chloride solution and in phosphate 
buffer. Similar to sodium chloride solution and phosphate buffer formulation 1 was also practically 
insoluble in simulated lung fluid. After 24 h, the pH value increased depending on the starting pH value 
in the phosphate buffer, while the zinc oxide content had an influence on the pH change: the higher the 
zinc oxide amount, the stronger the pH shift. In both the sodium chloride solution and simulated lung 
fluid, the pH value reached a plateau of approximately pH 7.5 after 24 h with the formulations for 
formulations 1 to 5 and of approximately pH 6.5 to pH 6.9 for formulation 6.  
After the solubility of the individual formulations was investigated in relation to zinc oxide, the release 
of ovalbumin from the formulations was also examined. While ovalbumin as reference showed a first-
order dissolution kinetic and formulation 6 showed a first-order release kinetic, formulations 4 and 5 
followed a zero-order release kinetic and formulations 1, 2 and 3 a Higuchi release kinetic. The type of 
release therefore depended on the concentration of zinc oxide in the formulation, with a difference 
between formulations containing primarily zinc oxide as a matrix (formulations 1, 2 and 3), formulations 
containing less zinc oxide than mannitol as a matrix (formulations 4 and 5) and the formulation 
containing no zinc oxide as a matrix (formulation 6). 
The concentration of zinc oxide played also an important role in the toxicity tests of the formulations. 
After 24 h incubation of Calu-3 with the formulations, the LD50 increased from formulation 1 to 
formulation 6, i.e., the toxicity decreased from formulation 1 to formulation 6 and is thus dependent on 
the zinc oxide concentration. The determined LD50 were used to test the resulting pH values of the cells 
in the air-liquid interface. All formulations showed a decreased pH value after 24 h. The formulations 
with a higher amount of zinc oxide (formulations 1, 2 and 3) had a pH value plateau at the beginning of 
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the measurement until 4 h with the highest pH value for formulation 1 with the highest zinc oxide 
amount. The formulations with a lower content of zinc oxide (formulations 4, 5 and 6) had a pH value 
plateau after 4 h. Again, the pH value was dependent on the zinc oxide concentration.  
The goal of spray drying with water as solvent was to increase the recovery of the protein loading from 
50 % to 100 % to use the pulmonary formulation, e.g., in in-vivo experiments to investigate pulmonary 
immunisation in mice. Almost 100 % of the used ovalbumin was recovered for all formulations after 
spray drying. SEC and SDS-PAGE were used to investigate the stability of the ovalbumin. The 
composition of the matrix had an influence on the denaturation of the ovalbumin in all formulations. As 
the amount of mannitol increased, the stabilising effect on ovalbumin during spray drying also increased. 
In conclusion, the increase in recovery of the protein loading from 50 % to 100 % of the used ovalbumin 
was successful. The composition of the matrix and thus the zinc oxide concentration had an influence 
on almost all experiments. In order to identify the optimal formulation for in-vivo experiments to 
investigate pulmonary immunisation in mice, in-vitro cell experiments were first necessary. Here, 
different immunological cell markers were examined to give an indication of an immunological effect 
in-vivo. In the cell activation experiments, the higher expression of MHC-II and the expression of CD80 
and CD86 indicated an activation of the used BMDC. The possibility of using zinc oxide as an alternative 
adjuvant for mucosal immunisation should finally be tested in an in-vivo mouse model.  
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7 Conclusion and outlook 
Mucosal immunisation via the respiratory tract is one non-invasive chance to prevent infectious diseases, 
especially as it mimics the natural entry of antigens that usually have their first contact with the nasal or 
pulmonary mucosa when entering the human body. In order to obtain an immune response from an 
antigen that is not sufficiently immunogenic, it has to be combined with an adjuvant. In this thesis, zinc 
oxide in formulation for respiratory vaccination was investigated. 
In the first part of the thesis, the adsorption properties of different zinc oxides were investigated. The 
adsorption of different proteins on zinc oxide tetrapods and zinc oxide in relation to their production 
method, their shape and their particle size was examined in more detail. It was found that the short 
milled zinc oxide tetrapods showed the best adsorption capacity, probably due to a combination of the 
production method, the shape and the particle size.  
In the second part of the thesis, spray dried formulations with different concentrations of zinc oxide and 
mannitol and constant concentrations of ovalbumin and hyaluronic acid were prepared and 
characterised. Initially, nasal formulations with a target particle size > 10 µm were prepared. Only 50 % 
of the ovalbumin used could be recovered in the spray dried formulations and the use of acetic acid (2 %) 
as a solvent or suspending agent in the spray drying process led to repeated difficulties in the 
characterisation. Acetic acid (2 %) was replaced by water and pulmonary formulations with a target 
particle size < 5 µm were prepared and characterised in the same way. Both, the goal of increasing 
protein loading to a recovery of 100 % and the aim of eliminating the problems caused by acetic 
acid (2 %), were achieved. The matrix composition of different concentrations of zinc oxide and mannitol 
had an influence in almost all experiments. Formulation 2 was identified as the formulation best suited 
for in-vivo studies in terms of the aerodynamic performance. In in-vitro immunological cell studies with 
BMDC and formulation 2, the expression in CD80 and CD86 as well as the higher expression in MHC-II 
indicated DC maturation. 
In summary, pulmonary formulation 2 had the most promising properties with regard to mucosal 
vaccination via the respiratory tract. However, since all the experiments had so far only been conducted 
in-vitro, it remained to be seen whether the promising properties will persist in-vivo. 
In in-vivo mice experiments, it will be tested whether pulmonary formulation 2 also retains the most 
promising properties in-vivo and can be finally identified as the formulation with the "right" 
concentration of zinc oxide for the use as an alternative adjuvant for mucosal vaccination via the 
respiratory tract.  
For the in-vivo studies, the immune response in mice vaccinated subcutaneously with formulations 2, 3 
and 4 will be tested. For this purpose, 36 6-week-old, female, C57BL/6 mice will be necessary. These mice 
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will be divided into six groups of six mice each and vaccinated subcutaneously with 200 µL each in 
week 0, 2 and 4. Group A will be again divided into two subgroups, whereby three mice will be vaccinated 
with 10 µg ovalbumin and three mice with saline. They will be used as negative control. Group B 
vaccinated with 10 µg ovalbumin and CAF01 (250 µg DDA/ 50 µg TDB) and group C with 10 µg 
ovalbumin and Alhydrogel (500 µg) will be used as positive control. Group D will be vaccinated with 
pulmonary formulation 2, group E with pulmonary formulation 3 and group F with pulmonary 
formulation 4, with the amount of powder adjusted to finally contain 10 µg ovalbumin. Two weeks after 
the third immunisation, spleen, blood and lymph nodes will be collected and different antibodies, 
cytokines and markers will be analysed. The formulation performing best in the immunological in-vivo 
studies using subcutaneous vaccination should then be investigated in an immunological in-vivo study 
using pulmonary vaccination. 
The next steps will certainly depend on the extent to which an immunological response can be induced 
in the in-vivo studies. If an immunological reaction can be observed, the model antigen ovalbumin 
should be replaced by other antigens in order to see which relevant properties an antigen must have in 
order to induce an immune response with zinc oxide as an adjuvant.  
More or less independent from the in-vivo results is the exchange of the starting material. If the case 
occurs that no immune reaction can be observed, the exchange of zinc oxide could possibly lead to an 
immune reaction. However, if an immune response can be observed, replacement of zinc oxide could 
result in further understanding of the immune response. In this context it would be interesting to 
standardise the zinc oxide tetrapods and investigate them further as a potential adjuvant. Also, the 
influence of particle size of zinc oxide on the immunological response would also be another interesting 
point, as an adjuvant effect has already been described for nanoparticles [249].  
In addition to the starting material, other formulation options could also be further investigated to obtain 
or increase the immune reaction. Although formulation development was the main focus of this thesis, 
the development of new inhalers for immunisation should also not be lost sight of. An interaction of the 






Active immunisation is the best option to prevent infectious diseases. Intramuscular application is the 
most commonly used administration route, because of systemic immune response and exact dosing 
possibilities. Due to its low cost and good effect, aluminium salts are the most frequently used adjuvants 
in adsorbate vaccines to enhance the immune response of an attenuated antigen or antigen 
components. While intramuscular administration requires the use of a needle and a sterile dosage form, 
mucosal immunisation is one opportunity of non-invasive administration. The respiratory tract comprises 
numerous immune competent cells as part of the MALT and thereby represents an excellent possibility 
to induce both local and systemic immune response. Since aluminium salts are ineffective as adjuvant 
on the mucosa, this work focussed on zinc oxide in formulations for respiratory vaccination. 
Zinc oxide is well characterised in a number of clinical studies and has many different uses. An 
immunomodulating effect of zinc oxide based on an increasing proliferation of T cells and high 
expression of MHC-II molecules is described in a number of papers. A special form of zinc oxide are the 
zinc oxide tetrapods. They have a three-dimensional tetrapodial structure and the potential uses are 
manifold due to their properties. Worth mentioning is the potential application as a prophylactic, 
preventive and/or adjuvant formulation for viral infection as they have among other things the ability to 
bind antigens. Viruses bound to zinc oxide tetrapods can therefore be absorbed by antigen-presenting 
cells in the mucosa and then presented to activate the immune system.  
In adsorption studies the adsorption capacity of zinc oxide, zinc oxide tetrapods, short milled and long 
milled zinc oxide tetrapods with five different proteins with varying isoelectric points and different 
molecular weights were investigated. While the zinc oxide tetrapods were able to adsorb mainly 
positively charged proteins due to their negatively charged surface, there was no discernible difference 
in the case of zinc oxide. All materials showed higher adsorption capacities towards the proteins with 
smaller molecular weights. 
Formulations for the delivery to the respiratory tract with zinc oxide were spray dried for nasal and 
pulmonary administration. Six different formulations with various amounts of zinc oxide were produced 
for each application route. Mannitol and hyaluronic acid were used as additional excipient and 
ovalbumin served as model antigen. Since spray drying with acetic acid (2 %) for the nasal formulations 
led to numerous difficulties in characterisation and undesired properties, the pulmonary formulations 
were spray dried with water as suspension medium. After spray drying, all six formulations were white 
powders with an x50 smaller than 5 µm and almost 100 % of the ovalbumin used was recovered. The 
composition of the formulation and thus the zinc oxide concentration had an influence on almost all 
experiments. Finally, cell activation experiments were performed to investigate whether zinc oxide 
presented its adjuvant effect when formulated as dry powder. Since formulation 2 showed the best 
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aerodynamic properties for in-vivo studies, it was therefore used as example. The expression of CD80, 
CD86 and MHC-II indicated an activation of the used murine bone marrow-derived dendritic cells. The 






Aktive Immunisierung ist die beste Möglichkeit Infektionskrankheiten zu verhindern. Neben der 
intramuskulären Gabe, die aufgrund der systemischen Immunantwort und der exakten 
Dosierungsmöglichkeit den beliebtesten Weg darstellt, gibt es zahlreiche nadelfreie Alternativen, die 
immer mehr an Interesse gewinnen. Die nicht-invasive Gabe und die dadurch entstehende Möglichkeit 
der Formulierung nicht steriler Darreichungsformen sind nur zwei Vorteile, die mit den alternativen 
kutanen und mukosalen Immunisierungswegen einhergehen. Der Respirationstrakt umfasst als 
Eintrittspforte der meisten Antigene und als Teil des Schleimhaut-assoziierten lymphatischen Gewebes 
zahlreiche immunkompetente Zellen und stellt damit eine hervorragende Chance dar, sowohl eine lokale 
als auch eine systemische Immunantwort zu induzieren. Die für die Immunisierung verwendeten 
abgeschwächten Antigenen oder Antigenkomponenten benötigen ein Adjuvans um die Immunantwort 
zu verstärken. Aluminiumsalze zählen hierbei zu den am häufigsten verwendeten Adjuvantien, u.a. 
aufgrund ihrer geringen Kosten und der guten Wirksamkeit. Die sogenannten Adsorbatimpfstoffe, die 
die abgeschwächten Antigene adsorbiert an Aluminiumsalzen enthalten, sind jedoch auf der 
Schleimhaut unwirksam. Im Rahmen dieser Arbeit wird Zinkoxid als Bestandteil von Formulierungen für 
die Immunisierung über den Respirationstrakt zunächst auf seine Adsorptionseigenschaften untersucht 
und anschließend als sprühgetrocknete Formulierungen charakterisiert und in in-vitro 
Zellexperimententen in Hinblick auf seine immunologische Aktivierung analysiert.   
Zinkoxid ist in einer Reihe klinischer Studien gut charakterisiert und hat viele verschiedene 
Anwendungsmöglichkeiten. Eine immunmodulierende Wirkung von Zinkoxid, die auf einer erhöhten 
Proliferation von T-Zellen und einer hohen Expression von MHC-II-Molekülen beruht, wird in zahlreichen 
Arbeiten beschrieben. Eine spezielle Form des Zinkoxids sind die Zinkoxid Tetrapoden, die eine 
dreidimensionale Tetrapodenstruktur aufweisen und deren Einsatzmöglichkeiten aufgrund ihrer 
Eigenschaften vielfältig sind. Besonders interessant ist im Kontext der Arbeit die mögliche Anwendung 
als prophylaktische, präventive und/oder adjuvante Formulierung bei viralen Infektionen, da sie z.B. die 
Fähigkeit besitzen, Antigene zu binden. An Zinkoxid Tetrapoden gebundene Viren können dann von 
Antigen-präsentierenden Zellen in der Schleimhaut aufgenommen und zur Aktivierung des 
Immunsystems präsentiert werden.  
In Adsorptionsstudien wurde zunächst die Adsorptionskapazität von Zinkoxid, den Zinkoxid Tetrapoden 
sowie kurz gemahlenen und lang gemahlenen Zinkoxid Tetrapoden mit fünf verschiedenen Proteinen 
mit unterschiedlichen isoelektrischen Punkten und Molekularmassen untersucht. Während die Zinkoxid 
Tetrapoden aufgrund ihrer negativ geladenen Oberfläche vor allem positiv geladene Proteine 
adsorbierten, gab es beim Zinkoxid keinen erkennbaren Unterschied in Hinblick auf die verschiedenen 
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isoelektrischen Punkte der Proteine. Alle Materialien zeigten höhere Adsorptionskapazitäten gegenüber 
den Proteinen mit kleineren Molekularmassen. 
Mithilfe der Sprühtrocknung wurden sowohl nasale als auch pulmonale Pulvern hergestellt. Für jede 
Darreichungsform wurden sechs verschiedene Formulierungen mit unterschiedlichen Mengen an 
Zinkoxid produziert. Als zusätzliche Hilfsstoffe wurden Mannitol und Hyaluronsäure verwendet. 
Ovalbumin diente als Modellantigen. Da die Sprühtrocknung mit Essigsäure (2 %) für die Herstellung 
der nasalen Formulierungen zu zahlreichen Schwierigkeiten bei der Charakterisierung und zu für die 
Anwendung unerwünschten Eigenschaften führte, wurden die pulmonalen Formulierungen mit Wasser 
als Suspensionsmedium sprühgetrocknet. Sechs weiße Pulver mit unterschiedlichen 
Zinkoxidkonzentrationen, einem x50 kleiner als 5 µm und einer Beladung von 100 % des verwendeten 
Ovalbumins wurden hergestellt. Die verschiedenen Zinkoxidkonzentrationen der Formulierungen hatten 
bei fast allen Versuchen einen Einfluss. In immunologischen in-vitro Zellexperimenten zeigte 
Formulierung 2, die für die Versuche aufgrund der besten aerodynamischen Eigenschaften ausgewählt 
wurde, eine Expression von CD80, CD86 und MHC-II. Diese Ergebnisse deuteten auf eine Aktivierung der 
verwendeten dendritischen Zellen aus dem Knochenmark von Mäusen hin und geben so einen ersten 
Hinweis auf eine adjuvante Wirkung. Die Verwendung von Zinkoxid als Adjuvans scheint also möglich 
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Table 11.1. 24-h-pH- and solubility study showing saturation solubility, starting pH and pH change of different 
solutions/suspensions after 24 h for zinc oxide in comparison to formulation 1. F1) 100 % ZnO and 0 % mannitol. 
n = 3, ±= standard deviation. 
 
ZnO 24 h, 
mg/mL 
F1 24 h, 
mg/mL 
pH 0 h 
ZnO 
pH 24 h 
F1  
pH 24 h 
Phosphate 
buffer 
pH 1.2 5.09 ± 0.20 5.16 ± 0.17 1.18 3.21 ± 0.03 3.08 ± 0.03 
pH 2.5 0.49 ± 0.01 0.47 ± 0.05 2.53 6.25 ± 0.33 5.09 ± 0.09 
pH 4.0 0.01 ± 0.00 0.01 ± 0.002 4.00 6.73 ± 0.16 6.39 ± 0.02 
pH 5.5 0.01 ± 0.004 0.01 ± 0.003 5.48 6.81 ± 0.32 6.63 ± 0.07 
pH 6.4 0.01 ± 0.001 0.01 ± 0.00 6.36 7.76 ± 0.20 7.10 ± 0.18 




pH 1.2 2.68 ± 0.01 4.01 ± 0.30 1.21 6.43 ± 0.11 6.08 ± 0.09 
pH 2.5 0.15 ± 0.001 0.92 ± 0.04 2.50 7.38 ± 0.15 6.88 ± 0.02 
pH 4.0 0.02 ± 0.001 0.91 ± 0.03 4.07 7.76 ± 0.01 6.93 ± 0.001 
pH 5.5 0.01 ± 0.002 0.86 ± 0.02 5.55 7.68 ± 0.05 6.95 ± 0.01 
pH 6.4 0.01 ± 0.001 0.82 ± 0.03 6.35 7.74 ± 0.03 6.98 ± 0.02 
pH 7.4 0.01 ± 0.001 0.92 ± 0.09 7.36 7.63 ± 0.004 6.89 ± 0.08 





Table 11.2. 24 h-pH study showing starting pH and pH change of different solutions/suspensions after 24  with zinc 
oxide as raw material (ZnO) in comparison to all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 
 pH 0 h ZnO F1 F2 F3 F4 F5 F6 
Phosphate 
buffer 










































































































































































































Table 11.3. Viability as a function of the zinc oxide concentration in all formulations, to identify whether toxicity is 
dependent on zinc oxide concentrations in the formulation. Zinc oxide as raw material (ZnO) is used as a reference. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol. n = 3, ± = standard deviation. 
 ZnO F1 F2 F3 F4 F5 
Formulation concentration: 0.005 mg/mL 
ZnO 
Concentration, mg/mL 














Formulation concentration: 0.010 mg/mL 
ZnO 
Concentration, mg/mL 














Formulation concentration: 0.050 mg/mL 
ZnO 
Concentration, mg/mL 














Formulation concentration: 0.100 mg/mL 
ZnO 
Concentration, mg/mL 














Formulation concentration: 0.500 mg/mL 
ZnO 
Concentration, mg/mL 
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 ZnO F1 F2 F3 F4 F5 
Formulation concentration: 1.000 mg/mL 
ZnO 
Concentration, mg/mL 
n/a n/a n/a n/a 0.360 0.180 





Formulation concentration: 2.500 mg/mL 
ZnO 
Concentration, mg/mL 
n/a n/a n/a n/a n/a 0.450 







Table 11.4. 24-h-pH- and solubility study showing saturation solubility, starting pH and pH change of different 
solutions/suspensions after 24 h for zinc oxide in comparison to formulation 1. F1) 100 % ZnO and 0 % mannitol. 
n = 3, ±= standard deviation. 
 
ZnO 24 h, 
mg/mL 
F1 24 h, 
mg/mL 
pH 0 h 
ZnO 
pH 24 h 
F1  
pH 24 h 
Phosphate 
buffer 
pH 1.2 5.09 ± 0.20 5.09 ± 0.02 1.15 3.16 ± 0.03 3.24 ± 0.02 
pH 2.5 0.49 ± 0.01 0.48 ± 0.01 2.56 3.82 ± 0.04 3.83 ± 0.04 
pH 4.0 0.01 ± 0.00 0.01 ± 0.001 4.08 6.19 ± 0.01 6.11 ± 0.05 
pH 5.5 0.01 ± 0.004 0.01 ± 0.00 5.60 6.33 ± 0.01 6.36 ± 0.04 
pH 6.4 0.01 ± 0.001 0.01 ± 0.001 6.44 6.72 ± 0.00 6.82 ± 0.01 




pH 1.2 2.68 ± 0.01 2.72 ± 0.14 1.29 6.51 ± 0.02 6.43 ± 0.02 
pH 2.5 0.15 ± 0.001 0.13 ± 0.01 2.55 6.98 ± 0.02 6.88 ± 0.06 
pH 4.0 0.02 ± 0.001 0.01 ± 0.002 4.02 7.45 ± 0.01 7.51 ± 0.07 
pH 5.5 0.01 ± 0.002 0.01 ± 0.001 5.49 7.56 ± 0.03 7.59 ± 0.02 
pH 6.4 0.01 ± 0.001 0.01 ± 0.002 6.38 7.61 ± 0.06 7.67 ± 0.03 
pH 7.4 0.01 ± 0.001 0.01 ± 0.002 7.30 7.62 ± 0.04 7.70 ± 0.04 





Table 11.5. 24 h-pH study showing starting pH and pH change of different solutions/suspensions after 24  with zinc 
oxide as raw material (ZnO) in comparison to all formulations. F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 
20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO and 60 % mannitol; F5) 20 % ZnO and 
80 % mannitol; F6) 0 % ZnO and 100 % mannitol. n = 3, ± = standard deviation. 
 pH 0 h ZnO F1 F2 F3 F4 F5 F6 
Phosphate 
buffer 










































































































































































































Table 11.6. Viability as a function of the zinc oxide concentration in all formulations, to identify whether toxicity is 
dependent on zinc oxide concentrations in the formulation. Zinc oxide as raw material (ZnO) is used as a reference. 
F1) 100 % ZnO and 0 % mannitol; F2) 80 % ZnO and 20 % mannitol; F3) 60 % ZnO and 40 % mannitol; F4) 40 % ZnO 
and 60 % mannitol; F5) 20 % ZnO and 80 % mannitol. n = 3, ± = standard deviation. 
 F1 F2 F3 F4 F5 
Formulation concentration: 0.005 mg/mL 
ZnO 
Concentration, mg/mL 












Formulation concentration: 0.010 mg/mL 
ZnO 
Concentration, mg/mL 












Formulation concentration: 0.050 mg/mL 
ZnO 
Concentration, mg/mL 












Formulation concentration: 0.100 mg/mL 
ZnO 
Concentration, mg/mL 












Formulation concentration: 0.500 mg/mL 
ZnO 
Concentration, mg/mL 
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 F1 F2 F3 F4 F5 
Formulation concentration: 1.000 mg/mL 
ZnO 
Concentration, mg/mL 
n/a n/a n/a 0.360 0.180 





Formulation concentration: 2.500 mg/mL 
ZnO 
Concentration, mg/mL 
n/a n/a n/a n/a 0.450 








APC  Antigen-presenting cells 
ATCC  American Type Culture Collection 
BALT  Bronchus-associated lymphoid tissue 
BCG  Bacillus Calmette-Guerin 
BET  Brunauer, Emmet, Teller 
BMDC  Bone marrow-derived dendritic cells 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
CD  Cluster of differentiation 
CMC  Carboxymethyl cellulose 
CNS  Central nervous system 
COPD  Chronic obstructive pulmonary disease 
CpG  Oligonucleotides 
CT  Cholera enterotoxin 
CTL  Cytotoxic T lymphocytes 
DC  Dendritic cell 
DHEA  Dehydroepiandrosterone 
DNA  Deoxyribonucleic acid 
DOC  Sodium deoxycholate 
DPI  Dry powder inhaler 
DPPC  Dipalmitoyl phosphatidylcholine 
DSC  Differential scanning calorimetry 
DVS  Dynamic vapor sorption 
EDS  Energy dispersive X-ray spectroscopy 
EMA  European Medicine Agency 
EU  European Union 
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F*  Formulation (followed by the number of the formulation) 
FACS  Fluorescence activated cell sorting 
FBS  Fetal bovine serum 
FDA  Food and drug administration 
FPF  Fine particle fraction 
FTS  Flame transport synthesis 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HA  Hyaluronic acid 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HES  Hydroxyethyl starch 
HIV  Human immunodeficiency virus 
HSV  Herpes simplex virus 
IEP  Isoelectric point 
iGC-SEA Inverse gas chromatography surface energy analyser 
Il  Interleukin 
ISCOM  Immunostimulating complex 
LALT  Larynx-associated lymphoid tissue 
LD  Lethal dose 
LPS  Lipopolysaccharide 
LT  Heat-labile enterotoxine 
MALS  Multi angle light scattering 
MALT  Mucosa-associated lymphoid tissue 
MDP  Muramyl dipeptide 
MHC  Major histocompatibility complex 
MMAD  Mass median aerodynamic diameter 
MOC  Micro-orifice collector 
MPL  Monophosphoryl lipid A 
m-RNA  Messenger ribonucleic acid 
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MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NALT  Nose-associated lymphoid tissue 
NEC  Nasal expansion chamber 
NFκB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGI  Next generation pharmaceutical impactor 
NiM  Nano-in-Microparticle 
OTC  Over the counter 
OVA  Ovalbumin 
PAMP  Pathogen-associated molecular pattern 
PBS  Phosphate buffer solution 
PCL  Polycaprolactone 
PEG  Polyethylene glycol 
PEI  Polyethyleneimine 
PET  Polyethylene terephthalate 
PGA  Polyglutamic acid 
PI-3  Phosphatidylinositol-3 
PLA  Polylactide 
PLGA  Polylactide-co-glycolic acid 
pMDI  Pressurised metered dose inhaler 
PMMA  Polymethyl methacrylate 
PVB  Polyvinyl butyral 
RNA  Ribonucleic acid 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus type 2 
SDS-PAGE Sodium dodecyl sulphonate polyacrylamide gel electrophoresis 
SEC  Size exclusion chromatography 
SEM  Scanning electron microscopy 
TEER  Transepithelial electrical resistance 
TLR 4  Toll-like Receptor 4 
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UDS  Unit dose powder system 
UK  United Kingdom of Great Britain and Northern Ireland 
USA  United states of America 
UV/Vis  Ultraviolet-visible spectroscopy 
WHO  World Health Organisation 
Zn  Zinc 
ZnO  Zinc oxide 







1,2-propanediol Merck KGaA, Germany 
Acetic acid glacial ≥ 99 % J. T. Baker Corporate, USA 
Acrylamide/bisacrylamide stock 
solution 
Carl Roth GmbH & Co. KG, Germany 
Alpha-Lactalbumin (from bovine milk) Merck KGaA, Germany 
Aluminium phosphate (Adju-Phos) Brenntag Biosector, Denmark 
Aluminium hydroxide (VAC20) SPI Pharma, USA 
Ammonium persulphate Carl Roth GmbH & Co. KG, Germany 
anti-CD11c-BUV737, HL3 BD Biosciences, Denmark 
anti-CD40-PE, 3.23 BD Biosciences, Denmark 
anti-CD80-APC, 16-10A1 BD Biosciences, Denmark 
anti-CD86-FITC, GL1 BD Biosciences, Denmark 
anti-MHC-II-eF450, M5/114.15.2 eBioscience, Thermo Fisher Scientific Inc., USA 
Avidin Merck KGaA, Germany 
Bovine serum albumin Merck KGaA, Germany 
Bromophenol blue Carl Roth GmbH & Co. KG, Germany 
Calcium chloride dihydrate Merck KGaA, Germany 
Coomassie brilliant blue Carl Roth GmbH & Co. KG, Germany 
Dimethylformamide Merck KGaA, Germany 
Di-sodium hydrogen phosphate Merck KGaA, Germany 
Di-sodium hydrogen phosphate 
dihydrate 
Merck KGaA, Germany 





Dulbecco’s Modified Eagle’s 
Medium – high glucose,  
w 4.5 g/L glucose, w L-glutamine, 
w sodium carbonate, w/o sodium 
pyruvate  
Merck KGaA, Germany 
Dulbecco's Phosphate Buffered Saline, 
w/o Ca2+, w/o Mg2+ 
Merck KGaA, Germany 
Ethanol Merck KGaA, Germany 
Fetal bovine serum Merck KGaA, Germany 
Gibco RPMI 1640 Medium, GlutaMAX 
Supplement, w GlutaMAX, w/o sodium 
pyruvate 
Thermo Fisher Scientific Inc., USA 
Glycerol 99 % AppliChem GmbH, Germany 
Glycine Carl Roth GmbH & Co. KG, Germany 
GM-CSF PeproTech Inc., USA 
Hanks’ salt solution – w 0.35 g/L 
NaHCO3, w Ca2+, w Mg2+, w/o Phenol 
red 
Merck KGaA, Germany 
Hyaluronic acid (sodium salt) Caesar & Loretz GmbH, Germany 
Hydrochloric acid 37 % AppiChem GmbH, Germany 
Isopropanol AppiChem GmbH, Germany 
Lysozyme Merck KGaA, Germany 
Magnesium chloride Merck KGaA, Germany 
Mannitol (Pearlitol 200 SD) Roquette Frères, France 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) 
Merck KGaA, Germany 
Mucin of porcine stomach type II Merck KGaA, Germany 
Non-essential amino acid Merck KGaA, Germany 




Penicillin-streptomycin Merck KGaA, Germany 
Penicillin-streptomycin (100 x) Invitrogen, Thermo Fisher Scientific Inc., USA 
peqGOLD Protein Marker III VWR Internationl GmbH 
Potassium chloride Carl Roth GmbH & Co. KG, Germany 
Potassium dihydrogen phosphate Carl Roth GmbH & Co. KG, Germany 
RBC Lysis Buffer (10 x) BioLegend Inc., USA 
Silver staining kit GE Healthcare GmbH, Germany 
Sodium acetate Merck KGaA, Germany 
Sodium chloride Carl Roth GmbH & Co. KG, Germany 
Sodium citrate dihydrate AppliChem GmbH, Germany 
Sodium dihydrogen phosphate 
monohydrate 
Merck KGaA, Germany 
Sodium dodecyl sulphonate Carl Roth GmbH & Co. KG, Germany 
Sodium hydrogen carbonate Merck KGaA, Germany 
Sodium hydroxide Carl Roth GmbH & Co. KG, Germany 
Sodium pyruvate Merck KGaA, Germany 
Sodium sulphate Merck KGaA, Germany 
Tetramethyl ethylenediamine Carl Roth GmbH & Co. KG, Germany 
Tris-base Merck KGaA, Germany 
Triton-X Merck KGaA, Germany 
Trypan blue 0.5 % (w/w) in 
physiological saline 
Merck KGaA, Germany 
Zinc oxide (for external use) Caesar & Loretz GmbH, Germany 
Zinc oxide tetrapods 
Working group “Functional Nanomaterials“ headed by 
Prof. Rainer Adelung, Institute of Material Science, Faculty 




Zincon Carl Roth GmbH & Co. KG, Germany 




BMDC from CF57BL/6N mice 
Vaccine Design and Delivery Group of Prof Camilla Foged, 
University of Copenhagen, Denmark 
Calu-3 American Type Culture Collection, USA 
RPMI2650 






Lumox 96 multiwell 
Microplate 96 well F 
TC-plate 96 well, Standard, F 
Sarstedt AG & Co. KG, Germany 
BD syringe (1 mL) BD (Becton, Dickinson and Company) Corporation, USA 
Carbon tabs (12 mm) Micro to Nano, The Netherlands  
Cellstar 12-well-plates Greiner Bio One International GmbH, Austria 
Cellstar 24-well plates Greiner Bio One International GmbH, Austria 
Chromafil Xtra PET 45/25 Macherey-Nagel GmbH & Co. KG, Germany 
Corning cell strainer, 40 µm blue Merck KGaA, Germany 
Cyclohaler Jenapharm GmbH & Co. KG, Germany 
DSC pans (40 µL) and covers PerkinElmer Inc., USA 




DURAN laboratory bottle (250 mL) DWK Life Science GmbH, Germany 
DURAN measuring cylinder (10 mL) DWK Life Science GmbH, Germany 
DURAN volumetric flask (500 mL) DWK Life Science GmbH, Germany 
Filter paper circles (125 mm) Whatman, Inc., UK 
Magnetic stir bar Brand GmbH & Co. KG, Germany 
Petri dishes, polystyrene (100 x 50 mm) Merck KGaA, Germany 
Pipette tips (10 mL, 5 mL,1 mL, 100 µL) Sarstedt AG & Co. KG, Germany 
Reaction tubes (2 mL, 1.5 mL, 100 µL) Sarstedt AG & Co. KG, Germany 
SEC glass column (C-MF-144, C-MF-
145, C-MF-146) 
Surface Measurement System Ltd., UK 
SEM pin stub (12.7 mm) Micro to Nano, The Netherlands  
Semi micro quartz cuvette Hellma GmbH & Co. KG, Germany 
TC flask T25, Stand., Vent. Cap Sarstedt AG & Co. KG, Germany 
TC flask T75, Stand., Vent. Cap Sarstedt AG & Co. KG, Germany 
TC flask T175, Stand., Vent. Cap Sarstedt AG & Co. KG, Germany 
ThinCerts (12 well) Greiner Bio One International GmbH, Austria 
Tubes (15 mL, 50 mL) Sarstedt AG & Co. KG, Germany 
Unit dose system powder device  Aptar Pharma, France 




Air jet sieve Alpine Air Jet Sieve e200 LS Hosokawa Alpine AG, Germany 





Centrifuge 5430 R Eppendorf AG, Germany 
Heraeus Biofuge pico Thermo Fisher Scientific Inc., USA 
Heraeus Biofuge 28 RS Thermo Fisher Scientific Inc., USA 
Differential scanning 
calorimetry 
Diamond DSC PerkinElmer Inc., USA 
Drying oven Heraeus Thermo Fisher Scientific Inc., USA 
Dynamic vapour 
sorption 
DVS 1 Surface Measurement System Ltd., UK 
Flow cytometer BD LSRFortessa 
BD (Becton, Dickinson and Company) 
Corporation, USA 
Flow meter DFM 2000 flow meter Copley Scientific, UK 
Friabilator Erweka Erweka GmbH, Germany 
Impactor 
Next Generation 
Pharmaceutical Impactor in 




Copley Scientific, UK 





iGC-SEA Surface Measurement System Ltd., UK 
Lab Balances 
Sartorius A200S Sartorius AG, Germany 
Sartorius MC1 Sartorius AG, Germany 
Sartorius MC5 Sartorius AG, Germany 
Laser diffractometer 
HELOS in combination with 
RODOS module, INHALER 
module, SPRAYER module 
Sympatec GmbH, Germany 




Microscope Olympus IMT-2 Olympus Deutschland GmbH, Germany 
Multi angle light 
scattering detector 
DAWN 8+ 
Wyatt Technology Corporation, 
Germany 
Orbital shaker 
Universalschüttler SM Edmund Bühler GmbH, Germany 
GFL Schüttelaparatur 3005 
GFL Gesellschaft für Labortechnik GmbH, 
Germany 




WTW Inolab pH 730 with 
SentTix 81 
Xylem Analytics Germany ales GmbH & 
Co. KG, Germany 
Mettler Toledo SevenCompact 
Benchtop Meter with InLab 
Ultra-Micro-ISM 
Mettler Toledo GmbH, Germany 
Pipetttes 
Accu jet pro Brand GmbH & Co. KG, Germany 
Eppendorf Reference 10 – 
100 µL 
Eppendorf AG, Germany  
Eppendorf Reference 100 – 
1000 µL 
Eppendorf AG, Germany  
Eppendorf Research Pro 1000 – 
5000 µL 
Eppendorf AG, Germany  
Eppendorf Multipette Eppendorf AG, Germany  
Tranferpipette-8 10 – 100 µL Brand GmbH & Co. KG, Germany 
Plate reader FluoStar Omega BMG Labtech GmbH, Germany 
Pumps  
HCP4 Copley Scientific, UK 
HCP5 Copley Scientific, UK 




Wyatt Technology Corporation, 
Germany 
Rheometer 
Bohlin CVO 120 High 
Resolution 






Phenom World XL Thermo Fisher Scientific Inc., USA 
SDS-PAGE Mini-Protean Tetra Cell Bio-Rad Laboratories Inc., USA 
Sieve 
Diameter 20 cm with different 
mesh sizes (45 µm, 75 µm) 
Retsch GmbH, Germany 
Size exclusion 
chromatograph 




SuperoseTM 6 Increase 10/300 
GL 
GE Healthcare Bio-Sciences AB, Sweden 
Software 
FACSDiva software 
BD (Becton, Dickinson and Company) 
Corporation, USA 
FlowJo software v 10 Tree Star, USA 
Sonicator 
SONOPLUS ultrasonic 
homogeniser HD 4100 in 
combination with sonotrode 
TS 103 
BANDELIN electronic GmbH & Co. KG, 
Germany 
Bandelin SONOREX SUPER RK 
514 BH ultrasonic water bath 
BANDELIN electronic GmbH & Co. KG, 
Germany 
Spectrometer Shimadzu UV-1280 Shimadzu Corporation, Japan 
Spray Dryer Mini Spray Dryer B-290 Büchi Labortechnik AG, Switzerland 
Sputter coater  
BAL-Tec SCP 050 Sputter 
Coater 
Leica Microsystems, UK 
Transepithelial 
electrical resistance 
EVOM World Precision Instruments, USA 
Vortex IKA Vortex 4 basic IKA-Werke GmbH & Co. KG, Germany 
X-ray powder 
diffractometer 
STOE STADI P in combination 
with a DECTRIS MYTHEN 1K 
detector 
STOE & Cie GmbH, Germany 
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